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Abstract 
Connexin and pannexin large-pore channels allow the regulated passage of small molecules at 
sites of cell-cell contacts, and from the cytosol to the extracellular milieu, respectively. Since 
it has been known for many years that Cx26 and Cx30 gap junction proteins are crucial in 
hearing we propose that Cx43 might also be important in hearing. Here we used two different 
genetically modified mouse lines that contain systemic Cx43 gene mutations that reduces gap 
junctional intercellular communication (GJIC) to examine whether Cx43 is also important for 
proper hearing function. Furthermore, since pannexins have also been postulated to be 
involved in auditory function we used three different Panx global knock-out mice to evaluate 
their hearing profiles. We showed that Cx43 mutant mice that had severe loss of Cx43 channel 
function had hearing loss, while mutant mice with a modest loss of Cx43 function exhibited 
normal hearing. Surprisingly, Panx1-/-, Panx3-/-, and double knock-out (dKO) mice did not have 
hearing loss, suggesting that pannexins do not play an important role in hearing. To evaluate 
whether large-pore channels played a role in noise-induced hearing loss (NIHL), we challenged 
Cx43 mutant and pannexin knock-out mice with a loud noise-exposure and examined their 
permanent hearing loss. Interestingly, only Panx3-/- and Panx dKO mice were slightly protected 
against permanent hearing damage. Finally, organotypic cochlear cultures from Cx43 mutant 
mice and a CRISPR Cas9 Cx43 ablated cochlear-derived cell line, revealed that GJIC does not 
exacerbate drug-induced hearing loss but does cause supporting cell reorganization. 
Collectively, our results highlight the importance of Cx43 GJIC in hearing function, but not 
noise- or drug-induced ototoxicity. Furthermore, our studies support the notion that Panxs are 
not involved in baseline hearing, but loss of Panx3 may lead to slight protection against 
permanent NIHL.  
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Lay Summary 
The cells of our body are in constant communication with each other to facilitate tissue health. 
Gap junction channels form the basis of direct cell to cell communication allowing the transfer 
of ions and small signaling molecules in a process known as gap junctional intercellular 
communication (GJIC). It has been known for many years now that GJIC is essential for proper 
hearing as many mutations in genes that encode connexin (Cx) gap junction proteins   cause 
the majority of inherited hearing loss. Another large-pore channel type found in the inner ear 
that has been proposed to be important in hearing is made from pannexins (Panx) that allow 
small molecules to exit the cell. We evaluated the importance of Cx43, a poorly studied gap 
junction protein found in the auditory track, as well as Panx channels in baseline hearing and 
in noise-induced hearing loss. In mice, we found that Cx43 function was important in baseline 
hearing function, however, moderate levels of Cx43 function was enough to maintain proper 
hearing. In addition, Panxs were not found to be involved in hearing function. Loss of either 
Cx43 or Panx1 did not result in more or less permanent noise-induced hearing loss. 
Interestingly, loss of Panx3 led to a slight protection of hearing loss after a loud noise-exposure, 
however, the mechanisms behind this remains unknown. Cisplatin, a commonly used 
therapeutic agent, is effectively used to treat solid cancer tumors but results in permanent 
hearing loss in 75-100% of patients. Blocking and/or loss of GJIC with cisplatin treatment did 
not result in any differences in inner ear cell death, however, gap junction proteins were 
reorganized after cisplatin treatment. Overall, we examined the importance of large-pore 
channels in the context of three different kinds of hearing impairments including genetics, 
noise, and drug induced hearing loss. Interestingly, we found that Cx43 was essential for 
baseline hearing, but not NIHL or cisplatin-induced hearing loss. Further Panxs were not 
involved in any type of hearing function. These studies will directly contribute to gaining 
insight into molecular therapy treatments for hearing loss.   
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1.1. Hearing loss 
Hearing loss remains one of the most prevalent chronic conditions faced worldwide. The World 
Health Organization estimated that as of 2019 approximately 466 million people worldwide 
have disabling hearing loss with a projection of reaching over 900 million people by 2050. The 
majority of hearing loss cases are sensorineural where the sensory receptors of the inner ear, 
the hair cells, or their connected auditory neurons are damaged [1]. Age-related hearing loss is 
extremely common where most people over 50 years old incur some degree of hearing loss 
[2]. Approximately 80% of congenital hearing loss is due to genetic mutations, while the other 
20% is due to environmental factors, such as exposure to loud noises or ototoxic drugs that 
induce hearing loss [3]. In addition, 70% of hearing loss cases are non-syndromic, where the 
patient does not have any other symptoms other than hearing loss, and the other 30% of cases 
are syndromic, where patients will have other symptoms in addition to hearing loss such as 
skin disease or blindness [3]. Hearing loss can be encompassed by three broad categories; 
genetically acquired, noise-induced, and drug-induced, all of which are of particular interest in 
this thesis. 
Hearing loss can be genetically inherited and identified at birth where mutations in many genes 
that are important for hearing (SLC26A5 encoding Prestin, Myo15A encoding Myosin, and 
OTOG encoding Otogelin), including connexin encoding genes, cause hearing loss [4,5]. 
Collectively, there have been over one hundred different genes identified that underlie non-
syndromic hearing loss [6]. When a child is first born with hearing loss they will be genotyped 
for mutations in common genes involved in hearing loss, such as GJB2 encoding Cx26, 
SLC26A4 encoding Pendrin, and OTOF encoding Otoferlin, to name a few; which can be used 
to help guide a treatment plan for the patient [4,7]. The most common hearing loss locus lies 
within chromosome 13q12 where DFNB1 is found. DFN refers to deafness, B refers to 
recessive, and 1 refers to the order the gene was identified. DFNB1 codes for GJB2 (Cx26) 
where mutations account for approximately 50-60% of genetically acquired hearing loss [8]. 
In this thesis, we will focus on other connexin genes that are expressed in the inner ear and 
may also be involved in genetically inherited hearing loss.  
Noise-induced and drug-induced hearing loss involves hearing impairment as a consequence 
of exposure to loud noise or ototoxic drugs, respectively, and will be discussed in more detail 
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in later sections. Generally, hearing loss treatment is limited to either hearing aids for mild to 
moderate hearing loss or cochlear implants for more severe cases [9,10]. Hearing aids are used 
to enhance the amplification of external sound into the inner ear and thus relies on a residual 
level of hair cell function [11]. For more severe hearing loss cochlear implants are used which 
directly bypasses the hair cells and stimulates auditory nerves, thus eliminating the need for 
functional hair cells [11]. Going forward the research community needs to understand the 
molecular mechanisms underpinning hearing loss in order to drive potential molecular 
therapies. This thesis will involve chapters examining genetic-based, noise, and drug-induced 
hearing loss with an emphasis on the role of large-pore channels that includes connexins and 
pannexins.  
1.2. Anatomy of the inner ear 
The intricate process of inner ear development leads to the formation of a mature organ of 
Corti; the sensory epithelium of the cochlea. In humans the onset of hearing is approximately 
5-6 months in utero [12] while physiological hearing of mice is acquired at approximately P10-
P14 [13,14]. The cochlea consists of approximately 3 turns; apical, middle, and basal regions 
which are tonotopically organized so that different frequency selectivity is represented at 
different regions along the length of the cochlea. Apical, middle, and basal regions represent 
low, mid, and high frequency ranges of hearing, respectively [15]. In examining a cross 
sectional area of the cochlea, key anatomical structures are observed (Figure 1.1). The cochlear 
lateral wall consists mostly of fibrocytes within the spiral ligament and the stria vascularis, an 
important structure in maintaining proper endolymphatic potential, (+100mV) in the 
endolymphatic space, that is necessary for proper hearing [16]. The stria vascularis houses 
three different cell layers; the marginal, intermediate, and basal cells which encompasses the 
blood vessels responsible for nourishing the cochlea [16]. The epithelial region of the organ of 
Corti (Figure 1.1B) consists of the sensory receptors of hearing, the hair cells, that are 
depolarized in response to K+ influx through their mechanoelectrical transducer channels and 
relay information to the higher order auditory system [17]. 
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Figure 1.1. Anatomical structure of the cochlea. 
Cross sectional area of the inner ear. (A) Cross section of the cochlear duct showing the 
anatomical arrangement of the cochlea with all main structures labelled. Red cells represent 
cells of the connective tissue gap junction network and green cells represent cells of the 
epithelial gap junction network. Boxed area represents region highlighted in (B). Figure 
obtained with permission from Jagger et al. 2010. (B) Schematic of the epithelial region of the 
cochlea and all cell types associated within this region. Sensory receptor hair cells are shown 
in black and all cochlear supporting cells are annotated in different colors. 
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The hair cells are surrounded by many supporting cells which maintain the structure and 
integrity of the organ of Corti. Deiter’s cells are located directly under the outer hair cells (at 
a 1:1 ratio) and have long phalangeal processes so they may stretch from the basilar membrane 
to the reticular lamina [18]. The pillar cells act as structural support to maintain the open tunnel 
of Corti as well as the thickness of the epithelium. Both inner and outer pillar cells are closely 
associated with the inner and outer hair cells, respectively, and act to provide structural support 
to the organ of Corti [19]. Hensen’s cells, which are columnar in nature, as well as Claudius 
cells form the outer sulcus region of the epithelium and lie adjacent to the outer hair cells [19]. 
The inner phalangeal cells act as support to the inner hair cells and together with the inner 
border cells form the inner sulcus region of the epithelium [19]. Supporting cells of the cochlear 
epithelium act to give structure to the epithelium and to maintain metabolic support for the 
organ of Corti as well as the hair cells.  
1.3. Connexins and gap junctions 
Connexins (Cxs) are integral membrane proteins that form gap junctions which allow 
intercellular exchange of small members of the metabolome that are less than 1 kDa in size 
[20,21]. Each connexin subunit passes the plasma membrane four times and is comprised of 
two extracellular loops (E1, E2), one intracellular loop (IL), as well as an amino and carboxyl 
terminus that faces the cytosol. The topology of connexins is crucial for channel gating and 
selectivity of transjunctional molecules [22]. To date, 21 and 20 different connexin encoding 
genes have been identified in the human and mouse genomes, respectively, and each connexin 
is named according to their molecular weight (eg. Cx43= 43 kDa) [21,23]. Connexins are co-
translationally integrated into the endoplasmic reticulum where they are then trafficked to the 
Golgi apparatus of the cell. Some connexins oligomerize in the ER (e.g., Cx26) while others, 
such as Cx43, oligomerize in the Golgi into hexameric structures called connexons that then 
traffic to the plasma membrane of the cell [24,25]. Once at the cell surface, it is thought that 
connexons typically remain closed under normal physiological healthy cell conditions [26,27]. 
However, recent evidence suggests that connexons can function as hemichannels in some 
dysregulated or pathological conditions allowing passage of small molecules between the 
cytosol and the extracellular space [28,29]. A gap junction channel is formed when a connexon 
from one cell docks with a compatible connexon from an adjacent cell establishing a point of 
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intercellular communication. The gap junction channels proceed to cluster together to form 
large gap junction plaques where hundreds to thousands of channels are found [21,30].  
Gap junctional intercellular communication (GJIC) is critical in early embryonic development 
as well as in many important physiological processes such as cell proliferation, differentiation, 
and apoptosis [31–33]. Because of the complex nature of gap junctions and cell-cell 
communication, cells need to be able to regulate their ability to exchange molecules and ions 
in response to varying physiological processes. To do this, gap junctions are rapidly degraded 
after internalization as connexosomes by subsequently fusing with lysosomes [21,34]. Other 
pathways of connexin clearing from the cells surface may exist but these are not well 
elucidated. In most tissues, the half-life of connexins is approximately 1.5-5 hours which 
allows for the quick and dynamic regulation of gap junctions necessary for efficient and well-
regulated cell-cell communication [35–38].  
Another means of regulating GJIC is via rapid channel gating. For example, voltage gating 
mechanisms exist where the channel conductance is sensitive to transjunctional and 
transmembrane voltages [39,40]. It is also important to note that gap junction channels exhibit 
subconductance states where the channel can remain in a partially opened or partially closed 
state [40]. These subconductance states enable the gap junction channel to have different 
selective permeability properties where the passage of larger members of the metabolome, such 
as secondary messengers in some cases, is reduced [40]. In order to fully appreciate the 
complexity of gap junction channels it is important to note that most cells/tissues in the human 
body express multiple connexin isoforms allowing for the possibility of structural diversity in 
channel constituents. Gap junctions can be composed of homomeric or heteromeric oligomers 
which consists of either the same or different connexin isoforms, respectively [41,42] (Figure 
1.2). For example, it has been well documented that Cx26 and Cx30 can form heteromeric 
channels in tissues co-expressing these connexins as seen in the inner ear [43–45].  
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Figure 1.2. The structure and oligomerization compatibility of connexins 
 (A) Structural topology of a connexin subunit with four a-helical transmembrane domains, 
two extracellular loops (ECL), an intracellular loop (IL), cytoplasmic amino terminal (AT), 
and carboxy termini (CT). (B) Connexins oligomerize to form hexameric channels and are 
categorized into different groups based on structural homology. Figure obtained with 
permission from Laird and Lampe, 2018. 
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Further, once connexons are formed they can also dock together to form a gap junction channel 
with different connexons from the opposing cell establishing heterotypic channels [42,46]. 
These different channel configurations can lead to distinct characteristics such as channels with 
unique conductance, gating properties, and transjunctional permeabilities [47].  
1.4. Pannexin large pore channels 
In the year 2000, a novel family of channel forming proteins called pannexins (Panxs) were 
discovered due to their sequence homology to the invertebrate gap junction proteins, innexins 
[49,51]. However, pannexins do not share similar sequence homology to the connexin gene 
family found in vertebrates [50]. Compared to connexins, the pannexin family is much smaller 
and comprised of only three members; pannexin1 (Panx1), pannexin2 (Panx2), and pannexin3 
(Panx3) [51,52]. Structurally, pannexins pass the membrane four times and have two 
extracellular loops (EL1 and EL2), one intracellular loop (IL), transmembrane domains (TM1-
TM4), and an amino and carboxy terminus that faces the cytosol (Figure 1.3A) [53,54]. 
Pannexins oligomerize and traffic to the cell surface where they can allow small molecules and 
ions of less than 1kDa in size to pass from the intracellular to the extracellular milieu (Figure 
1.3B) [55,56]. Further, Panxs undergo posttranslational modification of glycosylation at 
asparagine residues present in their extracellular loops [57]. 
Panx1 is the most well characterized of the three family members and is ubiquitously expressed 
throughout the body including in the muscles, central nervous system, eye, inner ear, and 
olfactory epithelium [53,58–61]. Panx2 was originally shown to be mostly distributed in the 
central nervous system, however, recent studies have reported a wider distribution of Panx2 
such as the skin, eye, small intestine, and heart [49,62,63]. Panx3 is mainly found in high 
abundance within the skin, cartilage, and bone, although recent studies have reported low levels 
of Panx3 mRNA transcripts in hippocampus and low levels of protein expression in the 
ventricles of the heart [49,64]. 
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Figure 1.3. The structure of pannexin channels 
 (A) Prototypical topology of Panx1, Panx2, and Panx3 having four a-helical transmembrane 
domains, two extracellular loops (ECL), an intracellular loop (IL), cytoplasmic amino terminal 
(AT), and carboxy termini (CT). Figure obtained with permission from Penuela et al. 2013. 
(B) Upon arrival at the plasma membrane pannexin channels function as single membrane 
channels. Figure obtained with permission from Penuela et al. 2014.  
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The majority of studies have shown that Panxs form single membrane channels. In fact, only 
a few reported cases have suggested that Panxs can form gap junction channels and these 
studies focused mainly on over-expression systems in non-mammalian cell cultures [65–67]. 
Most laboratories now concur that Panxs are unable to form gap junction channels, a 
conclusion based on  a plethora of functional studies performed  in various cell types  such as 
MDCK, N2A, erythrocyte, neuronal, and glial cells [64,68–70]. The glycosylation of Panxs 
also makes it unlikely that they dock together to form gap junction channels due to the expected 
hindrance imposed by the glycosylated moieties [68,71]. Additionally, Panx channels do not 
cluster and pack to form semi-crystalline structures as seen in connexin gap junctions. Further, 
pannexins do not share the same complement of cysteine residues in the extracellular loops as 
seen in connexins suggesting that these differences may further impact pannexin folding and 
assembly properties [49,51,54,68,72]. Thus, most of the evidence points to Panxs forming 
single membrane channels at the plasma membrane that are tightly regulated in their ability to 
release small molecules from cells  [73,74]. 
The regulation of Panx1 channel function has been shown to be activated through various 
mechanisms including: increased extracellular ATP, increased intracellular Ca2+, increased 
extracellular K+, cell depolarization, voltage changes, P2X7-mediated activation, and 
mechanical stimulation [75–80]. In addition, Panx1 channels can be irreversibly opened by the 
cleavage of the C-terminal tail by caspase3 [81,82]. Once opened, Panx1 channels have been 
shown to release ATP which can lead to purinergic signaling, Ca2+ wave propagation, and 
recruitment of macrophages to initiate apoptosis [52,81,83]. Panx1 channels also allow the 
passage of small molecules up to 1 kDa in size including UTP, and dyes such as To-Pro [81,84]. 
The channel is thought to be negatively regulated by a feedback loop where ATP can bind to 
the extracellular loop to prevent further ATP release [85]. One of the main goals of this thesis 
is to investigate the importance of Panxs in hearing function. 
1.5.  GJB2 mutations in hearing loss 
The ubiquitous expression of different connexin isoforms within the human body makes it 
unsurprising that there are many diseases caused by connexin gene mutations [86]. Currently, 
ten different connexin family members have mutations that cause twenty-eight different 
human-linked diseases that have been identified, with hearing loss being the most prevalent 
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[87]. Connexin gene mutations linked to hearing loss may be inherited in either an autosomal 
recessive or dominant manner, and may present with hearing loss as the only symptom (non-
syndromic) or also be associated with additional phenotypes such as skin disease (syndromic) 
[88]. Clinically, mutations in GJB2 (encoding Cx26) and GJB6 (encoding Cx30) are 
responsible for nearly 50-60% of congenitally acquired sensorineural hearing loss [5,8]. In 
Canada, approximately 1-2 in 2000 children will be born with hearing impairment due to an 
inherited Cx26 gene mutation, leading to an estimated 35,000 Canadians that suffer from Cx-
linked congenital hearing loss [8,87]. Consequently, in developed countries, if a child is born 
with a hearing impairment they will first be genotyped for both loss- and/or gain-of function 
GJB2 gene mutations of which currently there are approximately 135 different ones [5,87]. 
The most common Cx26 mutation in European and North American populations is the 35delG 
deletion of a single guanine nucleotide resulting in a frameshift and premature termination of 
protein translation. This mutation has a carrier frequency of approximately 2-4% in the human 
population [8,89]. 
Hearing loss-linked Cx26 mutations can be placed into two broad categories where they may 
either produce a loss-of function or gain-of-function phenotype. First, loss-of-function mutants 
can result in defective trafficking to the plasma membrane, misfolding and retention in 
intracellular compartments, defective interactome binding, or the formation of non-functional 
hemichannels or gap junctions [90]. The majority of non-syndromic recessive Cx26 mutations 
that cause hearing loss are grouped into this category and many of these have been studied in 
vitro. For example, N14D, G59A, D66H, R143W, and R184P mutants are unable to form gap 
junction channels at the plasma membrane [91–95]. G12R, N14K, R75W, W77R, and L214P 
mutants are able to traffic to the plasma membrane but form non-functional gap junction 
channels [95-98]. N14Y, V84L, R127H, and N206S mutants alter the biochemical coupling of 
gap junction channels formed [99–102]. On the other hand, gain-of-function mutants can cause 
aberrant oligomerization with non-compatible connexins, interact with different binding 
partners, and increase hemichannel and/or gap junction channel function [87,90]. Interestingly, 
syndromic Cx26 mutants that are associated with skin diseases fall into this category such as 
the S17F, G45E, D50N, and M163L mutants where they have abnormal hemichannel opening 
[97, 103-104]. Although these studies have been conducted in overexpression systems in vitro, 
the trafficking patterns and function of these mutants has yet to be examined in a cochlear 
 15 
relevant cell line. Collectively, each Cx26 mutation has a distinct mechanism of action on gap 
junction function, with the majority being loss-of function mutants either not trafficking to the 
plasma membrane or forming non-functional gap junction plaques. Discovery of how each 
mutation affects the fate of Cx26 will provide insight as to the possible types of intervention 
that can be implemented in human patients. 
1.6. Cx43 and oculodentodigital dysplasia 
Oculodentodigital dysplasia (ODDD) was the first human disease found to be linked to 
mutations in GJA1, encoding for Cx43 [105]. The ODDD locus was originally mapped to 
human chromosome 6q22-q24, close to where the GJA1 gene is found on chromosome 6q21-
23.2 [106]. Over 80 different Cx43 gene mutations have been linked to ODDD and most are 
inherited in an autosomal dominant manner, with the exception of a few cases that exhibit 
autosomal recessive inheritance [107,108]. Cx43 is the most ubiquitously expressed gap 
junction protein in the human body, thus it is not surprising that patients with ODDD have 
many different symptoms. Patients with ODDD generally present with more common 
symptoms such as cranial facial abnormalities, deformities of teeth and eyes, as well as 
syndactyly and fusion of digits [105,109]. In addition, patients may also exhibit more rare 
symptoms such as neuropathies, skin diseases, bladder incontinence, and hearing loss (which 
is of particular interest in this thesis) with a wide range of phenotypic variability [109–112]. 
Attempts to study the role of Cx43 in tissue and organ development have been hampered by 
the fact that Cx43 knock-out mice are embryonically lethal due to defects in the cardiovascular 
system [113]. However, novel insights into the role of Cx43 in organogenesis have benefited 
from the use of Cre-flox mice where Cx43 can be specifically and conditionally eliminated 
from targeted cells/tissues and organs. For the studies performed in this thesis we have relied 
on the use of mutant mice that model ODDD where Cx43-based gap junctional coupling is 
either moderately or severely compromised. Whether hearing loss is evident in mouse models 
of ODDD was evaluated in this thesis. 
1.7. Inner ear development 
In mice, the otic placode, a thickening of the ectoderm, is the structure that develops into the 
inner ear and begins to form at E8-8.5 [114]. During development, the otic placode proceeds 
to invaginate to form the otocyst which will pinch off from the ectodermal surface at E8.5-9.5. 
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In humans, the otic placode forms and subsequently invaginates at approximately 4 weeks in 
utero [114]. The developed otocyst must then differentiate into the different portions of the 
inner ear and the organ of Corti that harbours the sensory receptors of the inner ear. This 
process includes a period of cell proliferation within the prosensory domain followed by 
differentiation of the post-mitotic progenitor cells into hair cells and supporting cells [115]. 
At E12.5 in the mouse, the prosensory domain is established where Notch1, Jagged1, and Sox2 
transcription factors are expressed in all cells of the cochlear epithelium [116,117]. P27Kip1, 
an inhibitor of cell proliferation, is expressed in the epithelium apex at E12.5 prior to being 
expressed at the epithelium base by E14, creating a wave of terminal cell cycle division 
[118,119]. This stage defines the “Zone of nonproliferating cells; ZNPC” [118] from which 
different transcription factors mediate their cell fate into either hair cells or supporting cells. 
The differentiation of both hair cells and supporting cells in the organ of Corti begins between 
E13 and E14 starting at the basal region of the cochlea and over the next 4 days spreads towards 
the apex [120,121]. Thus, the first cells that terminally exit the cell cycle (from apex) are the 
last to differentiate and vice versa. Fate mapping studies, creation of genetically modified mice, 
as well as recently acquired single cell analyses of the organ of Corti have provided an 
understanding of specific transcription factors that are involved in determining both hair cell 
and supporting cell specific factors [122–124]. The two different gap junction networks of the 
cochlea are developed at E16 and P0 within the mouse cochlea [125]. 
1.7.1. Specification of hair cell fate 
ATOH1, a basic helix-loop-helix transcription factor, is the earliest and most crucial 
transcription factor involved in cells destined for a hair cell fate. Mice with loss of Atoh1 do 
not develop hair cells [121] and Atoh1 overexpression in the inner ear is sufficient to induce 
ectopic hair cells [126,127]. Atoh1 mRNA is expressed at E13.5 in cells of the sensory 
epithelium and at E16.5-E18 the Atoh1 positive cells express Delta and Jagged2 mRNA, other 
hair cell specific markers [116,128–130]. At E17, only the four rows of hair cells express Atoh1 
and the surrounding cells turn off Atoh1; a process that designates their fate as supporting cells 
[128]. Between P0-P3, hair cell fate genes Atoh1, Delta, and Jagged1 are downregulated and 
by P7 are no longer expressed as progenitor cells are fully committed hair cells at this point 
[128, 130]. There is currently no evidence to suggest that connexins or pannexins are involved 
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in designating hair cell fate and they are not expressed in hair cells [132-135]. Additionally, 
there is no GJIC between hair cells and supporting cells [136]. 
1.7.2. Specification of supporting cell fate 
As hair cell differentiation proceeds, expression of two Notch effectors Hey1 and Hey2 become 
restricted to supporting cells [137]. Supporting cell fate is initiated by inhibition of Notch 
signaling within lateral compartments of epithelial cells, where progenitor cells surrounding 
hair cells are prevented from becoming hair cells [116,128,138]. In the same manner, Hey1 
and Hey2 act as transcriptional repressors to repress hair cell differentiation of progenitors, 
specifically the suppression of Atoh1; ultimately allowing for supporting cell fate 
determination [137,139]. At E16-E17, notch1, Jagged1, p27kip1, Prox1, Sox2, and Hes5 are 
localized specifically to supporting cells [117,131,140,141]. An important transcription factor 
in supporting cell fate determination, Sox2, is expressed in the initial prosensory domain of the 
epithelium and is retained exclusively in supporting cells of the mature cochlea [142]. Cx26 
and Cx30 are first expressed around E16, after supporting cells have already been fated, where 
they start to form a gap junction network within supporting cells of the epithelium. Once hair 
cells and supporting cells are fated, they then undergo postnatal maturation. Although 
connexins and pannexins are not involved in designating supporting cell fate, connexins are 
crucial in postnatal inner ear development as conditionally ablating connexins in early 
postnatal development leads to malformation of the organ of Corti and hair cell loss [143–145]. 
Recent studies using tamoxifen inducible mouse models have highlighted the importance of 
Cx26 in early cochlear development as knocking down Cx26 at P0 and P7, led to severe 
hearing loss and cochlear malformation while knocking down Cx26 at P8 and P30 did not 
cause any hearing loss and produced a normal organ of Corti [145–147]. Further, a study using 
varying doses of tamoxifen to create “high”, “mid”, or “low” Cx26 knock-down groups 
showed that hearing loss was severe, mild, and not observable in each respective group [143]. 
Collectively, these key studies suggest that connexins are involved in early cochlear 
development after progenitor cells have already been fated, and that they are crucial for proper 
organ of Corti formation and hearing in early but not later postnatal developmental stages.  
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1.8. Connexin expression in the inner ear 
Gap junctions of the mature inner ear assemble into two independent networks, the epithelial 
and the connective tissue gap junction networks, both predominantly expressing Cx26 and 
Cx30 [132,148]. The epithelial gap junction network is formed at E16 and is composed of all 
supporting cells of the organ of Corti whereas the connective tissue gap junction network 
(formed at P0) is localized in the cochlear lateral wall and includes strial basal and intermediate 
cells, and fibrocytes in the spiral limbus [132,149]. In addition, other Cx family members 
including Cx31, Cx30.3, Cx32, and Cx43 are expressed in the inner ear, albeit at lower levels 
then the predominant isoforms Cx26 and Cx30 [45,150]. The expression patterns of the less 
abundant Cx isoforms are as follows; Cx29 (a Cx isoform only found in mice) is expressed 
within supporting cells surrounding spiral ganglion neurons [151], Cx31 is expressed in 
fibrocytes of the spiral ligament [152], Cx30.3 has been reported in the spiral limbus and spiral 
ligament [153], and Cx32 is expressed in the cochlear nerve region [151]. Cx43 localization is 
described in the next section. Importantly Cx hemichannels composed of Cx26 and/or Cx30 in 
the inner ear have also been reported in the cochlea through the use of extracellular loop 
specific antibodies. Using this approach, both Cx26 and Cx30 have been localized to the apical 
regions of cochlear supporting cells of the organ of Corti facing the endolymph [154]. 
Although homomeric Cx26 and Cx30 gap junctions are found in the cochlea, 
immunoprecipitation and immunofluorescent studies have shown that Cx26 and Cx30 form 
heteromeric mixed channels [43,44,155,156]. However, a recent study showed that in the 
human cochlea Cx26 and Cx30 were mostly located in separate gap junction plaques [157].  
1.8.1. Cx43 in the inner ear and hearing 
Cx43 is the most ubiquitously expressed Cx found within the body and has been reported to 
be expressed in many different regions of the auditory system depending on developmental 
time point and species [158,159]. In the young mouse, Cx43 expression has been found in the 
spiral limbus, connective tissue gap junction network and weakly in the epithelial gap junction 
network up until approximately P7 [158,160]. In the adult mouse, Cx43 expression was mostly 
found in the cochlear bone and in the higher order auditory brainstem regions [158,159]. In 
rats, Cx43 has been documented in supporting cells of spiral ganglion neurons from P0-P14 
[161] and then in adult rats is redistributed to supporting cells in the organ of Corti, in the stria 
vascularis, and the spiral limbus [162,163]. In guinea pigs, Cx43 was reported to be expressed 
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in cells surrounding spiral ganglion neurons [164], while in the human fetal cochlea Cx43 is 
found in fibrocytes of the cochlear lateral wall [165]. Taken together, these studies suggest that 
the localization profile of Cx43 may differ depending on species and age. With the hopes of 
elucidating the functional role of Cx43 in hearing, a study examining Cx43 in slice preparations 
of the inferior colliculus of the auditory brainstem tract found that Cx43 formed a glial like 
syncytium allowing for rapid dye transfer through Cx43 gap junctions, indicating GJIC within 
this region [166].  
Although Cx43 is localized within distinct regions of the auditory tract, its role in physiological 
hearing was unknown at the beginning of my studies and is one of the central themes examined 
in this thesis. In a small cohort of patients two different Cx43 mutations, L11F and V24A were 
associated with non-syndromic hearing loss [160]. However, it was later identified that these 
mutations were found in the GJA1 pseudogene on chromosome 5 [105], where other Cx43 
hearing loss-linked mutations have also been found [167]. In a patient cohort from Taiwan, 
two patients with hearing loss were found to have a Cx43 T326S mutation [167]. Overall, these 
data suggest that both the localization and function of Cx43 in the auditory system warrants 
further investigation.  
1.9.  Mouse models used to assess connexins in hearing loss 
Due to the fact that Cx26 knock-out mice exhibit embryonic lethality [168] and mutations in 
Cx26 cause the vast majority of congenital hearing loss, genetically modified mice from 
conditional knock-out mice or mice harbouring specific human linked missense mutations have 
greatly enhanced our knowledge of the importance of gap junctions in hearing. Table 1 
includes a complete list of Cx26 conditional and missense mouse models created and their 
specific auditory phenotypes. 
1.9.1. Conditional knock-outs using cochlear-specific Cre mice 
Cre mice using different cochlear-specific transcription factors have been used to cross Cx26 
floxed mice; creating Cx26 knock-out models specific to different cochlear regions. This 
approach alleviates the embryonic lethality of Cx26 knock-out mice by specifically deleting 
Cx26 in different cochlear regions while maintaining Cx26 expression elsewhere.  
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Table 1.1. Genetically-modified mice used to assess Cx26 in hearing 
Mouse Model Phenotype ABR EP/DPOAE Reference 
Cx26fl/fl x Otog-
Cre 
P14: IHC and SC loss  
P15-P16 onwards: 
OHC and SC loss, OC 
collapse 
3-12 weeks: 
Elevated by 
~30-40dB 
across 
frequencies 
P12-P13: similar 
EPs  
Adult: EP 
decreased by 60% 
[149] 
Cx26R75W/+ 
 
 
P14: OC collapse, 
deformed supporting 
cells 
7 weeks: degeneration 
of OC, HCs and spiral 
ganglia 
2 and 7 weeks: 
Elevated by 
~70dB 
No change [169] 
Cx26fl/fl x 
RosaCreER 
 
TMX at E19 
P8 onwards: SC 
degeneration 
P14: OHC loss 
-Delayed postnatal 
development 
P21: Elevated 
by ~30-50dB 
Further at 2 and 
4 months 
N/A [170] 
 
Cx26fl/flx Foxg1-
Cre  
 
and Cx26fl/fl x 
Pax2-Cre 
 
 
P8: degeneration of 
Claudius cells  
P13: dramatic cell 
death in OHCs and 
SCs, delayed OC 
development 
P30: cell death and 
SGN degeneration 
Elevated by 
~40-50dB 
N/A 
 
[171] 
Cx26S17F/+ 
 
 
No changes Elevated by 
~35dB 
-129SV 
background 
reduced by 42mV  
-C57BL/6 
background 
reduced by 25mV 
[172] 
Cx26fl/fl x Sox10-
Cre 
 
 
P30:Degeneration of 
sensory epithelium 
,HC loss  
Loss of SGNs 
Elevated by 
~70dB across 
frequencies  
Decreased by 66% [173,174] 
Cx26fl/fl x Pax2-
Cre 
P12, P18, and P21: 
Loss of OHC 
stereocilia and 
cuticular plate 
damaged 
N/A N/A [175] 
Cx26fl/fl x Prox1-
CreER 
 
TMX at P0 
No substantial HC 
loss, no SGN 
degeneration 
 
Elevated by 10-
50dB across 
frequencies and 
progressively 
Normal EP 
DPOAE: Similar at 
4kHz but decreased 
at 16 and 24kHz  
(Zhu et al., 
2013) 
[177] 
 
Cx26fl/fl x Rosa-
CreER 
 
TMX: P1, P6, P12 
Malformed OC, hair 
cell loss only in P1 
and P6 groups 
SGN loss in P1 and 
P6 groups 
P1: 40dB 
elevation 
P6: 25dB 
elevation 
N/A [144] 
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P12: 20dB 
elevation  
Cx26fl/fl x Foxg1-
CreER 
 
TMX at different ages 
E19 or P4: 
Degeneration of OC 
cells and spiral 
ganglia, closure of 
tunnel of Corti 
P0-P8 and >P8: 
Decreased ribbon 
synapses and 
increased spontaneous 
activity 
E19 and P4: 
Elevated by 
~40dB across 
frequencies 
N/A [147] 
Cx26fl/fl x  
P0-CreER 
 
3 weeks: OHC 
morphology disrupted 
Disruption of gap 
junction plaques  
N/A N/A [178] 
[179] 
Cx26V37I/+ 
 
 
1 year: normal 
cochlear morphology  
Minor loss of OHCs 
6 weeks:  
25-30dB 
elevation at 24 
and 32kHz 
N/A [180] 
Cx26fl/fl x Prox1-
CreER 
 
TMX at E19 
No cochlear 
abnormalities 
Tunnel of Corti 
remained open 
N/A DPOAE: similar at 
13 and 22kHz but 
decreased at 33, 
42, and 52kHz 
[181] 
Cx26fl/fl x Rosa-
CreER 
 
TMX: P0 and P8 
P0: Phalangeal 
structures of Deiter’s 
cells did not develop 
properly 
Significant reduction 
of microtubules in 
Pillar cells 
Tunnel of Corti closed 
P8: No changes 
P0: 
Elevated by 
~40dB across 
frequencies 
P8: No changes 
N/A [145] 
Cx26fl/fl xRosa26-
CreER 
TMX: P0, random null 
group 
Cx26fl/fl x Lgr5-
CreER 
TMX: P0, 
longitudinally null 
group 
Random null group: 
No significant OHC 
loss 
Longitudinal null 
group: 
Significant OHC loss 
No significant Deiter 
cell or SGN loss was 
observed in either 
group 
Random null 
group: 
Normal hearing  
 
Longitudinal 
null group: 
Late-onset 
hearing loss 
N/A [182] 
Cx26fl/fl x Rosa-
CreER 
 
TMX (different doses) 
Deformed organ of 
Corti, and loss of 
Pillar cell 
microtubules in Mid 
and High knock-down 
groups 
 
No changes in low 
knock-down group  
Low Cx26 KD: 
No change 
Mid Cx26 KD: 
20-30dB 
elevation 
High Cx26 KD: 
40-50dB 
elevation 
DPOA: normal in 
Mid KD group 
[143] 
ABR-auditory brainstem response, DPOAE-distortion product otoacoustic emission, EP- 
endocochlear potential, IHC- inner hair cell, KD- knockdown, OC- organ of Corti, OHC- outer 
hair cell, SGN-spiral ganglion neurons, TMX- tamoxifen. 
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The transcription factors that have been used to create these mice include; Otog, Foxg1, Pax2, 
Sox10, Prox1, and the Protein0 (P0) gene transcription factors [183–187]. These transcription 
factors can be further divided into two subgroups where they are involved in (1) early 
embryonic develop of the cochlea or (2) expressed specifically in the cochlear epithelium. 
Foxg1, Pax2, and Protein0 transcription factors are crucial in proper embryonic development 
of the cochlea [183,185,187]. Foxg1 knock-out mice have shortened cochleae and multiple 
rows of hair cells, delineating the importance of this gene in early cochlear development [183]. 
Pax2 (Paired box gene 2) is also involved during embryonic development and is important for 
the outgrowth of the cochlear duct [185].  
Protein0 is also expressed specifically in the otic vesicle and in the early development of the 
cochlea in rats has been shown in nonsensory areas of the embryonic inner ear [188]. Although 
expressed in the embryonic inner ear, it is important to note that these transcription factors are 
also involved in the development of other organ systems. For example, Foxg1 is essential for 
proper brain development especially of the telencephalon which will further develop into the 
brain [189]. These studies collectively show that when Cx26 is lost early on in postnatal 
development, the organ of Corti does not develop properly, leading to both hair cell and 
supporting cell loss causing hearing loss. However, when Cx26 is ablated from the inner ear 
in later stages of postnatal development these phenotypes are not observed, highlighting the 
importance of Cx26 in early cochlear development.  
1.9.2. Mouse models of missense GJB2 mutations causing hearing loss 
To date three Cx26 mutant mouse models harboring human linked hearing loss mutations have 
been created to examine their auditory profile. First, the Cx26 R75W mutant which has been 
associated with Palmoplantar keratoderma-deafness (PPK) syndrome characterized by skin 
abnormalities (developing unusually thick skin on hands and soles of feet) and hearing loss 
(ranging from mild to profound in the human population) [190,191]. These mice, developed 
on a C57BL/6 background, had cochlear deformities including closure of the tunnel of Corti 
as well as severe broadband hearing loss, measured by a click stimulus, that was elevated by 
approximately 70 dB at both two and seven weeks of age [169]. At the functional level, the 
R75W mutant impairs gap junction plaque formation, which was associated with increased 
expression of caveolin1 and caveolin2 suggesting increased endocytosis [179]. This was found 
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to be a dominant negative mutant, where co-transfection of WT and Cx26 R75W into HeLa 
cells significantly hindered the function of WT Cx26 and WT Cx30 [93].  
Next the Cx26 S17F mutation was examined in genetically-modified mice as this mutation 
causes keratitis ichthyosis deafness syndrome (KIDS) leading to defects of the cornea, skin 
defects that included red and rough thickened patches of skin, and severe hearing loss. This 
mutant mouse was created on both the  C57BL/6 and 129Sv backgrounds and had poor 
survival; however, the few mutants that survived had epidermal barrier malformations, 
hyperproliferation of the skin, and moderate hearing loss of approximately 20-40 dB across a 
wide frequency range of 4 kHz to 32 kHz [172]. At the cellular level, this Cx26 mutation did 
not form functional gap junctions [172,192]. When co-expressed with WT Cx43, the Cx26 
S17F formed functional hyperactive heteromeric hemichannels [192,193], of which under 
normal conditions are not compatible to oligomerize [46].  
The V37I mouse was the first Cx26 mutant mouse created that is linked to recessive non-
syndromic hearing loss in the human population [180]. Mutant mice, that were generated on a 
129T2/SvEmsJ background, had significantly elevated hearing thresholds by approximately 
15-35 dB across a wide range of frequencies from 4 kHz to 32 kHz [180]. This degree of 
hearing loss mimicked the degree of hearing loss found in patients harboring this mutation 
[194]. Hearing loss was found to be progressive over a 50 week period [180]. Interestingly, 
there were no cochlear morphology deficits and only minor outer hair cell loss in one year-old 
mice. HeLa cells transfected with this Cx26 mutation had significantly reduced coupling 
compared to WT Cx26 [195]; classifying this mutant as loss of function. Together, these 
mutant mice provide us with clinically-relevant models to study Cx26 linked hearing and show 
that each hearing loss-linked Cx26 mutant can have variable auditory phenotypes. As 
highlighted, the R75W mutant caused severe hearing loss, while the S17F and V37I mutants 
caused mild-moderate hearing loss. We anticipate that the evaluation of the severity and 
function of Cx26 mutants in mouse models will assist in providing insights into possible 
treatments for hearing loss in humans.  
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1.9.3. Mouse models of GJB6 mutations causing hearing loss 
Although the involvement of GJB2 in hearing is crucial for hearing, the importance of GJB6, 
encoding for Cx30, in hearing has been controversial. Table 1.2 includes a list of mouse models 
used to study Cx30 in hearing. Currently, no GJB6 mutations have been linked to recessively 
inherited hearing loss, however, three missense mutations have been associated with autosomal 
dominantly inherited hearing loss in the human population (T5M, G59A, A40V) [196–198]. 
The Cx30-T5M mutant mouse was found to have mild hearing loss and a significant decrease 
in Cx26 and Cx30 protein expression in the cochlea [199]. Further, dye transfer in cochlear 
supporting cells was reduced, suggesting that this mutant impacts GJIC within the cochlea 
[199]. 
Overexpression of Cx30-A40V mutant in vitro led to its retention in the Golgi apparatus and 
it had a dominant negative effect on both WT Cx30 and Cx26 function [198]. The trafficking 
pattern of the Cx30-G59A mutant has not yet been examined, however, the Cx26 G59A mutant 
was mostly retained within the Golgi apparatus with a small population trafficking to the 
plasma membrane forming defective channels [91]. Additionally, another GJB6 mutant, 
A88V, causes Clouston syndrome which is an autosomal dominant disorder where patients 
present with alopecia, and skin deformities. However, patients with the A88V mutation do not 
typically present with hearing loss. In fact a mouse model for the Cx30-A88V mutant was 
generated and found to rescue age related high-frequency hearing loss in mutants compared to 
their WT controls [200–202]. Interestingly, when the Cx30-A88V mutant was overexpressed 
in in vitro systems, including a cochlear relevant cell line, it exhibited toxic effects and 
ultimately caused cell death [200,203]. The mechanisms by which A88V mice have improved 
hearing requires further investigation.  
The original Cx30-/- mouse that was created had severe hearing loss with an approximately 50 
dB hearing threshold shift in P18 mice [204]. Cx30-/- mice also lacked an endocochlear 
potential and had a significantly decreased endolymphatic K+ concentration, both of which are 
necessary for proper hearing function [204].  
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Table 1.2. Genetically-modified mice used to assess Cx30 in hearing 
Model Phenotype ABR EP/DPOAE Ref. 
Cx30-/- 
 
 
Normal development 
up to P17 
P18: Gradual loss of 
sensory cells 
4 months: extensive 
HC loss 
Het mice no difference 
P17-P18: 50dB 
elevation in nulls 
Adult nulls (4 months) 
had no detectable ABR 
P13-P14:  
74mV vs 0mV 
 
Adult: 83mV vs 
3mV 
[205] 
Cx30T5M/+ Reduced Cx30 
expression by approx. 
1/3 in T5M mice 
Normal morphology 
in adult mice 
Electrical coupling 
similar 
 
Elevated by approx. 
15dB  
No difference 
121.2mV vs. 
122.2mV at P21-
P28 
[199] 
Cx30Δ/Δ Normal gross 
cochlear anatomy 
No change across 
frequencies 
N/A [206] 
Cx30A88V/+, 
Cx30A88V/A88V 
 
Syndromic 
hearing loss 
 
Normal gross 
cochlear anatomy  
 
Reduced Cx30 
expression in lateral 
wall of Cx30A88V/A88V 
mutant mice 
6-9 weeks: 
homozygous mice 
approx. 20dB elevation 
at low freq. tones  
-High freq. approx. 
40dB improvement in 
homozygotes also 
DPOAEs improved 
N/A [181,200,201] 
ABR-auditory brainstem response, EP- endocochlear potential, DPOAE: distortion product 
otoacoustic emission. 
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Further, the barrier of endothelial cells within capillaries of the stria vascularis was disrupted, 
and hair cell loss was observed in Cx30-/- mice compared to controls [170, 207]. However, it 
was later shown that Cx26 was significantly downregulated at both the mRNA and protein 
levels within cochlear supporting cells in Cx30-/- mice, suggesting that their hearing loss may 
be attributed to the loss of Cx26 [208]. To address this hypothesis, a second Cx30 null mouse 
(Cx30Δ/Δ) was created where Cx26 expression in the cochlea was preserved [206]. 
Interestingly, hearing was normal in Cx30Δ/Δ mice and indistinguishable from control mice, 
and no cochlear deficits were observed [206]. Taken together, these studies suggest that Cx26 
and Cx30 are closely regulated within the cochlea and that loss of Cx30 does not lead to hearing 
loss as long as Cx26 expression is maintained.  
1.10. Functions of connexins and gap junctions in the inner ear 
1.10.1. Potassium recycling and buffering 
The structural arrangement of two independent gap junction networks within the inner ear led 
to the original proposal that gap junctions were involved in maintaining proper potassium (K+) 
homeostasis. K+ is necessary for depolarization of hair cells in sound acquisition and thus K+ 
ions that exit hair cells after sound stimulation are then taken up by supporting cells 
immediately surrounding hair cells [209]. In support of this, cochlear supporting cells express 
K+ channels such as Kir4.1 [210,211]. Subsequently, the ions are then transferred through the 
epithelial gap junction network and are excreted to the connective tissue gap junction network 
through root cells where K+ may then be taken up by fibrocytes of the spiral ligament and 
secreted back into the endolymph by marginal cells of the stria vascularis through KCNQ 
channels [209,212,213]. In this manner, K+ ions are continuously being replenished in the 
endolymph region where it is necessary to maintain the positive endolymphatic potential. This 
arrangement is similar to what is observed in the glial network of the brain where connexins 
allow for spatial buffering of K+ [214]. Like above, this model allows for the redistribution of 
K+ ions from regions of high K+ concentration to areas of low K+ concentration in order to 
alleviate neural toxicity. To support this in the cochlea, it has been reported that shortly after 
birth cochlear supporting cells express glial fibrillary acidic protein (GFAP), a typical marker 
of glial cells, which after P15 is mostly restricted to supporting cells surrounding hair cells, 
suggesting that cochlear supporting cells have similarities to glial cells in the central nervous 
system which also express abundant GFAP [215]. However, it is important to note that this 
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hypothesis has been challenged due to the premise that not all Cx26 mutations cause decreased 
endolymphatic potential which would be expected if this was the sole function of gap junctions 
in the inner ear [216, 217]. 
1.10.2. Glucose and miRNA transport 
The epithelium of the organ of Corti is avascular and as such it has been hypothesized that gap 
junctions play a role in nutrient transport and cell nourishment. In flattened cochlear 
preparation samples, Cx30 null mice had decreased dye transfer in cochlear supporting cells 
including a decrease in transfer of 2-NBDG, an analog of glucose [218]. To further support 
this hypothesis another study showed that 6-NBDG, another glucose analog, was rapidly 
distributed through the spiral ligament and stria vascularis where Cx26, Cx30, and glucose 
transporter 1 (GLUT1) were colocalized [219]. Transfer of 6-NBDG was inhibited by 
carbenoxolone and octanol gap junction blockers, suggesting the importance of gap junctions 
in glucose uptake in the lateral wall [219].  
Micro RNAs (miRNAs) are small non-coding RNAs that have been reported to pass through 
gap junction channels where they can regulate gene expression by degrading mRNA targets 
[220, 221]. MiRNA-96 and -183 have been documented to be important in inner ear and hair 
cell development [222, 223]. For example, miRNA-183 is expressed during otic vesicle 
formation and involved in invagination to the otic placode [224]. In isolated preparations of 
cochlear supporting cells, miRNA-96 was found to transfer to neighbouring Hensen’s cells 
which was further blocked by gap junctions blockers and eliminated in Cx26 knock-out mice 
[225]. Therefore, it is reasonable to suggest that connexins may play a functional role in 
cochlear development by allowing transport of miRNAs that are essential in hearing.  
1.10.3. Connexin hemichannels: ATP release and purinergic signaling 
Recent evidence suggests that connexins may not only traffic to the plasma membrane for the 
sole purpose of docking with an adjacent connexin to form a gap junction, but that connexins 
may remain functional as undocked transmembrane channels [226]. Connexin hemichannels 
have been documented to preferentially open under conditions of low extracellular Ca2+ 
concentrations or through K+ stimulation, conditions not normally seen in healthy tissues. 
Thus, connexin hemichannels have been mostly studied in the context of pathological disease 
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such as ischemia and cardiovascular injury [227, 228]. Interestingly, the cochlear endolymph 
houses a unique ionic composition including high K+ and low Ca2+ (20 µM) concentrations, 
which would favour Cx hemichannel opening [229]. To support the hypothesis that Cx 
hemichannels are present in the inner ear, antibodies directed against the extracellular loop of 
Cx26 have been reported to bind to the apical domains of cochlear supporting cells in mouse 
organotypic cochlear cultures [154] suggesting that hemichannels exist in these cells. Further, 
with exposure to low Ca2+ concentration, guinea pig cochleae exhibited increased uptake of 
fluorescent dyes into supporting cells [230]. 
Connexin hemichannels can also release ATP that could bind to purinergic receptors on hair 
cells and supporting cells to initiate the propagation of Ca2+ waves. Cochlear cultures from 
mice lacking Cx26 failed to propagate calcium waves when ATP was applied [231]. Cx 
hemichannels can also release IP3, which is expressed in the epithelium of the inner ear [232]. 
Before the onset of hearing, inner hair cells spontaneously release glutamate onto spiral 
ganglion neurons which is necessary for their maturation [233]. Spontaneous ATP release was 
increased when subjected to low extracellular Ca2+ concentrations and was blocked with the 
addition of gap junction blockers, carbenoxolone and octanol. Lastly, the importance of Cx 
hemichannels in hearing is supported by the notion that many Cx26 hearing loss linked 
mutations that cause syndromic hearing loss (with various skin disorders) have aberrant 
hemichannel function. For example, the S17F KID syndrome mutant which causes a gain of 
function phenotype through aberrant oligomerization of Cx26 and Cx43 ultimately causing 
enhanced hemichannel activation and cell death [192]. 
1.11. Pannexin expression and function in the inner ear 
Increasing evidence has suggested a role for Panxs in proper auditory function in keeping with 
the fact that all three Panx isotypes have been found to be expressed along distinct regions of 
the auditory tract [135]. Specifically, Panx1 has been reported to be expressed centrally in 
neurons of the superficial and deep layers of the auditory cortex, and peripherally within the 
inner ear, including supporting cells of the organ of Corti [234, 235]. Panx2 is expressed in the 
cochlear lateral wall and in the boundary of the stria vascularis, and Panx3 is expressed in the 
cochlear bone [135, 235].  
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In the cochlea, ATP is found within both fluid filled spaces of the cochlea, the endolymph and 
the perilymph. Since Panx1 is known to act as an ATP release channel it was thought that 
pannexins served a role in ATP release within the inner ear, however, there have been 
contradictory reports on this conclusion. First, organotypic cochlear cultures from Panx1-/- 
mice had no effect on ATP release, suggesting that Panx1 was not necessarily the predominant 
ATP release channel in the cochlea [231]. However, a second study showed that mice with a 
conditional Panx1 ablation in the inner ear abolished ATP release in the cochlea [236]. ATP is 
an essential secondary messenger in the cochlea and can elevate intracellular Ca2+ 
concentration in hair cells modifying sound transduction, activating P2X receptors for various 
physiological processes such as EP generation, and synchronizing auditory nerve activity 
during development [233, 237, 238]. In addition, conditionally ablated Panx1 knock-out mice 
had decreased active cochlear amplification; a process that is required for outer hair cell 
motility [236]. The mechanisms behind these findings are unclear since Panx1 is not expressed 
in hair cells, and thus may be contributing to cochlear amplification in an indirect manner. 
1.11.1. Mouse models used to assess pannexins in hearing 
Shortly after pannexins were discovered to be expressed in the auditory system, various 
genetically-modified mice using either conditional ablation in the inner ear or global knock-
out models have been evaluated. Table 1.3. summarizes a list of mouse models used to assess 
pannexins in hearing. The two conditional knock-out mice created were done by crossing 
Panx1-/- mice with Pax2-cre and Foxg1-cre mice where both these transcription factors are 
involved in otocyst and embryonic development.  
Panx1 conditional knock-out mice using the Pax2cre and Foxg1cre mice were created on a 
C57BL/6 background. Both of these knock-out mice had mild-moderate (i.e. 10-30 dB 
threshold shift) sensorineural hearing loss at 8-, 16-, 24-, 32-, and 40 kHz tones and caused cell 
degeneration in the cochlea [236, 241]. They also showed that Panx1 is the predominant ATP 
release channel in the cochlea [236]. In contrast, it was previously shown that cochlear cultures 
from Panx1-/- mice were able to propagate intracellular calcium waves, suggesting no deficits 
in their calcium signaling [231]. It was further demonstrated that a global Panx1 knock-out 
mouse did not have auditory deficits even at high frequencies (32 kHz) [239]. 
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Table 1.3. Genetically-modified mice used to assess pannexins in hearing 
Mouse Model Phenotype ABR EP/DPOAE Reference 
Panx1-/- global 
knock-out 
B6;129-
Panx1tm1.1Fama/Cnrm 
Normal Ca2+ 
signal propagation 
in cochlear 
cultures 
N/A N/A [231] 
 
Pax2Cre;Panx1Fl/Fl Cell degeneration 
in Pax2Cre-
Panx1-/- mice 
10dB threshold shift 
(low freq.) 
20-30dB threshold 
shift (high freq.) 
DPOAE 
significantly 
reduced in 
Pax2Cre-Panx1-
/- mice 
[241] 
Foxg1Cre;Panx1Fl/Fl No hair cell loss 
and decreased 
ATP release in 
Foxg1Cre-Panx1-
/- mice 
20-30dB threshold 
shift at all 
frequencies 
EP and CM 
were 
significantly 
reduced in 
Foxg1Cre-
Panx1-/- mice 
[236] 
Panx1-/- global 
knock-out 
B6;129-
Panx1tm1.1Fama/Cnrm 
Normal cochlear 
morphology 
Normal ABRs; no 
hearing loss 
Normal 
DPOAEs 
[239] 
Panx1-/- global 
knock-out  
(Genentech) 
No loss of hair 
cells 
 
 
10-15dB threshold 
shift (low-mid freq.) 
30-40dB threshold 
shift  
(high freq.) 
DPOAEs and 
CM 
significantly 
reduced in 
Panx1-/- mice 
 
 
[240] 
ABR-auditory brainstem response, EP- endocochlear potential, DPOAE: distortion product 
otoacoustic emission. CM- cochlear microphonics. 
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However, one laboratory found that mice globally lacking Panx1 had mild hearing loss (i.e. 
10-15dB threshold shift) in frequencies at or below 24kHz but this hearing loss was more 
pronounced at higher frequencies of 32- and 40kHz with approximately 20-30dB shift [240]. 
Based on these previous findings one of our main objectives was to assess the auditory 
phenotype of globally ablated Panx1 knock-out mice to address these discrepancies. 
1.12. Pannexins and compensation 
Since all three pannexin channels share similar topology to one another, current research 
suggests that global loss of one pannexin family member could be compensated by the 
upregulation of another family member. Panx1 and Panx3 channels are the most similar to each 
other sharing 73.3% similarity at the amino acid level [242,243]. The first reports of 
compensation were observed in Panx1-/- mice where Panx3 protein expression was 
significantly upregulated in both skin and thoracodorsal arteries compared to WT controls 
[244, 245]. 
Similar findings were also found in the vomeronasal organ (VNO) where Panx3 mRNA and 
protein expression was upregulated in the VNO of Panx1-/- mice [243]. In addition, these 
authors found that Panx1 and Panx3 had similar dye uptake and ATP release efficiencies in 
N2A cells in vitro, suggesting that Panx3 may compensate for Panx1 at the functional level 
[243]. Evidence of pannexin compensation led researchers to create double knock-out mice in 
an effort to minimize the effects pannexin compensation may play on a tissue phenotype.  
The first pannexin double knock-out mouse created was Panx1-/-;Panx2-/- mice with the 
purpose of studying brain ischemia. Interestingly, after recovery of middle cerebral artery 
occlusion to induce stroke, brains of Panx1-/-;Panx2-/- mice had significantly smaller infarct 
sizes and better functional outcomes compared to both WT and both single pannexin knock-
out mice [246]. These studies highlighted the fact that single pannexin knock-out mice, 
although informative, have limitations as other pannexin family members may serve a 
compensatory role; hence single knock-out mice may be inadequate in revealing certain 
phenotypes. Therefore, it was deemed important to examine auditory phenotypes of mice 
lacking both Panx1 and Panx3 which is the subject of chapter 3 of my thesis.  
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1.13. Noise-induced hearing loss 
Intense and chronic exposure to loud sounds causing noise-induced hearing loss (NIHL), 
remains one of the most common causes of hearing loss. A large study in the United States 
showed that approximately 12.5% of American children and young adults had NIHL [247]. 
Hearing loss due to exposure to loud noises may be transient and temporary (i.e. temporary 
threshold shift) or if severe enough could lead to permanent hearing damage (i.e. permanent 
threshold shift) [248]. NIHL generally damages higher-frequency regions of 4 kHz as a 
primary target, that can then progress to neighboring frequencies of 3-6 kHz, which are 
especially important in daily speech recognition [249]. Many primary cochlear pathologies 
arise with NIHL including hair cell loss, spiral ganglion neuron degeneration, and swelling of 
the stria vascularis [250][251]. Spiral ganglion neuron degeneration can even last for months 
to years after noise-exposure [252]. 
The mechanisms of noise-induced hearing loss remains an active area of research and includes 
mechanical damage to the cochlea and biochemical pathways that induce cell death, 
particularly in the hair cells. Rodent studies have confirmed that NIHL increases apoptotic 
markers of cell death in the cochlea such as caspases, tumour necrosis factors, and 
morphological nuclear changes [253–255]. Noise-exposure causes an increase in the amount 
of cochlear ROS which peaks at approximately 7-10 days after noise-exposure, and then tends 
to decrease over time [256]. The transient increase in ROS leads to hair cell death and spiral 
ganglion neuron degeneration. To support the notion that ROS plays a critical role in NIHL, 
pre-administration of antioxidants to the cochlea have been shown to protect against noise 
damage [257]. In addition, the mitogen-activated protein kinase (MAPK) pathways, which can 
also be activated by ROS, are increased after noise-exposure in animal models [258, 259]. 
Additionally, noise damage causes an increase in the intracellular Ca2+ concentration of hair 
cells, particularly in the outer hair cells, which can trigger cell death [260]. Noise damage also 
causes a decrease in blood flow in the capillaries of the stria vascularis, which can lead to 
ischemia in this area and negatively impact the positive endolymphatic potential [261]. If the 
level of noise-exposure is sufficient enough to cause substantial hair cell death then hearing 
loss is irreversible.  
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On the other hand, the damage incurred by either shorter or less intense exposure to noise can 
result in a temporary hearing threshold shift (TTS). The result of a TTS is when hearing 
recovers to baseline levels in hours to weeks following the noise damage [248]. The 
mechanisms are distinct from permanent NIHL, and studies have found that loss of inner hair 
cell afferents may be the primary cause [262]. In fact, studies have shown swelling of inner 
hair cell afferents after noise exposure which is thought to be due to excessive release of 
glutamate at the synapse leading to excitotoxicity [263]. TTS can also be due to outer hair cells 
stereocilia breaking off from the tectorial membrane, which can be reversed subsequently 
leading to hair cells being saved [264]. In this manner, hair cells are not lost leading to hearing 
preservation in the long term. In a mouse model designed to induce only temporary noise-
induced hearing loss, it was found that hair cell synapses between hair cells and cochlear 
neurons can be destroyed well before the hair cells are damaged and can cause a delay in 
cochlear nerve degeneration [252]. 
1.13.1. The role of connexins in noise-induced hearing loss 
The link between NIHL and gap junctions was originally proposed when it was shown that rats 
exposed to loud noise had increased Cx26 protein expression in the cochlear lateral wall [265]. 
However, another study found that noise-exposure led to decreased Cx26 protein expression 
that also correlated with a decrease in Na/K ATPase [266]. No changes in mRNA and/or 
protein levels were detected in Cx30 or Cx43 after noise-exposure [266]. Using tamoxifen-
inducible conditional knock-out mice, it was found that mice with reduced Cx26 expression at 
P30 and P45 had enhanced susceptibility to noise-induced hearing loss and increased hair cell 
loss as a consequence of noise exposure compared to WT controls [267]. Finally, after mice 
were exposed to a loud noise-exposure, GJIC was significantly reduced in dissociated spiral 
ligament cultures, suggesting that noise-exposure has a direct impact on gap junctions in the 
spiral ligament of the cochlear lateral wall [268]. Currently only one patient cohort study has 
examined the correlation between Cx26 mutations and NIHL. In a cohort of 703 patients, 
carriers of the most common Cx26 deletion involved in hearing loss, 35delG, did not have 
enhanced susceptibility to NIHL [269]; although future studies using larger cohorts may be 
needed to further evaluate a potential correlation between connexin mutations and NIHL. 
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1.14. Cisplatin-induced ototoxicity 
One of the most effective and commonly used chemotherapy drugs to treat solid tumors in 
cancer treatment is cisplatin (cis-diamminedichloroplatinumII). This drug has been widely 
used in testicular, ovarian, bladder, cervical, lung, head and neck cancers in both young 
children and adults [270]. Side effects of cisplatin chemotherapy include nephrotoxicity, 
neurotoxicity, and ototoxicity causing hearing loss [271]. While nephrotoxicity can be 
routinely managed through saline fluid absorption and diuretics, there are currently no 
treatments for neuro- or ototoxicity. Cisplatin-induced hearing loss occurs in approximately 
75-100% of patients that undergo treatment and can range from moderate to severe in nature 
[272]. Children in particular generally exhibit severe hearing loss as a consequence of cisplatin 
treatment which can significantly hinder their cognitive and speech skills throughout their 
development [273, 274].  
Although cisplatin is a highly effective chemotherapeutic agent, it causes significant hearing 
loss in many patients which is usually progressive and irreversible [270,275]. Hearing 
impairment in individuals can be variable in its severity and can depend on the concentration 
and accumulation (one administration or multi-dose) of the drug [276]. Generally, cisplatin 
causes high frequency hearing loss in humans (approximately 6-8 kHz) [277,278]. Within the 
cochlea, cisplatin induces cell death in three main locations. The most studied consequence is 
hair cell loss and structural damage with the outer hair cells being more preferentially impacted 
[279, 280]. Since then studies have found that cisplatin first causes damage to the stria 
vascularis on the cochlear lateral wall, a structure that is essential for the transport of potassium 
ions to the endolymph as well as damage to supporting cells in the organ of Corti [281–283]. 
Finally, cisplatin causes degeneration of the spiral ganglion neurons as well as disorganization 
of their afferents to hair cells [284, 285]. GJIC has been postulated to play an important role in 
cisplatin-induced cell death through the “bystander effect” whereby gap junctions transfer 
toxic compounds from cell to cell [286]. Alternatively, gap junctions may also be involved in 
transferring beneficial compounds to neighboring cells, thereby diluting toxic compounds 
known as the “Good Samaritan” effect [287]. 
Although the exact molecular mechanisms are unknown, cisplatin produces reactive oxygen 
species (ROS) accumulation within cells [288, 289]. These free radicals can then bind to 
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protein, DNA, or nucleic acid to cause cell death. Cisplatin can also directly bind to 
mitochondrial DNA causing cisplatin-DNA adducts leading to mitochondrial dysfunction 
[290]. Generation of ROS triggers apoptosis within cells by altering the mitochondrial 
membrane potential and damaging the electron transport chain [291]. One of the enzymes that 
can produce superoxide radicals that can lead to the formation of hydrogen peroxide, in the 
cochlea is an isoform of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
NOX-3, which is specifically expressed in the cochlea [292]. Cisplatin activates NOX-3, 
leading to an increase in superoxide formation, which has been shown to be increased in 
cisplatin-treated rats [292].   
The specific compounds and/or signals that pass through gap junctions as a consequence of 
cisplatin treatment are not fully known but could include reactive oxygen species, reactive 
nitrogen species, superoxide radicals, calcium, and/or IP3 [293–295]. It is also important to 
note that based on the charge and size of cisplatin (300 Da), it too can theoretically pass through 
a gap junction channel. In vitro studies have suggested that Cx43 can act to enhance cisplatin-
induced cell death of HEI-OC1 cells [296]. Further, downregulation of Cx43 in HEI-OC1 cells 
through siRNA or application of 18a-GA gap junction blocker, mildly protected auditory cells 
against cisplatin-induced ototoxicity [296]. It was also found that cisplatin treatment itself 
caused a decrease in GJIC and Cx expression in HEI-OC1 cells, which is due to direct 
interaction of cisplatin with Cx channels thereby reducing their expression levels [296–298]. 
To support these findings, in vitro studies have shown that cisplatin-induced cell death is most 
extensively observed when cells are plated at high density suggesting GJIC plays a key role in 
this process [299,300]. However, some cell death is still observed after cisplatin treatment in 
low density in vitro cultures of different cell lines, suggesting that there may also be some gap 
junction-independent functions involved [299, 300]. 
1.14.1. Structure/activation of cisplatin 
Cisplatin is a platinum based compound surrounded by two chloride and two amine ligands, in 
turn having a square planar structure and a half-life between 1.5-3.6 hours [301]. Cisplatin 
concentrations in patient plasma levels ranges from approximately 10-25 µM [298, 302]. For 
cisplatin to take its chemotherapeutic effect it must first be taken up by the cell. Although some 
cisplatin may passively diffuse through the plasma membrane of the cell, the most efficient 
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and studied mechanism of uptake of cisplatin are copper transporter such as CTR1, CTR2, and 
organic cation transporters 1 and 2 (OCT1, OCT2) [279,303]. Once cisplatin enters the cell, it 
undergoes hydrolysis by replacement of a H2O molecule for a chloride ion which is favored 
due to the low concentration of Cl- ions inside the cell relative to the extracellular environment 
(100 µM) [304]. The hydrolyzed cisplatin then binds to a single nitrogen of a purine base of 
DNA. Subsequently, the other chloride ion gets replaced for another H2O molecule and the 
platinum ion binds to another nitrogen of the DNA, thereby crosslinking DNA causing cell 
damage [270, 304].  
1.14.2. Uptake/efflux of cisplatin from cochlear cells 
The high incidence of cisplatin-induced hair cell loss is due to the fact that hair cells express 
an abundant amount of copper transporters that are involved in cisplatin uptake including Ctr1, 
OCT2, and OCT1 [303,305]. These transporters, located on the apical regions of hair cells, 
enable a rapid and efficient influx of cisplatin into hair cells where cisplatin will then elicit the 
DNA repair response ultimately leading to cell death [275]. Importantly, supporting cells and 
spiral ganglion neurons were reported to also express OCT2 copper transporter [306]. Cisplatin 
is moved out of the cell through two specific efflux transporters ATPase7A, expressed in hair 
cells, and ATPase 7B, expressed in pillar supporting cells [285].  
1.15. Modelling the inner ear using organotypic cochlear cultures 
The inner ear is extremely complex to study due its complex structure and encapsulation within 
the cochlear bone. One challenge that is faced in inner ear biology remains the inability of hair 
cells to be immortalized. Inner ear ex vivo explants from rodents have now been used for 
approximately 40 years and offer a method of maintaining the full organ of Corti including the 
hair cells, and supporting cells [307]. These organotypic cochlear cultures have been widely 
used to study the function and structure of the inner ear and have been extensively used to 
study ototoxicity of various drugs [308, 309]. Therefore, this thesis will make use of 
organotypic cochlear cultures derived from different connexin mutant mice in order to more 
readily examine molecular processess involved in ototoxicity. Figure 1.4 shows a diagram 
illustrating the structure and cell types within organotypic cochlear cultures that will be used 
in this thesis. 
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Figure 1.4. Schematic diagram of organotypic cochlear culture  
 (A) Ex vivo preparation of the organ of Corti in an organotypic cochlear culture. These cultures 
are ideal for assessing the effect of drug treatment in an in vitro environment. 
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1.16. HEI-OC1 immortalized cochlear cells as a tool to model the in vivo 
cochlea 
In depth functional studies of the inner ear are hindered by the small size and working 
availability of the cochlea making it difficult to evaluate complex in vivo cellular processes. 
To circumvent these obstacles Dr. Federico Kalinec and his group derived an immortalized 
cell line from organotypic cochlear cultures of the immortomouse, HEI-OC1 cells [310]. In 
this manner, the in vitro cell line can act as a tool to examine molecular functions, including 
connexin functions, that can be extrapolated to the in vivo mouse from which this cell line was 
derived. HEI-OC1 cells mimic cochlear progenitor cells of which, in the in vivo setting, would 
be later fated to become either sensory (hair cells) or non-sensory (supporting cells) [310, 311].  
Due to the temperature sensitivity of cells obtained from the immortomouse, in permissive 
conditions these cells stay in a de-differentiated state as cochlear progenitors. However, under 
non-permissive conditions (33ºC, 10% CO2), HEI-OC1 cells will differentiate into a “hair cell-
like” phenotype expressing and upregulating markers that are expressed in hair cells such as 
myosinVI and prestin [310, 312]. Therefore, to evaluate cellular mechanisms of connexins in 
hearing, HEI-OC1 cells (generously obtained from Dr. Kalinec) will be used in this thesis as a 
tool to assess specific cellular processes that we would be otherwise unable to examine in the 
cochlea.  
1.17. Mouse models used in this study 
To examine the roles of Panx1, Panx3, and Cx43 in the auditory system, we have obtained 
and/or generated five different genetically modified mice. First, the Panx1-/- mice were 
originally obtained from Genentech [313]. Since then they have been backcrossed to C57BL6 
mice for approximately 5 generations. Second, the Panx3-/- mice were generated in house and 
were previously characterized in regards to their gross phenotypes [314]. To eliminate the 
possibility of Panx1 and Panx3 compensating for one another, we generated the first Panx1 
and Panx3 double knock-out mouse in house through crossing heterozygous Panx1+/- and 
Panx3+/- mice together and selecting for double null mice. The Cx43I130T/+ mutant mice were 
generated by site-directed mutagenesis with mice maintained on a mixed C57BL/6 and CD1 
background and backcrossed to C57BL/6 mice for over 5 generations [315]. These mice were 
generously obtained from Dr. Glen Fishman’s laboratory. The Cx43G60S/+ mutant mice were 
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generated by using an ENU mutagenesis approach whereby this mouse model phenotypically 
mimicked ODDD and has therefore been used as a mouse model to study this disease [316]. 
These mice were generously obtained from Dr. Janet Rossant’s laboratory. Both the Cx43I130T/+ 
and the Cx43G60S/+ mutant mice have a moderate (50%) and severe (80%) reduction in Cx43 
gap junctional intercellular communication, respectively, as has been demonstrated in different 
in vitro and in vivo tissue culture systems such as cardiomyocytes, mammary glands, and 
granulosa cells [315–319].  
1.18. Rationale 
It has been well known for two decades now that GJB2 mutations cause the majority of 
congenitally acquired hearing loss. GJA1 has also been documented within the literature to be 
expressed in the inner ear, however its expression pattern and function remains unclear. 
Importantly, the function of Cx43 in the auditory system remains unknown. Thus, we sought 
to further investigate the importance of Cx43 in hearing using two different Cx43 mutant mice 
that mimic a human linked disease, ODDD and examine their auditory phenotypes. Further, 
since Panx1 conditional knock-out mice have been documented to have hearing loss, we 
evaluated the auditory profiles of a global Panx1 and Panx3 knock-out mouse. Given that 
Panx1 and Panx3 may compensate for one another we further created a Panx1/Panx3 double 
knock-out mouse to eliminate the potential of compensation between these large pore channels 
and examined their auditory phenotypes. Finally, since Cx43 has been proposed to be involved 
in cisplatin-induced ototoxicity in cancer cell lines, Cx43 may also affect cisplatin induced cell 
death in cochlear relevant cells; including organotypic cochlear cultures from Cx43 mutant 
mice as well as an immortalized cochlear cell line. 
1.19. Hypothesis 
It is hypothesized that deletions of Panx1 and/or Panx3 will cause hearing loss, and Cx43 
mutants will cause hearing impairment, and enhanced vulnerability to ototoxicity.  
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1.20. Objectives  
 
The overall research objectives of this thesis are the following: 
 
Objective 1 – Manuscript 1: Chapter 2 
Determine the importance of Panx1 and Panx3 in mouse hearing before and after loud noise-
exposure. 
 
Objective 2 – Manuscript 3: Chapter 3 
Characterize a novel Panx1 Panx3 double knock-out mouse and assess the impact on hearing. 
 
Objective 3 – Manuscript 2: Chapter 4  
Examine auditory function and susceptibility to noise-induced hearing loss in mice harboring 
a disease-linked Cx43 mutant. 
 
Objective 4 – Manuscript 4: Chapter 5 
Investigate the consequence of Cx43 mutations and gap junction blockage on the 
susceptibility of organotypic cochlear cultures to ototoxicity. 
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Chapter 2 : Differential effects of pannexins in noise-induced hearing 
loss 
 
Pannexins have previously been shown to be localized to distinct regions of the mammalian 
cochlea. Previous studies have shown controversial results whereby some mice with Panx1 
ablation have hearing loss while others so not. The purpose of this study was to examine mice 
with global ablation of Panx1 to determine if these channels are important in auditory function. 
In addition, the second goal of this study was to examine the impacts of globally ablating Panx3 
in a mouse model to determine whether Panx3 is important in hearing.  
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter is published:  
Abitbol JM, Kelly JJ, Barr K, Schormans AL, Laird DW, Allman BL. Differential effects of 
pannexins on noise-induced hearing loss. Biochem J. 473(24):4665-4680, 2016.  
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2.1. Introduction 
Hearing loss is one of the most disabling sensory deficits, affecting approximately 360 million 
people worldwide [1]. Currently, cochlear implants and hearing aids are the most commonly 
used interventions for managing hearing impairment. The lack of drug therapies for hearing 
loss hinges upon the fact that the molecular aspects and mechanisms that regulate the 
transduction of sound waves into electrical impulses along the auditory pathway are not fully 
understood.  
Connexin (Cx) channels, which allow the passage of small molecules and ions between cells 
and their external environments, make up the two gap junction networks of the inner ear [2]. 
These networks are formed before hearing onset [3] and are essential for cochlear ionic and 
metabolic homeostasis and maintenance of the endocochlear potential [2, 4-6]. Although Cxs 
are not expressed in the sensory receptor hair cells of the cochlea [7-10], they are still critical 
for hearing as loss of Cx26 and Cx30 function mutations lead to deafness [2, 11, 12]. Recently, 
it was discovered that a unique family of glycoproteins that share similar topology to Cxs, 
called Pannexins (Panxs), are expressed in the cochlea and other resident cell types of the 
auditory pathway [13, 14]. Pannexins, of which there are three subtypes (Panx1, -2, and -3), 
are all proposed to form single membrane channels at the cell surface but they may also serve 
other roles that have yet to be characterized [15, 16]. These channels connect the extracellular 
and intracellular environments by allowing the passage of small members of the metabolome 
across the plasma membrane [17, 18]. By far, the most understood and studied member of the 
pannexin family is Panx1. Panx1 plays a role in many cellular processes, such as Ca2+ wave 
propagation, ATP release, and apoptosis [19-21].  
Under normal conditions, Panx1 channels may be opened via mechanical stimulation, 
intracellular calcium, extracellular potassium, ATP, membrane depolarization, and caspase3 
cleavage [19-23]. In contrast, Panx1 channels are blocked by the negative feedback of ATP, 
carbon dioxide-mediated acidification, or in the presence of channel blockers such as 
probenecid and carbenoxolone [23-26]. In the cochlea, Panx1 expression was found in the 
spiral limbus, the spiral prominence in the cochlear lateral wall, Reissner’s membrane, spiral 
ganglion neurons, and supporting cells of the organ of Corti, including pillar cells, Hensen 
cells, Boettcher cells, and Claudius cells [13, 14, 27]. In addition, Panx1 mRNA expression 
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was found in neurons of the auditory cortex [28]. Similar to Cxs, Panx1 was not detected in 
the hair cells that are responsible for initiating the transduction of electrical impulses through 
the auditory pathway [14].  
 
Recently, mice lacking Panx1 in a subset of cells in the cochlea were generated through the 
crossing of Panx1 floxed mice with Paired box 2 (Pax2) Cre mice and were shown to exhibit 
sensorineural hearing loss [29]. Another study crossed Panx1 floxed mice with a Forkhead box 
G1 (Foxg1, which is required for proper morphogenesis of the cochlea [30]) Cre mouse line 
and showed that these mice also exhibited hearing loss [31]. The hearing loss in these mice 
may be linked to the finding that Panx1 is reported to be a predominant ATP release channel 
in the cochlea [31]. ATP acts as a signalling molecule in the inner ear, regulates 
mechanoelectrical transduction processes, and maintains proper cochlear mechanics [32-35]. 
To further support a possible role for Panx1 in hearing, a human patient was recently identified 
that harbored a loss-of-function PANX1 gene mutation. This patient exhibited sensorineural 
hearing loss, required bilateral cochlear implants from a young age, and had neurological 
deficits among multiple symptoms [36]. Therefore, increasing evidence suggests the 
importance of Panx1 in hearing when conditionally ablated within the inner ear. However, a 
conditional ablation does not account for expression of Panx1 along the entire auditory 
pathway, including its presence within the auditory cortex [28]. Therefore, it is important to 
assess the comprehensive and developmental role of Panx1 in the entire auditory pathway from 
hair cell transduction to the transmission of electrical impulses along the successive relay 
nuclei in the central auditory system. 
Compared to Panx1, Panx3 appears to have a more restricted expression pattern, being found 
mostly in bone, skin, and cartilage tissues [22, 37-40]. Panx3 plays a role in the differentiation 
of chondrocytes and osteoblasts, and is involved in growth and development of bone [37, 38, 
41]. Panx3 has recently been described in the cochlea, where it was found to be expressed in 
the cochlear bone and the modiolus of the inner ear [14]. Sound conduction through the middle 
ear bones and the cochlea can be impaired by improper bone growth, leading to otosclerosis 
[42]. Patients with otosclerosis often show signs of sensorineural hearing loss due to improper 
bone growth in the middle ear and/or the cochlear bone, which ultimately affects sound 
transduction to the hair cells and neurons within the inner ear [43]. In addition, loss of proteins 
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that assist in endochondral ossification in the ear lead to deafness in mice, and abnormalities 
in middle ear bone formation can leave them in a non-functioning state [44, 45]. Therefore, 
because Panx3 is important in bone, it may be essential for proper middle and inner ear bone 
formation and morphology, but this has yet to be examined.  
Since Panxs have recently been implicated in baseline hearing, it is reasonable to predict that 
they may also be involved in noise-induced hearing loss. Approximately 5% of the population 
worldwide will suffer from industrial, military, or recreational noise-induced hearing loss, 
which is most commonly caused by loss of hair cells due to apoptosis [46, 47]. Hair cells as 
well as cochlear neurons do not regenerate, and as a consequence, excessive exposure to loud 
noise can result in permanent hearing loss. Currently, there are no completely-accepted 
pharmacological treatments for noise-induced hearing loss, thus emphasizing that the 
development of molecular targets to prevent or reduce noise-induced hearing loss is essential 
[46]. Due to the expression of Panx1 in the inner ear and its role in ATP release and Ca2+ 
propagation functions, as well as the expression of Panx3 in the cochlear bone; both Panx1 and 
Panx3 may be potential molecular candidates implicated in noise-induced hearing loss through 
cochlear homeostasis and/or sound conduction. Thus, we set out to evaluate the impact of 
Panx1 and Panx3 ablation on acute loud noise-damage and recovery.  
To that end, we have obtained and/or generated Panx1 and Panx3 null mice, to account for the 
potentially broad distribution of both Panxs along the entire auditory pathway. In the present 
study, we assessed if these Panx channels are crucial in baseline hearing and/or noise-induced 
hearing loss, and we evaluated the importance of Panx3 in the development of the middle ear 
bones. In contrast to our expectations, we discovered that Panx1 and Panx3 are not necessary 
for baseline hearing. However, mice lacking Panx3, but not Panx1, are partially protected from 
acute loud noise-damage. 
 
2.2. Materials and methods 
2.2.1. Animals 
Pannexin1 null mice (Panx1-/-) were obtained from Genentech (San Francisco, CA) and were 
previously described [48]. Briefly, the targeting construct used loxP sites to flank exon2 and 
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its deletion was achieved by breeding to the ubiquitously active Cre deleter mouse, C57BL/6-
Gt(ROSA)26Sortm16(Cre)Arte (TaconicArtemis) and has since been backcrossed several times to 
C57BL/6 mice, allowing Cre recombinase to have been bred out. Mice were genotyped to 
confirm Panx1 ablation using the following primers; Forward: 5’-GGA GAA GCA GCT TAT 
CTG G-3’, Reverse: 5’-ACT GTG CAA TAC TAC ACG GA-3’. Panx1 expression has been 
shown to be ablated in several organs of these mice including; muscle, lung, liver, kidney, tail, 
brain, heart, thymus, spleen and skin tissues, validating this mouse model as a Panx1-/- mouse 
[48-50]. Panx3 null mice (Panx3-/-) were bred in-house and were previously described [51]. 
Briefly, Panx3 floxed mice were crossed with C57BL/6 Cre deleter mice (B6.C-Tg(CMV-
cre)1Cgn/J; Jaxmice #006054). Cre recombinase was bred out following generation of the 
Panx3-/- mouse line. Mice bred on the same background (C57BL/6) were used as age and sex 
matched wildtype (WT) controls. Mice were genotyped to confirm Panx3 ablation using the 
following primers; Forward: 5’-TGC CCT CCA CAG AAA GCT ACC-3’, Reverse: 5`-GGC 
CAG CCT TGT CCT GCG TAT G-3’. All mice tested were male and 2-3 months of age (P60-
P90) unless otherwise stated. Mice were housed in the animal care facility at the University of 
Western Ontario, and maintained on a 12/12- hour light/dark cycle and fed ad libitum. Animal 
experiments were approved by the Animal Care Committee on animal care of the University 
of Western Ontario. 
 
2.2.2. RNA Extraction and RT-PCR 
Following euthanasia by CO2, cochleae were dissected from mice and flash frozen in liquid 
nitrogen. RNA was extracted from tissues using a Qiagen RNeasy mini kit (catalog #74104) 
and an RNAse Free Dnase kit (catalog #79254) or by a combination of Trizol reagent, Qiagen 
RNeasy mini kit, as well as RNase Free Dnase treatment modified from a previous publication 
[52]. A Nanodrop spectrophotometer was used to measure absorbance of RNA. Subsequently, 
one-step RT-PCR was performed using an RT-PCR Qiagen kit (catalog #210210). The PCR 
profile was as follows: 50°C for 30 minutes, 95°C for 15 minutes, 94°C for 30s, 64°C for 30s 
and 72°C for 1 minute for 30 cycles. Panx1 specific primers (forward: 5’-ACA GGC TGC 
CTT TGT GGA TTC A-3’ and reverse: 5’-GGG CAG GTA CAG GAG TAT C-3’) and Panx3 
specific primers (forward: 5’-TTT CGC CCA GGA GTT CTC ATC-3’ and reverse: 5’-CCT 
GCC TGA CAC TGA AGT TG-3’) were used. 18s rRNA was used as a control (forward: 5’- 
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GTA ACC CGT TGA ACC CCA TT-3’ and reverse: 5’-CCA TCC AAT CGG TAG TAG CG- 
3’). The amplified products were run on a 2% agarose gel with ethidium bromide for 
visualization. 
 
2.2.3. Quantitative RT-PCR 
Following euthanasia by CO2, cochleae were dissected from mice and flash frozen in liquid 
nitrogen. RNA was extracted as described above and converted into cDNA using a SuperScript 
VILO cDNA Synthesis kit (Thermo-Fisher catalog #11754050). Two-step qPCR reactions 
were performed using a SYBR Green PCR master mix by Life Technologies (catalog 
#4309155) in order to quantify Panx1 and Panx3 expression in the cochleae. The Panx1 PCR 
protocol was as follows: 50°C for 2 min, 95°C for 2 min, 95°C for 3 sec, 60°C for 30 sec, for 
40 cycles followed by a melt curve. The Panx3 PCR protocol was as follows: 50°C for 2 min, 
95°C for 2 min, 95°C for 3 sec, 65°C for 30 sec, for 40 cycles followed by a melt curve. Panx1 
and Panx3 transcripts were normalized to 18S rRNA transcript level. The same primers as 
mentioned above were used for Panx1 and Panx3. The following primers were also used in 
this study; Cx26; (forward: 5’-CCGTCTTCATGTACGTCTTTTACAT- 3’ and reverse: 5’ 
ATACCTAACGAACAAATAGCACAGC- 3’), Cx30; (forward: 5’- 
GGCCGAGTTGTGTTACCTGCT- 3’ and reverse: 5’- TCTCTTTCAGGGCATGGTTGG- 
3’), Cx43; (forward: 5’- ACAACAAGCAAGCCAGCGAG- 3’ and reverse: 5’- 
TCGTCAGGGAAATCAAACGG- 3’), and Panx2; (forward: 5’- 
TGGTACCCATCCTGCTGGT- 3’ and reverse: 5’- GGGTGAAGTTGTGCGGAGT- 3’). For 
all three Cxs and Panx2 the PCR profile was as follows: 50°C for 2 min, 95°C for 2 min, 95°C 
for 5 sec, 60°C for 15 sec, followed by a melt curve. 
 
2.2.4. Immunoblotting 
Following euthanasia by CO2, cochleae and brain tissues were dissected from mice, flash 
frozen in liquid nitrogen, and stored at -80°C. For cochlear tissues, a litter of mice 
(approximately 6-10 cochleae) were pooled together for one lysate due to the small amount of 
tissue. Cochleae were crushed using a mortar and pestle with liquid nitrogen, and protein was 
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extracted using a Triton-X 100 based immunoprecipitation buffer as previously described [22]. 
Lysates (30 µg) were run on 10% polyacrylamide gels using SDS-PAGE and protein was 
transferred to a nitrocellulose membrane using an iBlot transfer machine (Invitrogen). 
Membranes were blocked with 3% bovine serum albumin (BSA) in Tween-PBS for one hour. 
Blots were probed overnight with custom-made site directed antibodies; anti-Panx1 (CT-295) 
at a 1:2500 dilution, and anti-Panx3 (CT-379) at a 1:5000 dilution as previously described [22]. 
Blots were then washed and stained with AlexaFluor 680 secondary antibody (1:5000 dilution, 
Life Technologies) for two hours and subsequently stained with anti-mouse GAPDH (1:10000 
dilution, Chemicon) as a loading control. IRdye800 (1:5000 dilution, Rockland) was used as 
the secondary antibody for GAPDH. Membranes were visualized with an Odyssey infrared 
imaging system (LiCor).  
 
2.2.5. Hearing Assessment with an Auditory Brainstem Response 
Hearing levels were determined using the auditory brainstem response (ABR), which measured 
the electrical activity in the brainstem evoked by the repeated presentation of a given acoustic 
stimulus. Mice were anaesthetized using a combination of ketamine (100 mg/kg) and xylazine 
(10 mg/kg) administered via intraperitoneal injections (i.p.), and positioned in a double-walled 
sound-attenuating chamber. The electrical activity of the ABR was recorded by subdermal 
electrodes (27 gauge; Rochester Electro-Medical, Lutz, FL) that were positioned at the vertex 
(active electrode), over the mastoid of the stimulated (right) ear (reference electrode), and on 
the mid-back (ground electrode). Throughout the ABR recordings, body temperature was 
maintained at ~37°C using a homeothermic heating pad (507220F; Harvard Apparatus, Kent, 
UK).  
Acoustic stimuli were generated by a Tucker-Davis Technologies (TDT, Alachua, FL) RZ6 
processing module at 100 kHz sampling rate and delivered by a magnetic speaker (MF1; TDT) 
positioned 10 cm from the animal’s right ear. The left ear was occluded with a custom foam 
earplug. Acoustic stimuli for the click ABR and noise exposure procedure (described below) 
were calibrated with custom Matlab software (The Mathworks, Natick, MA) using a ¼-inch 
microphone (2530; Larson Davis, Depew, NY) and preamplifier (2221; Larson Davis) and 
tonal acoustic stimuli were calibrated using BioSig software by Tucker-Davis Technologies 
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(TDT, Alachua, FL) using a ¼-inch microphone (2530; Larson Davis, Depew, NY) and 
preamplifier (2221; Larson Davis). 
The auditory evoked activity of the ABR was collected using a low-impedance headstage 
(RA4L1; TDT), preamplified and digitized (RA16SD Medusa preamp; TDT), and sent to a 
RZ6 processing module via a fiber optic cable. The signal was filtered (300 – 3000 Hz) and 
averaged using BioSig software (TDT). Acoustic stimuli consisted of a click (0.1 ms) and four 
tones (4, 8, 16 and 24 kHz; 5 ms duration and 1 ms rise/fall time). The click stimulus served 
as an indicator of general hearing, as it encompasses a range of frequencies that stimulate the 
cochlea. Mouse hearing frequency ranges from approximately 1-100 kHz [53] and thus the 
different tonal stimuli tested provided a measure of frequency-specific hearing sensitivity, as 
each tonal frequency stimulates a restricted portion of the cochlea. The click and tonal stimuli 
were each presented 1000 times (11 times/second) at decreasing intensities from 90 to 50 dB 
sound pressure level (SPL) in 10 dB SPL steps. From 50 dB SPL to ~15 dB SPL, the successive 
steps were at 5 dB, with each sound level presented twice in order to best determine ABR 
threshold offline. Ultimately, for each of the stimuli (click and 4-24 kHz tones), an 
experimenter who was blinded to the animal cohort and treatment condition determined the 
ABR threshold using the criteria of just noticeable deflection of the averaged electrical activity 
within the 10-ms time window [54].  
 
2.2.6. Noise Exposure 
For a subset of mice, the initial ABR was followed immediately by a loud noise exposure while 
the mice were maintained under anesthesia. While positioned in the double-walled sound-
attenuating chamber, mice were bilaterally exposed to a calibrated 12 kHz tone at 115 dB SPL 
for one hour. The tone was generated with TDT software and hardware (RPvdsEx; RZ6 
module), and delivered by a super tweeter (T90A; Fostex, Tokyo, Japan) which was placed 10 
cm in front of the mouse. A homeothermic heating pad was used to maintain body temperature 
at ~37 °C, and supplemental doses of ketamine and xylazine were administered as needed to 
maintain anesthesia. Immediately following the noise exposure, ABR thresholds were re-
assessed. Mice were then given antipamezole (1 mg/kg) to reverse anesthesia effects, and 
allowed to recover in their home cage. Seven days after noise exposure, mice were once again 
anesthetized and a final ABR recording was performed to determine the extent of permanent 
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hearing damage incurred by the loud noise exposure. Upon completion of the final ABR 
recordings, mice were then euthanized by cervical dislocation while under deep anesthesia, 
and tissue samples were collected for further processing.  
 
1.2.7 Auditory Ossicle Dissection and Imaging 
In a subset of 2-3 month old WT and Panx3-/- mice, the three auditory ossicles (malleus, incus 
and stapes) contained within the middle ear were carefully microdissected. Ossicles were fixed 
in 4% PFA overnight and then imaged using a Zeiss light microscope. An experimenter blinded 
to the treatment groups used ImageJ software to make measurements of the ossicles, including 
the length of the malleus, distance between the tips of the incus, and length of the stapes 
window.  
 
1.2.8  Statistical analysis 
Two-tailed independent unpaired student T-tests were used for comparisons for ABR wave I 
analysis between WT and Panx1-/- as well as WT and Panx3-/- mice, and the measurements of 
middle ear bone morphology between WT and Panx3-/- mice. One-way analysis of variance 
(ANOVA) with a Tukey’s posthoc test was used to compare Panx1, Panx2, Panx3, Cx26, 
Cx30, and Cx43 expression by qPCR in WT, Panx1-/-, and Panx3-/- cochleae. Two-way 
ANOVA was used to compare WT, Panx1-/- and Panx3-/- groups for ABR thresholds with a 
Sidak’s post hoc test. Two-way repeated measure ANOVAs were used for noise exposure 
analysis (where each individual frequency was analyzed separately), followed by a Sidak’s 
post hoc test. All statistical analyses were performed using GraphPad Prism 6.0, *p<0.05. 
N≥3 for all experiments. 
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2.3. Results 
2.3.1. Panx1 and Panx3 are expressed in the cochlea and are ablated in 
knock-out mice 
To confirm that both Panx1 and Panx3 knock-out mice had pannexins ablated from the cochlea, 
we used RT-PCR and qRT-PCR to determine the mRNA levels for Panx1 and Panx3 in 2-3 
month-old WT, Panx1-/-, and Panx3-/- cochleae. We found that both Panx1 and Panx3 mRNA 
transcripts were expressed in the cochlea of WT mice and were ablated in their respective 
knock-out cochleae as revealed when normalized to 18S rRNA (Figure 2.1A-D). Interestingly, 
there was no evidence of Panx1 or Panx3 compensation in the cochleae of their reciprocal null 
mice (Figure 2.1C-D). Western blots for Panx1 at postnatal day 1 and 8 (P1 and P8), revealed 
the loss of Panx1 in mutant mice, where age and sex matched brains were also used as controls 
(Figure 2.1E).  
 
2.3.2. Panx1-/- and Panx3-/- mice do not exhibit reduced hearing sensitivity or 
cochlear nerve deficits 
To assess baseline hearing sensitivity in mice lacking Panx1 or Panx3, we measured ABR 
thresholds in response to various acoustic stimuli (click and 4-24 kHz tones). ABR trace 
recordings from a representative WT, Panx1-/-, and Panx3-/- mouse had similar waveform 
characteristics in response to a click stimulus at decreasing sound levels (90 to 30 dB SPL; 
Figure 2.2A). To further validate the finding that mutant mice had normal hearing, the ABR 
waveform traces for a 90 dB SPL click stimulus were averaged for each group (WT: n=17, 
Panx1-/-: n=17, Panx3-/-: n=18) to create a composite ABR waveform for each group of mice 
(Figure 2.2B). There were no observable deficits in ABR waveforms in either Panx1-/- or 
Panx3-/- mice (Figure 2.2B). Furthermore, there were no significant differences in ABR 
thresholds between WT and Panx1-/- or Panx3-/- mice at any of the stimuli tested (click and 4-
24 kHz tones; Figure 2.2C-D). Additionally, we examined the amplitudes and latencies of the 
first wave of the ABR (wave I), which is representative of the activity at the level of the 
cochlear nerve, in response to a click stimulus at 90 dB SPL as well as 20 dB above the animal’s 
ABR threshold, to determine if there were any deficits in neuronal synchrony or speed, 
respectively, at this point in the auditory pathway. We found that there were no differences in 
cochlear nerve amplitude or latency between WT and Panx1-/- mice, indicating no neuronal 
deficits within this region (Figure 2.2E,G). 
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Figure 2.1. Panx1 and Panx3 are expressed in the cochlea and are ablated in knock-out 
mice  
RT-PCR of cochlear RNA confirmed Panx1 (A) and Panx3 (B) mRNA transcript expression 
in wild-type (WT) cochleae and loss of expression in knock-out cochleae. 18S rRNA was used 
as a reference gene. NTC+ P= No template control + primer, NTC= No template control. Panx1 
(C) and Panx3 (D) mRNA expression was quantified in WT, Panx1-/-, and Panx3-/- cochleae 
using RT-qPCR (N=3 (biological replicates), n=9 (technical replicates)) for all groups; P<0.01; 
one-way ANOVA). (E) Postnatal day 1 (P1) and P8 brain and cochlear protein lysates showed 
Panx1 expression with the expected glycosylated banding pattern (Gly0, Gly1, and Gly2). 
There was no Panx1 expression in the brain or cochleae of Panx1-/- mice (-/-). An unspecific 
band was observed above the Gly2 species (E). (F) Panx3 was developmentally regulated in 
the cochleae of P1, P8, P16, and 2 month (2M)-old wildtype and Panx1-/- mice. 
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Figure 2.2. Panx1-/- and Panx3-/- mice do not exhibit hearing or vestibulocochlear nerve 
deficits. 
 (A) Representative examples of a click stimulus for WT, Panx1-/-, and Panx3-/- mice. (B) ABR 
waveforms for a click stimulus were averaged together to create a composite waveform for 
WT, Panx1-/-, and Panx3-/- mice. (C) ABR thresholds showed no difference between WT and 
Panx1-/- mice for all stimuli tested. (D) Similarly, ABR thresholds showed no difference 
between WT and Panx3-/- mice for all stimuli tested. Amplitudes and latencies of wave I, the 
vestibulocochlear nerve, for a 90dB and 20dB above threshold click stimulus were analyzed. 
There were no differences in wave I amplitudes (E) or latencies (G) between WT and Panx1-/- 
mice. (F) At a 90dB click stimulus, Panx3-/- mice had a significant increase in the amplitude 
of the vestibulocochlear nerve compared to WT mice, (*p<0.05, unpaired t test). However, 
there was no difference at 20dB above threshold. (H) There were no differences observed in 
the latencies of ABR wave I at 90dB or 20dB above threshold between WT and Panx3-/- mice. 
WT: n=18, Panx1-/-: n=17, Panx3-/-: n=17. Bars represent mean ABR threshold ± SEM.  
  
 78 
 
 
 
A
B
H
E
G
F
WT Panx1-/- Panx3-/-
90
80
70
60
50
45
40
35
30
90
80
70
60
50
45
40
35
30
25
90
80
70
60
50
45
40
35
30
dB dB dB
DC
9 0  d B  C lic k 2 0  d B  A b o v e  T h re s h o ld
0 .0
0 .4
0 .8
1 .2
W
a
ve
 I
 A
m
p
lit
u
d
e
 (
µ
V
) W T
P an x1 -/ -
9 0  d B  C lic k 2 0  d B  A b o v e  T h re s h o ld
0 .0
0 .5
1 .0
1 .5
2 .0
W
a
ve
 I
 L
a
te
n
cy
 (
m
s)
Click 4 8 16 24
0
20
40
60
AB
R
Th
re
sh
ol
d
(d
B
SP
L ) WT
Panx1-/-
kHz Tone
Click 4 8 16 24
0
20
40
60
AB
R
T h
r e
sh
ol
d
( d
B
SP
L) WT
Panx3-/-
kHz Tone
9 0 d B  C lic k 2 0 d B  A b o v e  T h re s h o ld
0 .0
0 .4
0 .8
1 .2
W
a
ve
 I
 A
m
p
lit
u
d
e
 (
µ
V
) W T
P an x3 -/ -
*
9 0 d B  C lic k 2 0 d B  A b o v e  T h re s h o ld
0 .0
0 .5
1 .0
1 .5
2 .0
W
a
ve
 I
 L
a
te
n
cy
 (
m
s)
Figure 2.2
 79 
To our surprise, Panx3-/- mice had significantly increased wave I amplitudes compared to WTs 
in response to the 90 dB SPL click stimulus; however, there were no differences observed in 
wave I latencies (Figure 2.2F, H). Taken together, these results suggest that gene ablation of 
Panx1 or Panx3 does not lead to sensorineural hearing loss nor any deficits at the level of the 
cochlear nerve.  
 
2.3.3. WT and Panx1-/- mice are equally susceptible to noise-induced hearing 
loss 
To assess whether Panx1 channels play a role in noise-induced hearing loss, we exposed WT 
and Panx1-/- mice to a loud noise (12 kHz tone at 115 dB SPL for 1 hour) and let them recover 
for seven days following the exposure. ABR thresholds were recorded for each stimulus (click 
and 4-24 kHz tones) at three time points: (1) baseline, (2) immediately after noise exposure 
(Post NE) and (3) seven days after noise exposure, in an attempt to discern whether ablation 
of Panx1 channels would exacerbate or protect against acoustic trauma. At baseline, there were 
no differences observed in click, 4, 8, 16 or 24 kHz ABR thresholds between WT and Panx1-/- 
mice, (Figure 2.3A-D; 8 kHz data not shown). Immediately after noise exposure, ABR 
thresholds were significantly elevated in both WT and Panx1-/- mice compared to baseline 
(Figure 2.3A-D), with the most severe elevation in ABR threshold being at the higher 
frequencies, 16- and 24 kHz tones (Figure 2.3C-D). There were no differences between WT 
and Panx1-/- ABR thresholds immediately after noise exposure at any of the stimuli tested 
(Figure 2.3A-D), suggesting that a similar auditory insult occurred in both groups. Seven days 
after noise exposure, ABR thresholds recovered near baseline levels at the low-frequency 
stimuli (Figure 2.3A-B), with no difference between WT and Panx1-/- ABR thresholds. As 
expected after exposure to a loud 12 kHz tone for 1 hour, ABR thresholds were still elevated 
seven days later at the 16 kHz (WT: 86 ± 2 dB SPL; Panx1-/-: 86.5 ± 3 dB SPL) and the 24 kHz 
(WT: 86 ± 1.6 dB SPL; Panx1-/-: 86.5 ± 2 dB SPL) stimuli, but there were no differences found 
between WT and Panx1-/- mice. Collectively, these results suggest that ablation of Panx1 does 
not impact noise-induced hearing loss.  
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Figure 2.3. WT and Panx1-/- mice show similar susceptibility to noise-induced hearing 
loss. 
Noise exposure caused a significant increase in ABR thresholds immediately after noise-
exposure (Post NE) for (A) click, (B) 4 kHz, (C) 16 kHz, and (D) 24 kHz tonal stimuli, 
confirming auditory damage in both WT and Panx1-/- mice. The highest ABR thresholds Post 
NE were found at the higher frequency stimuli, (C) 16 kHz and (D) 24 kHz tones. However, 
there were no significant differences between WT mice 7 days after noise-exposure (7 days 
after NE). ABR thresholds recovered slightly but did not recover to baseline levels at any of 
the stimuli. At all three different time points, there were no significant differences between 
WT and Panx1-/- mice. Two-way repeated measures ANOVAs were performed for each 
individual stimuli. WT: n=10, Panx1-/-: n=10. Bars represent mean ABR threshold ± SEM. 
P<0.05, ns = not significant. 
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2.3.4. Panx3-/- mice exhibit enhanced 16- and 24 kHz hearing recovery after  
loud noise exposure 
Panx3-/- mice were exposed to a loud 12 kHz tone for 1 hour to assess whether Panx3 channels 
play an important role in noise-induced hearing loss. At baseline, there were no differences 
observed in ABR thresholds of click, 4, 8, 16 or 24 kHz tones between WT and Panx3-/- mice 
(Figure 2.4A-D; 8 kHz data not shown). Immediately after noise exposure, ABR thresholds 
were significantly elevated compared to baseline levels at all stimuli, with the most severe 
elevation occurring at the higher frequencies, 16- and 24 kHz tones (Figure 2.4C-D). WT and 
Panx3-/- mice showed a similar elevation of ABR threshold for all of the stimuli tested (Figure 
2.4A-D). Seven days after noise exposure, ABR thresholds recovered to baseline levels at the 
lower frequencies, with no differences found between WT and Panx3-/- mice (Figure 2.4A-B). 
Interestingly, seven days after noise exposure, Panx3-/- mice had significantly less hearing loss 
at both the higher frequency stimuli (16- and 24 kHz) tested, as indicated by lower ABR 
thresholds than those observed in the WT mice (Figure 2.4C-D). The most profound 
enhancement of post-noise exposure recovery was found at the 16 kHz stimulus (WT: 86dB ± 
2dB, Panx3-/-: 66dB ± 5dB), where the Panx3-/- mice showed approximately a 20 dB 
improvement in hearing recovery compared to the WT mice (Figure 2.4C). Collectively, these 
data suggest that ablation of Panx3 has a protective function against exposure to a single bout 
of loud noise.  
 
2.3.5. Panx3-/- mice have morphological changes of inner ear bones 
We examined the morphological characteristics of the middle ear bones (malleus, incus, and 
stapes) to determine if ablation of Panx3 would alter their formation during development. 
Representative images of each middle ear bone from both WT and Panx3-/- mice revealed that 
there were no gross changes in anatomical structures (Figure 2.5A). However, analysis of the 
total length of the malleus (i.e. distance from the head of the malleus to the end of malleus) 
was significantly decreased in Panx3-/- mice (WT: 1.6 mm± 0.014, Panx3-/-: 1.54 mm± 0.014; 
Figure 2.5A-B). In addition, the distance between the processes of the incus was significantly 
increased in Panx3-/- mice (WT: 0.59 mm ±0.009, Panx3-/-: 0.62 mm ±0.006; Figures 2.5A-C).  
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Figure 2.4. Panx3-/- mice have enhanced recovery 7 days after auditory insult. 
Noise-exposure caused a significant increase in ABR threshold immediately after noise-
exposure (Post NE) for (A) click, (B) 4 kHz, (C) 16 kHz, and (D) 24 kHz tonal stimuli, 
confirming auditory damage in both WT and Panx3-/- mice. Following noise exposure, the 
highest ABR thresholds Post NE were found at the higher frequency stimuli, (C) 16 kHz and 
(D) 24 kHz tones. ABR thresholds for each stimulus recovered to some degree 7 days after 
noise-exposure but did not reach baseline ABR thresholds at any stimulus. At the lower 
frequencies, (A) click and (B) 4 kHz, there were no significant differences between ABR 
thresholds 7 days after noise-exposure between WT and Panx3-/- mice. However, at the higher 
frequencies (C) 16 kHz, and (D) 24 kHz, Panx3-/- mice had significantly decreased ABR 
thresholds compared to WTs 7 days after noise-exposure, suggesting better recovery after 
auditory insult, (p< 0.0001, p<0.05, respectively). Two-way repeated measures ANOVAs were 
performed for each individual stimulus, with a Sidak’s post hoc test. WT: n=10, Panx3-/-: n=10. 
Bars represent mean ABR threshold ± SEM. P<0.05, ns = not significant. 
  
 
 
 84 
 
 
  
A B
C D
B a s e lin e P o s t N E 7  d a y s  a f te r  N E
0
2 0
4 0
6 0
8 0
1 0 0
A
B
R
 T
h
re
sh
o
ld
 (
d
B
 S
P
L
)
C lic k
W T
P an x3 -/ -
a a
b
b
a c
a c
n s
n s
n s
B a s e lin e P o s t N E 7  d a y s  a f te r  N E
0
2 0
4 0
6 0
8 0
1 0 0
A
B
R
 T
h
re
sh
o
ld
 (
d
B
 S
P
L
)
4  k H z  T o n e
a a
b
b
a c
a
n s
n s
n s
B a s e lin e P o s t N E 7  d a y s  a f te r  N E
0
2 0
4 0
6 0
8 0
1 0 0
A
B
R
 T
h
re
sh
o
ld
 (
d
B
 S
P
L
)
1 6  k H z  T o n e
a
a
b b
b
c
n s
n s
****
B a s e lin e P o s t N E 7  d a y s  a f te r  N E
0
2 0
4 0
6 0
8 0
1 0 0
A
B
R
 T
h
re
sh
o
ld
 (
d
B
 S
P
L
)
2 4  k H z  T o n e
a a
b b b
c
n s
n s
*
Figure 2.4
 85 
 
 
 
 
 
Figure 2.5. Panx3-/- mice have morphological alterations of middle ear bones. 
 (A) Representative images of middle ear bones (malleus, incus, and stapes) from 2-3 month 
old WT and Panx3-/- mice. Middle ear bones were imaged and extensive measurements were 
taken. (B) The total length of the malleus was significantly decreased in Panx3-/- mice 
compared to WTs (n=17 and 24), respectively (**p<0.01, unpaired t test). (C) The distance 
between the tips of the incus bone was significantly increased in Panx3-/- mice compared to 
WTs (n=17 and 24), respectively (**p<0.01, unpaired t test). (D) The length of the stapes 
window was significantly decreased in Panx3-/- mice (n=13 and 19), respectively (*p< 0.05, 
unpaired t test). Bars represent mean length ± SEM.  
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The length of the stapes window was significantly decreased in Panx3-/- mice (WT: 0.36 mm 
±0.01, Panx3-/-: 0.33 mm ±0.008; Figures 2.5A-C). Thus, the ablation of Panx3 leads to small 
morphological changes of middle ear bones.  
 
2.3.6. Panx3-/- mice have enhanced Cx26, Cx30, Cx43, and Panx2 mRNA 
transcript levels 
In order to assess for possible compensatory mechanisms that Cxs may be playing in Panx1 or 
Panx3 null mice, we examined Cx26, Cx30, and Cx43 mRNA expression levels in WT,    
Panx1-/-, and Panx3-/- mice at two-three months of age. Interestingly, all three Cxs were 
upregulated in Panx3-/- mice compared to wild-type or Panx1-/- mice, while their expression in 
Panx1-/- remained similar to WT levels (Figure 2.6A-C). In addition, we assessed Panx2 
mRNA expression in all three mice to determine if Panx2 may be upregulated in either Panx1 
or Panx3 null mice. Panx2 mRNA expression was upregulated in Panx3-/- mice compared to 
Panx1-/- mice, however, no significant differences were observed in comparison to WT mice 
(Figure 2.6D). Panx1-/- mice had similar Panx2 expression to WT mice (Figure 2.6D).  
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Figure 2.6. Assessment of connexin and Panx2 mRNA transcript levels in Panx3-/- mice. 
Using RT-qPCR, Cx26, Cx30, and Cx43 were all detected in 2-3 month old cochleae of WT, 
Panx1-/-, and Panx3-/- mice (A-C). Cx30 and Cx43 were upregulated in Panx3-/- mice compared 
to both WT and Panx1-/- mice while Cx26 was only significantly higher than Panx1-/- mice 
(*p<0.05, **p<0.01 one way ANOVA with Tukey’s multiple comparison test), N=5, n=15. 
However, no differences were found between WT and Panx1-/- mice. In addition, qPCR 
showed no upregulation of Panx2 transcript levels in Panx1-/- (D). However, although similar 
to WT mice, Panx3-/- mice had upregulation of Panx2 mRNA expression compared to Panx1-/- 
mice (*p<0.05, one way ANOVA with Tukey’s multiple comparison test), N=4, n=12. Bars 
represent mean ± SEM. 
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Figure 2.6. 
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2.4. Discussion  
Since their discovery in 2000, Panx large-pore channels have been implicated in a large number 
of human diseases [15, 18, 55]. Most recently, Panx1 was found to be linked to hearing loss in 
two tissue-specific mouse models where Panx1 was selectively ablated from resident cells of 
the cochlea [29, 31]. In the current study, we addressed the possibility that Panx1 null mice, 
where Panx1 has been ablated throughout the entire animal, would exhibit even more severe 
hearing loss. Furthermore, we are the first group to assess if Panx3 is essential for normal 
hearing, and whether either Panx1 or Panx3 exacerbates or provides protection against noise-
induced hearing loss. Surprisingly, Panx1-/- mice had normal hearing, and they exhibited no 
protection nor increased sensitivity to loud noise exposure. Panx3-/- mice also exhibited normal 
hearing but were partially protected from noise-induced hearing loss, possibly through 
morphological changes that were observed in the middle ear bone structures and/or 
compensatory upregulation of other large-pore channels found in the cochlea. Collectively, the 
present findings challenge the position that Panx1 ablation will lead to hearing impairment but 
support the concept that Panx3 ablation partially protects against loud noise-induced hearing 
loss. 
Recently, it has been suggested that the most extensively studied Panx, Panx1, is the 
predominant ATP release channel in the cochlea [31], although connexin hemichannels have 
also been implicated in this process [56]. ATP acts as a signaling molecule in the cochlea and 
plays a role in the mechanoelectrical transduction processes throughout the auditory pathway 
[32] and in propagating Ca2+ waves in response to hair cell damage [57]. ATP also causes 
discrete bursts of action potentials in primary auditory neurons, an essential component in the 
development of central auditory pathways [32, 58, 59]. Pannexins have also been implicated 
in Ca2+ wave propagation, and Ca2+ is essential for inner hair cell development through its role 
in creating spontaneous Ca2+-driven action potentials in early stages of development [60, 61]. 
Within the cochlea, Panx1 is expressed in the spiral limbus, supporting cells of the organ of 
Corti, the spiral prominence in the cochlear lateral wall, Reisner’s membrane, and the spiral 
ganglion neurons [13, 14]. Moreover, Panx1 mRNA transcripts were detected in neurons of 
the auditory cortex [13, 14, 28]. Mounting evidence supports a role for Panx1 in hearing as a 
patient with a loss-of-function PANX1 germline mutation exhibited multi-system defects, 
including severe hearing loss [36]. Perhaps more impacting, mutant mice lacking Panx1 in 
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Pax2 and Foxg1 expressing cells of the cochlear duct exhibited sensorineural hearing loss [29, 
31]. Pax2 is a transcription factor expressed in the endolymphatic duct and in hair cells of the 
cochlea [62-64]. Foxg1 is part of a forkhead gene family and is required for morphogenesis of 
the cochlea and is expressed in most cell types of the inner ear [30]. To account for the 
potentially broad distribution of Panx1 within the peripheral and central auditory systems, we 
predicted that Panx1-/- mice would have even more severe hearing loss than mice lacking Panx1 
in Pax2 or Foxg1 expressing cells only, but to our surprise both Panx1-/- and Panx3-/- mice did 
not exhibit sensorineural hearing loss. Moreover, the functional integrity of the auditory nerve 
was intact with no detrimental changes in neural transmission, which was observed by 
amplitude and latency analysis of ABR waveforms [65]. Consistent with Panx1 not playing a 
major role in the auditory pathway, Panx1 null mice were equally susceptible to noise-induced 
hearing damage compared to controls, further validating the conclusion that Panx1 does not 
contribute to impairments in hearing sensitivity of mice. Thus, the ablation of Panx1 does not 
lead to sensorineural hearing loss, cochlear nerve deficits, or altered susceptibility to noise-
induced hearing loss. 
Our findings were surprising and in contrast to previous studies that showed conditional 
ablation of Panx1 in the cochlea led to sensorineural hearing loss [29, 31]. On first pass, one 
might predict that a Panx1-/- mouse would have a more severe hearing loss phenotype than 
when Panx1 is only ablated from a subset of resident cochlea cells; however, systemic gene 
ablated mice have more opportunity for compensatory mechanisms to rescue a potential 
disease phenotype. For example, previous studies have shown that when Panx1 was ablated in 
mice, Panx3 was upregulated in dorsal skin and blood vessels; findings that support a 
compensatory mechanism [49, 66]. In the present study, we confirmed Panx1 ablation in the 
cochlea of Panx1-/- mice by assessing both mRNA transcripts and protein expression levels. 
We also showed that cochleae of Panx1-/- mice did not exhibit upregulation of Panx2 mRNA 
expression or Panx3 at either the mRNA transcript level, minimizing a potential compensatory 
role for the residual pannexins in the Panx1-/- mice. That said, we cannot exclude the possibility 
that baseline levels of Panx2 and/or Panx3 channels are hyperactive. Alternatively, it is worth 
noting that because Cx hemichannels have been proposed to have similar functions to Panx 
channels [67], it is possible that Cxs in the cochlea are acting to compensate for the loss of 
Panx1. However, no increase in the levels of Cx26, Cx30, or Cx43 was observed in Panx1-/- 
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mice. Thus, the reasons for the phenotypic differences in hearing competence identified in the 
previously published conditional Panx1 ablation mouse models versus the present global 
ablation model remain elusive. It is interesting that a recent paper suggested that many 
genetically-modified mouse models harbor passenger mutations when bred back to different 
backgrounds, potentially influencing phenotypic outcomes [68]. It is unknown if this issue may 
be a complicating factor in Panx1 mouse ablation studies. In the human context, we recently 
discovered the first patient worldwide harboring a PANX1 gene mutation linked to severe 
hearing loss [36]. This suggests a possible link between PANX1 mutants and hearing loss that 
may be mechanistically distinct from cases where the PANX1 gene is completely ablated. 
Future studies will need to resolve what findings in Panx1-/- mice best translates to the human 
condition.  
Panx3, the second Panx examined in our study, is involved in proper bone formation and 
development. Panx3 is expressed in prehypertrophic chondrocytes and acts to accelerate their 
terminal differentiation through ATP release [38]. Recently, it was shown that Panx3-/- mice 
were protected against surgically-induced osteoarthritis and had alterations in their long bones 
[51, 69]. Panx3 is found mostly in bone and cartilage tissues, as well as in the cochlear bone 
and modiolus of the inner ear [14, 18]. In the present study, we found that Panx3 expression in 
WT cochleae was developmentally regulated peaking at P8 and there were morphological 
alterations to the middle ear bones. Interestingly, this finding correlates with previous findings 
that Panx3 regulates osteoblast differentiation [37], which our study suggests may be essential 
in the cochlear bone and auditory ossicles. The middle ear bones are essential for conveying 
sound from the external environment into the inner ear, as malformations of the middle ear 
bones can lead to hearing loss [45]. We found that Panx3-/- mice, despite having morphological 
alterations in the three ossicles, did not exhibit impaired hearing sensitivity. In fact, compared 
to WTs, Panx3-/- mice showed enhanced neural synchrony at the level of the cochlear nerve. 
At present, however, it is not possible to conclude the physiological mechanism underlying 
this finding. Since the developing cochlea is formed through signaling between the developing 
bone and sensorineural structures [70], and the auditory transduction pathway becomes 
embedded in bone, diseases changing bone remodeling can impact hearing. For example, 
patients with the human genetic condition cleidocranial dysplasia, resulting from RUNX2 
haploinsufficiency, leads to bone deformities resulting in hearing loss, which can be 
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sensorineural, conductive or a combination of the two [71]. Interestingly, the Panx3 promoter 
can be trans-activated by RUNX2 [38]. This suggests that Panx3 expression could be regulated 
by RUNX2 and may explain some of the symptoms associated with cleidocranial dysplasia. 
Similarly, some patients with cochlear otosclerosis exhibit sensorineural hearing loss without 
morphological damage to the sensory tissues [43, 72]. Thus, the enhancement of cochlear nerve 
synchrony that was observed in Panx3-/- mice could be due to cochlear and/or middle ear bone 
shape changes. Alternatively, the enhanced neural synchrony observed in the cochlear nerve 
of Panx3-/- mice may be due to ablation of Panx3 in cell types that directly contribute to 
sensorineural processing. While Panx2 levels were increased in Panx3 ablated mice, this 
increase was not statistically significant compared to wild-type mice suggesting that the 
compensating role of Panx2 in assisting in neural synchrony remains to be firmly established. 
Finally, it is possible that the upregulation of cochlear connexins in Panx3-/- mice could be 
contributing to the increased synchrony observed in their cochlear nerve, as demonstrated by 
increased wave I amplitudes in response to the 90dB click stimulus.  
To our surprise, when we challenged the auditory system of Panx3-/- mice with a loud noise 
exposure, they showed decreased susceptibility to 16- and 24 kHz hearing loss seven days after 
the acoustic insult. Similar to the enhanced neural synchrony in the auditory nerve of these 
mice, the mechanism by which Panx3 ablation allowed the auditory system to be more resilient 
to noise-induced hearing loss remains unknown and difficult to dissect. We suggest that 
various mechanisms, including morphological changes in the middle ear bones, and/or 
compensatory upregulation of Cxs may underlie the increased resistance to acoustic trauma 
observed in Panx3-/- mice in the present study. For example, since Panx3 is expressed in bone, 
the enhanced protection observed in Panx3-/- mice may also be due to differences in conveying 
mechanical sound through the middle ear bones during noise exposure. Furthermore, the 
morphological alterations observed in middle ear bones of Panx3-/- mice could perhaps 
contribute to the enhanced 16- and 24 kHz hearing protection through differences in sound 
conduction correlating to better tolerance of loud noise. 
It is important to acknowledge that the hearing protection observed in the Panx3-/- mice may 
have occurred by mechanisms associated with Panx3 that extend beyond its expression in bone, 
such as Ca2+ or ATP release. It is well established that loud noise exposure causes an increase 
in metabolic activity that alters the cellular redox state of the cochlea, leading to reactive 
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oxygen species (ROS), that cause excessive cochlear damage [73, 74]. This damage can 
ultimately lead to hair cell death, which is associated with intracellular accumulation of 
potassium, as well as auditory nerve degeneration [75, 76]. Interestingly, dexamethasone 
administration in the cochlea was shown to have a protective function by preserving hair cell 
survival and reducing ototoxic injury through inhibition of Ca2+ entry in auditory cells [74, 77-
79]. Since Panx3, among other functions, releases Ca2+, it is reasonable to propose that ablation 
of Panx3 may have provided protection against noise-induced hearing loss in the present study, 
by reducing ototoxic injury through inhibition of Ca2+ release within the cochlea. 
 
2.5. Conclusions 
In considering the potential role that connexin compensation may play in Panx3-/-mice, it is 
worth noting that previous studies have shown that reduced Cx26 expression leads to increased 
susceptibility to noise-induced hearing loss, and following a loud noise-exposure, Cx26 
expression decreases [80, 81]. In the current study, we found that Cx26, Cx30, and Cx43 were 
all upregulated in Panx3-/- mice at baseline which could potentially act in a protective manner 
against an acute loud noise exposure. Alternatively, because the expression pattern of Panx3 
in the auditory system is not fully characterized, it is possible that the hearing protection 
observed in the Panx3-/- mice occurred via mechanisms associated with Panx3 that extend 
beyond its expression in bone. Ultimately, future studies will be needed to uncover the 
mechanism(s) by which ablation of Panx3 provides hearing protection from excessive noise 
exposure, and thus, whether Panx3 could serve as a novel molecular target in the clinical 
protection against traumatic hearing loss. 
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Chapter 3 : Double deletion of Panx1 and Panx3 affects skin and 
bone but not hearing 
 
 
 
 
Both Panx1 and Panx3 are expressed in the inner ear and our previous study showed that single 
global knock-out mice of Panx1 or Panx3 did not cause any hearing deficits. To determine 
whether compensation of Panx channels was occurring in single knock-out mice, we created 
the first of its kind Panx1 and Panx3 double knock-out mouse and characterized the skin, bone, 
and hearing phenotypes.  
Importantly this paper was strategically performed by the collaboration of three different labs 
(Penuela, Allman, and Willmore). My specific data contributions to this paper was all the 
hearing data, with the rest of the data being performed by others.  
 
 
 
 
 
 
 
 
 
 
 
 
A version of this manuscript is published: 
Abitbol JM, O’Donnell BL, Wakefield CB, Jewlal E, Kelly JJ, Barr K, Willmore KE, Allman 
BL, Penuela S. Double deletion of Panx1 and Panx3 affects skin and bone but not hearing. J 
Mol. Med. 2019. 97:723-736. 
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3.1. Introduction 
Pannexins (Panxs; Panx1, Panx2, and Panx3), are a family of three glycoproteins that form 
large pore channels at the plasma membrane [1-3] to allow passage of ions and metabolites 
through the intracellular and extracellular space [4, 5]. Panx1 is expressed in most mammalian 
organs [2, 6-10], while Panx2 has a more restricted expression pattern [2, 11]. Panx3 is 
expressed predominantly in skin, cartilage and bone [2, 9, 12].  
Panx1 plays a role in many cellular processes such as ATP release, Ca2+ wave propagation, 
and apoptosis [13-15]. Panx1 channels can be opened through mechanical stimulation, an 
increase in intracellular calcium concentration, extracellular potassium concentration, 
membrane depolarization, as well as caspase 3 cleavage. [13-16]. Panx1 is highly expressed in 
young mouse skin, but decreases in aged skin [17] and is important in keratinocyte 
differentiation [18]. We previously found that Panx1-/- (KO) mice had reduced dermal area, but 
increased hypodermal thickness in dorsal skin compared to wild-type (WT) mice [17]. Panx1-
/- mice displayed increased fibrosis and delayed wound healing [17]. Panx3 is also expressed 
in adult human skin and embryonic mouse skin tissues and participates in wound healing [16, 
18].  
Panx3 is found in bone and cartilage tissues [19, 20] and is involved in the differentiation of 
osteoblasts [21]. Panx3 is also expressed in pre-hypertrophic chondrocytes and acts to 
accelerate their terminal differentiation through increased ATP release[19]. Our group 
previously generated a global Panx3-/- (KO) mouse that was shown to be less prone to 
surgically-induced osteoarthritis [22]. Although gross skeletal phenotypic changes were not 
observed in this global Panx3-/- mice, analyses of micro-CT images of long bones of adult 
Panx3-/- and WT mice revealed that KO mice had shorter long bone diaphyses, larger areas of 
muscle attachment, and greater cross-sectional areas at mid-diaphysis compared to WT mice 
[23].  
Our group has recently shown that the global Panx1-/- mouse did not exhibit hearing loss nor 
changes in the timing/amplitude of the sound-evoked electrical activity recorded in the 
auditory brainstem [24]. In contrast, studies using conditional ablation of Panx1 in the cochlea 
exhibited severe hearing loss at all frequencies, reduced endocochlear potential, and reduced 
cochlear microphonics [25], [26]. In a recent study, we investigated the role of Panx1 and 
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Panx3 in noise-induced hearing loss. Although no differences were found between Panx1-/- 
mice and their WT littermates, Panx3-/- mice had slightly better hearing recovery after noise 
exposure than WT mice [24]. Illustrating the potential compensation between pannexins, single 
Panx1-/- and Panx2-/- mice were subjected to ischemic stroke and had similar degrees of infarcts 
compared to controls [27]. However, Panx1-/-Panx2-/- double knock-out mice had smaller 
infarct sizes to the brain and better central nervous system functional outcomes, suggesting 
that ablation of both genes was necessary to observe the phenotype [27].  
Panx1 and Panx3 share protein sequence homology, and thus, it is postulated that the lack of 
gross overt phenotypes observed in one Panx-/- mice could be due to functional compensation. 
In fact, Panx3 was upregulated in skin, blood vessels and the vomeronasal organ of Panx1-/- 
mice [17, 28, 29]. To address this compensation issue, we have generated the first Panx1 and 
Panx3 double knock-out mouse (dKO) and focused our characterization on the skin, bone, and 
the auditory system that are known to express both pannexins. 
3.2. Materials and methods 
3.2.1. Generation of dKO mice 
Panx3-/- mice were generated in house [22]. Panx1-/- mice were a kind gift from Genentech Inc. 
(San Francisco, CA) and were previously described [30]. Panx3-/- mice were crossed with 
Panx1-/- mice to generate offspring heterozygous (HT) for both Panx. These mice were 
backcrossed with either Panx3-/- or Panx1-/- mice to generate Panx1+/-/Panx3-/- or Panx1-/-
/Panx3+/-. The HT/KO and KO/HT mice were crossed, and mice null for both pannexins (dKO) 
were selected and kept in a closed colony. C57BL/6 mice were used as controls. Mice were 
maintained on a 12h-light-12h-dark cycle and fed ad libitum. All experiments followed the 
guidelines and protocols for animal care approved by the Animal Care Committee at the 
University of Western Ontario.  
3.2.2. Genotyping 
Tail tips from P4-5 were digested in EDTA in a protein kinase solution. PCR was used to verify 
the lack of exon 2 in both genes. Primers are listed in Suppl. Table 1. P anx1 #1 flank floxed 
exon 2 and yields a 662 bp WT DNA and a 450 bp Panx1 KO fragment. For Panx3, two 
reactions were needed. Reaction 1 uses Panx3 #1 primers flanking exon 2 and yield a 1326 bp 
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WT DNA fragment and a 600 bp DNA fragment indicates at least one mutant allele. To 
distinguish between a Panx3 HT or full KO, a second reaction is conducted using Panx3 #2 
primers where WT and Panx3 HT mice produce a 770 bp band, not seen in a Panx3 KO.  
3.2.3. Ribonucleic acid extraction and quantitative polymerase chain reaction 
Two-to-three-month-old cochleae, P4-P5 skin, and P4-P5 hindlimb tissues were dissected from 
mice and flash-frozen in liquid nitrogen. Ribonucleic acid (RNA) was extracted using a 
combination of Trizol and a Qiagen RNeasy mini kit as was previously described [24]. A 
NanoDrop spectrophotometer was used to measure the absorbance of RNA and was converted 
to cDNA using Superscript VILO or high-capacity cDNA reverse transcription kit (Thermo 
Fisher). Two-step quantitative PCRs (qPCRs) were performed using a SYBR green PCR 
master mix by Life Technologies. The PCR protocol for all primers were as follows: 50°C for 
2 min, 95°C for 2 min, 95°C for 5 s, 60°C for 15 s (except 65°C for Panx3), followed by a melt 
curve. Primers used are listed in Table 3.1. Normalized mRNA expression levels were analyzed 
using the delta-delta CT method which was calculated using BioRad CFX Manager Software. 
A WT sample was set as the control for all calculations. 
3.2.4. Protein extraction and immunoblotting 
Skin and limbs of P4-5 WT and dKO mice were pulverized in liquid nitrogen and digested 
using a RIPA buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP-40 (Igepal), 0.5% 
sodium deoxycholate) which contained 1mM sodium fluoride, 1 mM sodium orthovanadate 
and complete-mini EDTA-free protease inhibitor (Roche, Mannheim, Germany). Protein was 
quantified using the bicinchoninic acid (BCA) assay (Thermo Fisher Scientific), separated on 
a 10% SDS-PAGE gel (50 μg) and transferred onto a nitrocellulose membrane using an 
iBlotTM system (Invitrogen, USA). Membranes were blocked with 3% bovine serum albumin 
(BSA) in 1X phosphate buffered saline (PBS) with 0.05% Tween20 overnight and then 
incubated with either anti-Panx1 CT-395 (1:2000), anti-Panx2 CT-523 (1:500), or anti-Panx3 
CT-379 (1:1000) overnight at 4˚C [2]. Anti-mouse GAPDH (Millipore Sigma, 1:5000) was 
used as a protein loading control.  
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Table 3.1. List of primers 
 Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Cx26 CCGTCTTCATGTACGTCTTTTACAT ATACCTAACGAACAAATAGCACAGC 
Cx30 GGCCGAGTTGTGTTACCTGCT TCTCTTTCAGGGCATGGTTGG 
Cx43 ACAACAAGCAAGCCAGCGAG TCGTCAGGGAAATCAAACGG 
Panx1 ACAGGCTGCCTTTGTGGATTCA GGGCAGGTACAGGAGTATG 
Panx3 TTTCGCCCAGGAGTTCTCATC CCTGCCTGACACTGAAGTTG 
Panx2 TGGTACCCATCCTGCTGGT GGGTGAAGTTGTGCGGAGT 
IL-6 CAAGCCAGAGTCCTTCAGAG GAGCATTGGAAATTGGGGTA 
TNF- α CTGTGAAGGGAATGGGTGTT GGTCACTGTCCCAGCATCTT 
Hif1- α GCAGCAGGAATTGGAACATT GCATGCTAAATCGGAGGGTA 
GluPx1 GTCCACCGTGTATGCCTTCT CCTCAGAGAGACGCGACATT 
MnSOD GGCCAAGGGAGATGTTACAA CCTTGGACTCCCACAGACAT 
Caspase3 TGTCATCTCGCTCTGGTACG AAATGACCCCTTCATCACCA 
Bcl2 CCTGTGGATGACTGAGTACC GAGACAGCCAGGAGAAATCA 
18SrRNA GTA ACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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For detection, IRDye® – 8000CW and -680RD (Life Technologies, USA) were used as 
secondary antibodies at 1:10000 dilutions and blots were imaged using a Li-Cor Odyssey 
infrared imaging system (Li-Cor, USA). Expression levels of Panx1 and Panx3 were quantified 
and normalized to GAPDH and presented relative to the WT mean value. Panx1 and Panx3 
overexpressed Human embryonic kidney cells (HEK 293T- ATCC) were used as positive 
controls as previously described [17].  
3.2.5. Body mass composition 
Fat and lean mass composition of 10-11 week old male mice, were measured using quantitative 
magnetic resonance (echo-MRI) analysis with an echo magnetic resonance imaging mobile 
unit (Avian Facility of Advanced Research, University of Western Ontario, London, ON, 
Canada) as described by (Guglielmo et al. 2011), with the modification of placing live mice in 
the apparatus and measuring on the ‘small animal’ setting omitting water content. 
Measurements were taken in triplicate to verify the results. 
3.2.6. Histology 
Histology assays were performed on skin samples collected from WT and dKO male mice at 
P0, P4, 4 weeks, and 2 years of age for dorsal skin and, P0, P5, 4 weeks, 9 weeks and 22 weeks 
of age for paw skin. Parallel tissue sections (5 μm) were deparaffinized using two 5-minute 
xylene treatments, rehydrated by immersion in an ethanol gradient (100%, 95% then 70% for 
5 minutes each) and stained with hematoxylin (Sigma) for 2.5 minutes, followed by water 
rinses and stained with eosin (Lerner Laboratories) for 5 minutes. Samples were subjected to 
three changes of 95% and then 100% ethanol for 3 minutes each, followed by two xylene 
treatments in 5-minute intervals. Stained samples were mounted using Permount Mounting 
Medium (Electron Microscopy Sciences) and imaged on a Leica DMIL LED brightfield, 
inverted microscope using 5X (P4, 4 weeks and 2 years) and 20X (P0) magnifications for 
dorsal skin and a 20X magnification for all paw samples. Epidermal and dermal areas 
(excluding the stratum corneum) and hypodermal areas were manually segmented for dorsal 
skin and measured using ImageJ. Measurements from dKO and WT samples across each age 
were compared for each tissue type using unpaired sample t-tests (GraphPad Prism 7). 
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3.2.7. Skull shape and size comparisons- Imaging 
Micro computed tomography (μ-CT) images were obtained from a sample of 11 dKO and 11 
WT mice at P0, and 6 dKO and 5 WT at three months. Skulls were fixed in 4% 
paraformaldehyde overnight and embedded in 1% agarose in 50 mL Falcon tubes. Scans of P0 
mice were conducted with a GE Locus RS-9 scanner (GE Healthcare, Waukesha, WI, USA). 
Scan parameters saw 900 views acquired each 0.4 degrees over a 360-degree rotation of the 
gantry. Each projection lasted for 4500 ms and two projections were averaged at each view 
angle. Potential was measured as 80 kVp and current as 450 μA. Images were obtained at an 
isotropic voxel size of 20 μm and reconstructed as 3D volumes. Scans of adult mouse skulls 
were conducted using the eXplore speCZT μCT scanner (GE Healthcare, Waukesha, WI, 
USA). Scan parameters followed those used for P0 mouse imaging except that each projection 
lasted 16 ms and images were obtained at 50 μm isotropic voxel size and reconstructed at 100 
μm. Calibration of each scan to Hounsfield Units was done using a sample of air, water and 
cortical bone-mimicking epoxy (SB3, Gamex, Middleton, WI, USA) with density 1100 mg 
cm-3 [23, 31]. 
3.2.8. Data collection: Landmarking 
Surface reconstructions were generated from μ-CT volumes of each skull, and 3D landmark 
coordinate data was collected using Checkpoint (Stratovan Corporation, Davis, CA, USA). A 
set of 45 and 53 homologous skull landmarks as well as 19 homologous mandibular landmarks 
were collected from P0 and three month-old mice, respectively [32, 33]. Two landmark trials 
were conducted by the same observer and deviations between the two trials were restricted to 
0.05 mm [34] and then averaged for further analyses.  
3.2.9. Geometric morphometric analyses- skull shape and size  
Geometric morphometric statistical analyses were used for quantification and comparison of 
subtle shape and size differences. Landmark data underwent Procrustes superimposition using 
the R package geomorph [35] (R Foundation for Statistical Computing, Vienna, Austria, 2017) 
and subsequent analyses were conducted on Procrustes coordinate data. Due to the multivariate 
nature of geometric morphometric shape analyses, separate Procrustes superimpositions were 
necessary for the whole skull, face, cranial base, cranial vault and mandible Differences in each 
sections’ shape were compared with a non-parametric MANOVA using the ProcD function in 
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the R package geomorph, R Foundation for Statistical Computing, Vienna, Austria, 2017); 
[36]. This function includes resampling of 10,000 iterations to create a probability distribution 
from which significance can be determined (α=0.05). 
3.2.10. Principle component analyses  
Differences in skull shape were compared using principal components analysis (PCA) 
performed on the variance/covariance matrix of Procrustes coordinates using the geomorph 
package in R; R Foundation for Statistical Computing, Vienna, Austria, 2017). Scores for each 
individual for PC1 and PC2 are presented as a scatterplot. Qualitative differences in shape are 
visualized by the density of the clustering of points and the separation between genotypes 
across the principal components. Visualization of shape changes between dKO and WT mice 
along PC1 was accomplished by morphing the Procrustes superimposed landmark data of the 
average WT and average dKO mouse for PC1 mice onto the mouse with a PC1 score closest 
to zero. 
Differences in overall skull size as well as size of the cranial base, cranial vault, face, and 
mandible were compared using centroid size. Centroid size is measured as the square root of 
the sum of the squared distances between each landmark coordinate and the centroid of the 
landmark configuration [8]. Centroid size was calculated as part of the Procrustes 
superimposition, using the geomorph package in R [35]; R Foundation for Statistical 
Computing, Vienna, Austria, 2017). Differences in size were compared using ANOVA and 
Tukey’s post-hoc test. 
3.2.11. Limb bone length comparisons 
Limb bones of P0 dKO and WT mice were double stained with alizarin red /alcian blue as 
previously described [37]. Briefly, mouse pups were placed in PBS and skin, fat and muscles 
were dissected. Dissected mice were then fixed overnight in 95% ethanol. The next day, mice 
were placed in acetone and left overnight. The following day, mice were stained in a solution 
of 0.015% alcian blue (Sigma-Aldrich, Cat. No. A25268), 0.05% alizarin red (Sigma-Aldrich, 
Cat. No. A5533) and 5% acetic acid in 70% ethanol for five days. Post-staining, remaining soft 
tissues were dissolved by placing mice in a solution of 2% potassium hydroxide in PBS for 
one day and then transferred to a solution of 1% potassium hydroxide and PBS until most of 
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the soft tissues were removed. Double stained limb bones were examined using a Leica S6-D 
stereomicroscope and a Leica EC3 camera (Leica Microsystems, Wetzlar, Germany). The 
length of the ossified portion of each bone was measured using ImageJ and then compared 
between genotypes using a MANOVA. Differences in length for specific bones were 
determined using Welch’s t-tests with Bonferroni correction. All analyses were performed in 
R (R Foundation for Statistical Computing, Vienna, Austria, 2017).  
3.2.12. Growth plate comparisons of P0 WT and dKO tibiae  
Tibiae were dissected from a sample of six WT and five dKO P0 mice, fixed in 4% 
paraformaldehyde, decalcified, embedded in paraffin and sectioned length-wise. Safranin-
O/Fast Green staining was used to visualize the growth plate. Length of the proximal growth 
plate, as well as the length of the proliferative and hypertrophic zones were measured using 
ImageJ and compared between WT and dKO mice using Welch’s t-tests in R.  
3.2.13. Cross-sectional geometric properties of humerus and femur  
Cross-sectional measures were obtained from 20 µm thick cross-sections of the right humerus 
and femur from µ-CT scan data. Statistical comparison of each geometrical property was 
performed using Welch’s two-sample t-tests in R (R Foundation for Statistical Computing, 
Vienna, Austria, 2017) with Bonferroni corrections for multiple comparisons. 
3.2.14. Hearing assessment using the auditory brainstem response (ABR) 
Hearing levels were determined using the ABR technique, which was previously described 
[24]. Hearing levels were determined using the ABR technique, which measures the electrical 
activity in the brainstem evoked by the repeated presentation of a given acoustic stimulus to 
ultimately assess hearing sensitivity. Mice were deeply anaesthetized with ketamine (100 
mg/kg) and xylazine (10 mg/kg) administered via intraperitoneal injections, and electrical 
activity was recorded through subdermal electrodes placed at the vertex (active electrode), 
mastoid of the stimulated ear (reference electrode) and on the mid-back (ground electrode). 
Mice were maintained at ~37°C on a digital homeothermic heating pad throughout the duration 
of the experiment. Five individual acoustic stimuli were used in our studies which allowed us 
to test auditory function at various regions along the sensory epithelium in the cochlea which 
code for different sound frequencies. These stimuli included a broadband click stimulus which 
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comprises the 1- 10 kHz frequency region of the cochlea, and four tonal specific stimuli of 4-
,8-, 16-, and 24 kHz to assess both broadband as well as tonal specific frequencies. In this 
manner, the low to midfrequency ranges spanning the apical and middle turns of the cochlea 
would be tested. For ABR waveform analysis, BioSig software program was used to measure 
the amplitudes and latencies of 90 dB sound pressure level (SPL) click stimuli for each wave 
and each mouse group tested.  
3.2.15. Noise exposure  
For a separate cohort of mice at one month of age, an initial ABR was followed immediately 
by exposure to a loud 12 kHz tonal stimulus at 115 dB SPL to both ears for a one hour time 
period, as has been previously described [24]. During the procedure, mice were deeply 
anaesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), while noise exposures were 
performed in a sound attenuated chamber. Immediately following noise exposure, mice were 
reassessed with a second ABR to confirm elevation of thresholds at high frequencies. Mice 
were then administered antipamezole (1 mg/kg) to reverse the effects of anaesthesia and 
allowed to recover in their home cages. 7 days after the noise exposure, a third and final ABR 
was performed to determine the extent of permanent hearing damage incurred by the loud noise 
exposure. 
3.3. Results 
3.3.1. Characterization of dKO mice 
Genotyping of dKO mice showed loss of both Panx1 and Panx3 (Figure 3.1A). Although gross 
morphology of Panx1-/-Panx3-/- mice (dKO) did not show any major differences, adult dKO 
mice were slightly smaller than WT as evidenced in representative pictures (Figure 3.1B). 
Weaned litter sizes of dKO mice were significantly smaller compared to both WT and       
Panx1-/- weanlings (Figure 3.1C). Additionally, overall body weight of dKO mice were 
significantly decreased at postnatal day 0 (P0), 2-3 months, and 16 months of age compared to 
aged-matched WT controls (Figure 1D-F).  
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Figure 3.1. Characterization of dKO mice 
Representative genotyping gels for dKO and WT mice for Panx1 and Panx3 exon 2 deletions. 
R1: reaction 1 (primers Panx3F1 and reverse Panx3R1) primers flank exon 2 and yield a 1326 
bp WT DNA fragment and a 600 bp DNA fragment which shows the presence of at least one 
mutant allele. To distinguish between Panx3 HT or full KO, a second reaction (RT) is 
conducted using Panx3F1 and reverse Panx3RT that yields a 770 bp in the WT but not in the 
KO. Lines denote lanes from the same gel shown after removal of extra lanes (A). 
Representative pictures of WT and Panx1-/-Panx3-/- mice at three months of age (B). Litter sizes 
of WT, Panx1-/-, Panx3-/- and dKO mice at time of weaning where N= 71, 49, 45, and 36, 
respectively. One-way ANOVA followed by posthoc Tukey’s test (C). Body weights of 
postnatal day 0 (P0) (WT: N=6, dKO: N=8), 2-3 months-old (WT: N=16, dKO: N=16) and 16-
month-old (WT: N=4 and dKO: N=8) WT and dKO mice (D-F). Unpaired students t-tests 
**p<0.01, ***p<0.001, ****p<0.0001. N= number of biological replicates. 
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Figure 3.1. 
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However, qMRI tests revealed that the lean mass and fat mass normalized to body weight did 
not significantly change between WT and dKO mice at 2 months of age (Figure 3.S1). 
3.3.2. Panx1 and Panx3 are ablated in skin, limb, and cochleae of dKO mice  
Panx1 and Panx3 mRNA transcripts were present in skin, hindlimb, and cochleae of WT mice 
and absent in dKO (Figure 3.2A-C). At the protein level, low but detectable amounts of Panx1 
and Panx3 were observed in skin tissues which was ablated in dKO mice (Figure 3.2A-C). In 
the hindlimb, Panx1 protein was undetectable in both WT and dKO, but high Panx3 protein 
expression was observed in WT mice (Figure 3.2A-C). Other immunoreactive bands are 
apparent at 50 and 70 kD, but are not ablated in the dKO, indicating that they are non-specific. 
We assessed the expression of Panx2 and other large pore channels in WT and dKO tissues. In 
skin, Panx2 full length was not detected, while Panx2 isoform X1 was observed at similar 
levels in WT and dKO mice (Figure 3.S2A). Cx26, Cx30, and Cx43 mRNA transcripts were 
also similarly detected in both WT and dKO mice (Figure 3.S2B). No differences in the 
expression of any of the tested Cxs or Panx2 channels were observed in WT and dKO 
hindlimbs or cochlear tissues (Figure 3.S3A,B).  
3.3.3. Neonatal dKO mice exhibit decreased epidermal and dermal area in 
dorsal and paw skin 
Analysis of dorsal skin showed a significant decrease in the epidermal and dermal area of dKO 
mice at P0 compared to WT (Figure 3.3). At P4, there was a significant increase in the 
hypodermal area of dKO compared to WT mice (Figure 3.3). However, no significant 
differences were seen at any other time point (Figure 3.3). dKO paw skin at P0 showed a 
significant decrease in epidermal area, however, no differences were found at any other age 
(Figure 3.4A-C).  
3.3.4. Skull shape is significantly altered in neonatal but not adult dKO mice 
Overall skull shape comparisons between dKO and WT mice at P0 was assessed using a 
MANOVA and found to be significant (p=0.00165). Significant shape changes between dKO 
and WT mice were detected for all regions of the skull: face (p=0.00335), base (p=0.00035), 
cranial vault (p=0.00405), and the mandible (p=0.00045) at P0.  
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Figure 3.2. Quantitative PCR confirms ablation of Panx1 and Panx3. 
Skin (A), hindlimb (B), and cochleae (C), mRNA transcript levels for Panx1 and Panx3 were 
assessed using 18S rRNA or GAPDH to calculate normalized mRNA expression using the 
delta-delta CT method. No Panx mRNA was found in the dKO tissues. Panx1 and Panx3 
western blots for P4 skin (A) and hindlimbs (B). Panx1 is glycosylated and runs in a multiple-
banded pattern (Gly2, Gly1, Gly0) as shown in human embryonic kidney cells (HEK 293T) 
ectopically expressing Panx1 (bracket) and WT skin (not detectable in hindlimb). Panx3 
protein (~43 kDa) shown in WT skin, bone and transfected HEK 293T cells (bracket). 
Unspecific bands are evident at ~50 and 70kDa (also in dKO). GAPDH was used as a loading 
control. Markers in kDa. Lines in blots indicate that positive control lanes (HEK Panx) are 
from the same blot but scanned at a lower intensity due to high ectopic expression. Bars: mean 
± SEM. N=3 in skin and limbs and N=4 in cochleae.  
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Figure 3.2.  
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Figure 3.3. dKO mice dorsal skin, epidermal and dermal area is decreased at P0 and 
hypodermal area is increased at P4 compared to WT mice. 
Histological analysis of mouse dorsal skin at various ages showed the area of epidermal 
(excluding the highly variable stratum corneum) and dermal areas at P0, P4, 4 weeks, and 2 
years of age in dKO and WT mice. N =3, n=9 for all time points and genotypes, except P0 
(N=4, n=12). Error bars represent SEM. Scale bars represent 50μm at P0 and 100μm at P4, 4 
weeks and 2 years. N= biological replicates, n= technical replicates. Independent student t-
tests were performed. NS= no significance. ***p < 0.001, and ****p < 0.0001. 
 
 
 118 
Figure 3.3. 
 
  
 119 
 
 
 
 
 
 
 
 
Figure 3.4. Thick skin epidermal area is reduced in dKO paws of P0 mice. 
Histological analysis and area of measurements in the epidermal area of mouse thick paw skin 
at P0, P5, 4, 9, and 22- weeks of age was quantified. N = 3, n=9, error bars represent SEM. 
Scale bars represent 25μm. Unpaired student t-tests were performed. NS= no significance, 
**p<0.01. N= biological replicates, n= technical replicates.  
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However, at three months, no statistically significant shape changes were observed. Skull 
shape differences were visualized using principal component analyses (PC). At P0 distinct 
separation was evident between WT and dKO mice across PC1 for the whole skull (Figure 
3.5A) as well as for each region of the skull, particularly in the cranial base (Figure 3.5B). In 
contrast, in adult mice there was no separation between genotypes across PC1 and PC2 (Figure 
3.5D,E). Heat morphs allow visualization of shape changes in P0 dKO across PC1 (Figure 
3.5C,F). 
3.3.5. dKO mice have significantly smaller mandibles, shorter hindlimbs, and 
altered femoral and humeral cross-sectional properties 
Size of the whole skull, face, cranial base and cranial vault did not differ significantly between 
genotypes at P0 or in adult mice (Figure 3.5G). Mandible size was significantly smaller in dKO 
mice at P0 and at three months (Figure 3.5G). Lengths of the ossified portion of fore- and hind 
limb bones of P0 pups were measured and showed that P0 dKO mice have significantly shorter 
hind limb bones than WT (Figure 3.6A). Qualitative assessment revealed no differences in the 
general histomorphology of the tibial growth plate between WT and dKO P0 mice (Figure 
3.6C). Measures of growth plate length were not statistically different between genotypes. 
Similarly, proportional lengths of the prehypertrophic and hypertrophic zones relative to total 
growth plate length were similar between genotypes (Figure 3.6D). At P0, polar second 
moment of area (J) (p=0.0000034) and cortical area (CA) (p=0.0024) of the humerus are larger 
in dKO than WT mice (Figure 3.6E). At three months, dKO mice have significantly larger 
%CA of the humerus than WT mice (p=0.014) and significantly larger femur Imax/Imin 
(p=0.009) (Figure 3.6E). 
3.3.6. dKO mice have normal hearing 
Representative ABR trace recordings of WT and dKO mice for a click stimulus showed that 
ABRs were similar in both genotypes (Figure 3.7A). No significant differences were observed 
between WT and dKO mice at any of the stimuli tested (Figure 3.7B). In addition to measuring 
hearing thresholds, analysis of ABR waveforms provided an indication of the integrity of 
neurotransmission throughout the auditory brainstem.  
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Figure 3.5. Skull shape is altered in dKO mice compared to WT mice at P0 but not in 
adult mice. 
Principal components analyses (PCA) were used to visualize differences in shape between 
dKO and WT mice at P0 for the whole skull, face, cranial base, cranial vault and mandible. 
Small circles represent PC scores for PC1 and PC2 for each individual, large circles represent 
the average score for each genotype along PC1 and PC2. The two genotypes are clearly 
separated along PC1 for all regions of the skull at P0 (A, B). At three months (adult), no clear 
separation between genotypes was found for any of the regions analyzed (D, E). Specific shape 
changes associated with variation across PC1 are represented as heat morphs (C,F). Red 
colouration demonstrates regions of the skull that differ the most between the average dKO 
mouse and the group mean, whereas grey colouration represents differences between the 
average WT mouse and the group mean. At P0, the greatest shape differences in dKO mice are 
found in the cranial vault and cranial base (C), in agreement with our regional PC plots (B). At 
three months, the main differences in skull shape are concentrated on the inferior surface of 
the cranial base and face (F). Note that while these regions of the skull look markedly different 
due to the red colour, the actual difference (<0.5mm) is quite small for an adult mouse skull. 
Overall skull size, as well as face, cranial base, cranial vault and mandibular size were 
compared between dKO and WT mice at P0 and three months. For both age groups, WT mice 
have significantly larger mandibles than dKO mice (G), ** p<0.01. 
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Figure 3.6. dKO mice have significantly shorter hind limb bones than WT mice and 
altered femoral and humeral cross-sectional properties. 
At P0, measures of femoral and tibial lengths are significantly shorter in dKO compared with 
WT mice (A). Geometric properties of the humerus and femur were calculated from diaphyseal 
cross-sections as shown (B). The general organization of the proximal tibial growth plate (GP), 
proliferative zone (PZ) and hypertrophic zone (HZ) is similar between genotypes at P0 (C) and 
no differences were found between dKO and WT mice for length measures of the total growth 
plate, or the prehypertrophic or hypertrophic zones as measured as percent of the total growth 
plate (D). Analysis of (B), showed that humeri of dKO mice have significantly larger cortical 
area (CA) and polar second moment of area (J) than WT mice at P0, while at three months 
percent cortical area (%CA) is significantly larger in dKO mice (E). No significant differences 
in femur cross-sectional measurements were detected at P0 between genotypes, but at three 
months dKO mice have significantly larger Imax/Imin values (E).* p<0.05, ** p<0.001, *** 
p< 0001.  
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dKO mice had significantly larger amplitudes in wave I (cochlear nerve), wave III (superior 
olivary complex), and wave IV (lateral lemniscus/inferior colliculus) of the ABR; findings 
which could result from a greater number of neurons along the auditory pathway being 
activated by the acoustic stimulus, and/or because the population of neurons in a given 
brainstem region discharged with more precise timing (Figure 3.7C). That said, no differences 
were detected in the latencies of ABR waveforms in dKO (Figure 3.7D), suggesting that the 
speed of neurotransmission was not affected by genotype. Collectively, these data suggest that 
dKO mice do not exhibit hearing deficits, and even have enhanced activation and/or neural 
synchrony in distinct auditory brainstem regions. 
3.3.7. dKO mice have slightly decreased susceptibility to noise-induced 
hearing loss 
As expected, ABR thresholds to all stimuli (click, 4-24 kHz tones) were elevated immediately 
after the noise exposure in both WT and dKO mice (Figure 3.8A-D), with the greatest degree 
of hearing impairment evident at the higher frequencies (Figure 3.8C-D). Interestingly, 7 days 
after the noise exposure, the 24 kHz hearing thresholds of dKO mice had recovered to a greater 
degree (i.e., lower ABR threshold values) than the WT mice; findings which show that the 
dKO mice were slightly less susceptible to permanent noise-induced hearing loss (Figure 
3.8D).  
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Figure 3.7. Double knockout mice have normal hearing. 
Representative auditory brainstem response (ABR) traces of a broadband click stimulus in both 
WT and dKO mice (A). Hearing assessment of 2-3-month-old mice through ABRs of WT and 
dKO mice for a broadband click stimulus and tonal specific frequencies (4, 8, 16, and 24 kHz 
tones) (B). ABR waveforms were further analyzed at the 90dB click stimulus by their 
amplitudes (C) and latencies (D), representing neural synchrony and speed, respectively. Bars 
represent mean ± SEM. *p<0.05, ****p<0.0001, One-way ANOVA followed by Sidak’s post-
hoc tests. Ns= no significance. WT: N=12, dKO: N=13. One outlier, as determined by 
GraphPad was removed from (B). N= number of biological replicates. 
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Figure 3.8. dKO mice exhibit slight protection against noise-induced hearing loss. 
Noise exposure (NE) increased ABR thresholds immediately after NE (Post NE) for all stimuli 
tested, confirming auditory damage in both WT and dKO mice (A-D). The highest ABR 
thresholds were found at the higher frequency stimuli (C) 16 kHz and (D) 24 kHz tones. N=7 
for each genotype. Bars represent mean ± SEM. Two-way repeated measures ANOVAs with 
Sidak’s post-hoc tests were performed for each individual stimulus, ***p<0.001. N= number 
of biological replicates. 
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Figure S 3.1.  qMRI of WT and dKO mice show no significant differences in normalized 
fat or lean mass. 
Young adult (10-11 weeks) WT and dKO mice were fed normal chow ad libitum and analyzed 
using echo-MRI (qMRI) to determine raw lean mass (A) and raw fat mass (B). Overall lean 
mass (C) and overall fat mass (D) were normalized to body weight. N=4 for both WT and dKO 
mice. *P < 0.05. Bars represent mean ± SEM. N = number of biological replicates. 
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Figure S 3.2. In dorsal skin, dKO mice show no differences in Panx2, Cx26, Cx30, or 
Cx43 expression compared to WT mice. 
Panx2 full length and Panx2 isoform 202 (ENSMUST00000161372.1) qPCR and Western blot 
for P4-P5 skin. Panx2 transfected HEK cells were used as a positive control and represent full 
length Panx2. GAPDH was used as a positive control. Protein markers in kDa. (B) mRNA 
expression for Cx26, Cx30 and Cx43 in P5 skin. 18SrRNA or GAPDH was used to calculate 
normalized mRNA expression using the delta delta CT method. Bars represent mean ± SEM. 
N=4 for both WT and dKO in skin western blot, N=3 for both WT and dKO skin in Panx2 full 
length transcript in qPCR, and N=7 for both WT and dKO skin in Panx2 202 isoform, Cx26, 
Cx30 and Cx43 qPCR. N = number of biological replicates.  
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Figure S 3.3. In both hindlimb and cochlea there are no differences in Panx2, Cx26, 
Cx30, or Cx43 between WT and dKO mice. 
 (A) Panx2 Western blot and Panx2, Cx26, Cx30 and Cx43 mRNA expression via qPCR for 
P4-P5 hindlimb. Panx2 transfected HEK cells were used as a positive control and represent 
full length Panx2. GAPDH was used as the loading control. Protein measured in kDa. (B) 
mRNA expression for Cx26, Cx30 and Cx43 in P4-P5 cochleae. GAPDH was used to 
calculate normalized mRNA expression using the delta delta CT method. Protein markers in 
kDa. Bars represent mean ± SEM. N=3 for both WT and dKO in limbs and N=7 for both WT 
and dKO in cochleae. N = number of biological replicates. 
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3.4. Discussion 
Single pannexin knockout mice have been used to assess the impacts of Panx channels in 
various organs [3]. However, recent findings suggest potential compensatory mechanisms 
between Panx family members, reinforcing that dKO mice are necessary to examine their true 
functions within different organ systems. We created the first Panx1 and Panx3 double knock-
out mouse model (dKO) which was not trivial, since both Panx1 and Panx3 genes are closely 
located in chromosome 9 within 22 Mb of each other in the mouse genome (NCBI), thus 
making the recombination efficiency of this event very low.  
dKO mice showed decreased body weight, and this change was not previously observed in 
either of the two single KO models of Panx1 and Panx3 [22, 30]. However, qMRI of adult 
dKO mice did not show any differences in fat mass or lean mass, when normalized to body 
weight. In addition, dKO mice had significantly decreased litter sizes (fewer pups per litter) 
compared to controls; a finding that was also shown for Panx3-/- mice [22] and that may be due 
to higher intra-uterine death but remains to be studied.  
At P0, dKO mice had reduced dorsal skin thickness which was similarly found in our previous 
study for Panx1-/- mice [17]. At P4, however, this finding was no longer evident and instead 
dKO mice exhibited increased hypodermal area where subcutaneous fat is found. The Panx1-/- 
mice also had a significant increase in hypodermal area and an increase in overall fat content 
due to the enhanced differentiation capacity of adipose stromal cells from the Panx1-/- to form 
adipocytes with higher fat content [38].  
While an overt skeletal phenotype has not been associated with Panx1 KO mice, Panx3 KO 
mice have been reported to have shortened long bones, and hypo- mineralization of the skull 
and long bones [23, 39, 40]. Thus, the relatively mild skeletal phenotype observed in our dKO 
mice is unexpected, but similar to our previous report on the bone morphology of the global 
Panx3 KO mouse [23]. While we found significant skull shape differences between dKO and 
WT mice at P0, by three months dKO mouse skull morphology appeared to “recover”. This 
could be due to a combination of the minor phenotypic effects observed at P0 coupled with the 
rapid growth and remodeling of the mouse skull within the first two months of post-natal 
development [23]. The main skull shape changes we observed in dKO mice at P0 were 
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localized to the cranial base and cranial vault. Early postnatal growth of these regions is quite 
rapid, plateauing by P14-P21 in mice [41].  
Tibial and femoral lengths were shorter in dKO than WT mice at P0. However, no differences 
in tibial growth plates were observed at P0 between genotypes suggesting that subsequent tibial 
growth would be similar to WT, potentially enabling recovery of the phenotype through post-
natal development. For the humerus, cortical area (CA) and polar second moment of area (J) 
are significantly larger in dKO mice than WT at P0, suggesting that dKO humeri have an 
increased resistance to compressive and torsional forces respectively. By three months, CA 
and J of the humerus are similar between genotypes but the proportion of cortical area to total 
subperiosteal area (%CA) is significantly greater in dKO mice, indicating thicker cortical bone. 
At three months, dKO mice have significantly larger Imax/Imin ratios for the femur which 
indicates that the distribution of cortical bone within the cross-section is altered. Previously, 
we reported that humeri and femora of adult Panx3 KO mice have increased J and CA 
compared to WT mice [23]. While we expected similar results in our dKO model, it appears 
that knocking out both genes results in a phenotype separate from the single Panx3 KO. 
Previous studies showed that a conditional ablation of Panx1 in the cochlea resulted in severe 
hearing loss [25]. Additionally, a human patient harbouring a Panx1 mutation was found to 
exhibit many clinical symptoms including hearing loss [42]. In contrast, another Panx1-/- 
mouse had normal hearing and did not exhibit any auditory brainstem morphology deformities 
[24]. Recently, that same Panx1-/- model was found to have mild hearing loss at low frequencies 
which was more pronounced at higher frequencies (i.e. 32 and 40 kHz) [43]. Zorzi and 
colleagues re-examined the auditory phenotype of the first-generated Panx1-/- mice, and found 
that they did not have hearing loss [44]. To rule out the possibility that in the global Panx1 KO, 
Panx3 could be compensating for its function, we tested the dKO hearing and found that both 
pannexins are dispensable for hearing function. In fact, dKO mice had increased ABR wave 
amplitudes representing enhancement of the neural synchrony within these auditory brainstem 
regions. 
The double deletion of Panx1/Panx3 did not show more overt phenotypes than the single KO 
models and in some cases, reduced the severity of the phenotypes observed. As with Panx1 
and Panx3 single KOs, we might see more pronounced phenotypes once they are challenged 
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with different insults. In the dKO, there was no upregulation of Panx2 and connexins known 
to be expressed in some of these tissues [11, 45-47], plus in hindlimb we could not detect any 
expression of Panx2, Cx26 or Cx30. However, it is possible that these and other large pore 
channels can still functionally compensate for the missing Panxs deleted from germline 
throughout development. Therefore, in some instances, the use of conditional KOs may be 
necessary to avoid this potential issue with compensation that could mask some phenotypes.  
3.5. Conclusions 
In conclusion, we have shown that dKO mice have alterations in skin and bone at early stages 
but do not exhibit hearing loss, and show better recovery upon noise damage. Our findings 
suggest that Panx1 and Panx3 may be important in early development of musculoskeletal 
tissues but are not required for hearing. 
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Chapter 4 : Mice harbouring an oculodentodigital dysplasia-linked 
Cx43 G60S mutation have severe hearing loss 
 
 
 
The purpose of this study was to  characterize the localization profile and functional role of 
Cx43 within the mammalian cochlea in two different mouse models harbouring Cx43 
mutations. This study also aimed to examine the relationship between the functional status of 
Cx43 and auditory function. 
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4.1. Introduction 
Connexin (Cx), gap junction proteins form channels that allow for direct intercellular 
communication via the passage of small molecules and ions between contacting cells [1-3]. 
Although less understood in vivo, connexins may occasionally act as hemichannels at the cell 
surface to allow for transient exchange of small molecules between the cell cytosol and the 
extracellular environment [4]. Gap junctional intercellular communication (GJIC) is essential 
for the maintenance of key cellular processes such as apoptosis, proliferation, and 
differentiation in many tissues in the body including the inner ear [5, 6]. Gap junctions are 
critical in hearing as they form two specific networks in the cochlea; the epithelial and 
connective tissue gap junction networks [7, 8]. These networks allow passage of small 
molecules and ions throughout the syncytium and are thought to play roles in potassium 
buffering and metabolite transport [9, 10]. Gap junction channels are also thought to maintain 
ionic homeostasis through recycling of small molecules and secondary messengers within the 
cochlear duct [11-13]. In addition, connexin hemichannels may play a role in hair cell 
maturation and development, through release of calcium and ATP which are both required in 
early stages of hair cell development [14-17].  
The auditory system is broadly divided into two sub-categories; the peripheral auditory system 
which is made up of the outer (ear canal and eardrum), middle (middle ear bones) and inner 
(cochlea) ear, and the central auditory system which consists of the neurons that ultimately 
connect the mechanosensory hair cells in the cochlea to the brain. The auditory system is 
known to express multiple connexin family members including; Cx26, Cx30, Cx31, Cx29, 
Cx32 and Cx43, which are all expressed in various locations along the auditory tract [8, 10]. 
Importantly, the two types of mechanosensory hair cells, which either amplify sound coming 
into the cochlea (“outer” hair cells) or transform sound waves into electrical signals (“inner” 
hair cells) within an area of the cochlea called the organ of Corti, are devoid of any known 
connexins [6, 18]. Cx26 and Cx30, which are the most abundant connexins in the inner ear, 
form the two gap junction networks in the cochlea and have thus been the most studied 
connexins within the auditory system. Mutations in the genes encoding Cx26 are prevalent in 
patients with inherited hearing loss. Over 100 different gain or loss-of-function GJB2 (Cx26) 
gene mutations have been identified. In addition, mice harbouring both ablations and/or 
mutations in GJB2 (Cx26) and GJB6 (Cx30) have hearing deficits as well as altered cochlear 
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morphology in some cases [19-24]. Thus, due to the prevalence of GJB2 and GJB6 mutations 
in hearing loss, there is a strong need to identify molecules that can regulate connexin 
expression or function as a possible means to compensate for genetic deficiencies caused by 
connexin gene mutations.  
Cx43 is the most ubiquitously expressed connexin family member in the body and has been 
documented in various regions of the auditory tract including the stria vascularis, supporting 
cells [25], spiral ligament [26], and Schwann and satellite cells of the spiral ganglion neurons 
[27-29], all of which reside within the inner ear. In addition, Cx43 has been found in the 
cochlear bone that encapsulates the cochlea [30] as well as in resident cells of the auditory 
brainstem and midbrain relays (eighth cranial nerve, cochlear nucleus, olivary complex, lateral 
lemniscus, and the inferior colliculus) that are responsible for propagation of electrical signals 
throughout the brain [31, 32]. Although studies have identified Cx43 in these different regions 
along the auditory tract, its functional role and link to hearing remains unclear. Few studies 
have examined the prevalence of Cx43 mutations in patients harbouring hearing loss, with 
variable findings. In a group of Taiwanese patients with hearing loss, GJA1 (Cx43) gene 
mutations were found to be the second most common after GJB2 (Cx26) mutations [33]. 
However, other studies have found no evidence of Cx43 mutations in Turkish and African 
patients with hearing loss [34-36]. Interestingly, two recessive gene mutations in GJA1 (Cx43) 
leading to L11F and V24A amino acid substitutions in the cytoplasmically-exposed N terminal 
domain and the first transmembrane domain of Cx43, respectively, have been discovered in 
human patients and linked to non-syndromic hearing loss [37].  
In addition to genetic forms of hearing loss, environmental factors such as exposure to loud 
sound can lead to hearing impairments. Both Cx26 and Cx30, connexin family members that 
are critical for hearing, are thought to play a role in the active transport of sodium and 
potassium within the cochlea to maintain its proper function and homeostasis [7]. Recently, a 
study found that both Cx26 and Cx30 protein levels were significantly decreased after noise 
exposure [38]. Since then, another study has shown that when Cx26 was conditionally knocked 
down at postnatal day 18, these mice exhibited more pronounced noise-induced hearing loss 
than their wildtype counterparts [39]. At present, it is unknown if patients harbouring GJA1 
(Cx43) mutations are more susceptible to auditory damage after a loud noise exposure.  
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The limitations of examining the functional roles of Cx43 in the auditory system have been 
hindered by the fact that global Cx43 knock-out mice are lethal at birth [40]. To overcome this 
limitation, it is now possible to use genetically-modified mice to model human-linked Cx43 
diseases that typically manifest as the developmental abnormality known as oculodentodigital 
dysplasia (ODDD) [41-43]. ODDD is a human-linked disease that is inherited in mostly an 
autosomal dominant manner, where patients typically exhibit craniofacial abnormalities, 
fusion of soft tissue digits, small eyes, enamel defects, and in some rare cases neurological 
defects and/or hearing loss [41]. Previously, to assess the role of Cx43 in a wide variety of 
tissues and organs such as the skin, heart, mammary glands, bone, and brain, Cx43I130T/+ and 
Cx43G60S/+ mice have been used, which reduce Cx43 function to ~50% and ~20% of controls, 
respectively [44-48]. Given the differential levels of Cx43 function in these mutant mice, they 
become excellent surrogates to assess the role of Cx43 in hearing as we postulated that hearing 
loss might be found in both mutant mice or only mice that have little remaining Cx43 function 
(i.e. the Cx43G60S/+ mice).  
The aim of this study was to use mouse models of ODDD to investigate the impact of Cx43 in 
auditory function through various physiological assessments. First, to examine if fully 
functional Cx43 is crucial for proper development of the auditory tract. Secondly, to examine 
if the level of functional Cx43-based GJIC impacts auditory function and finally, to determine 
if the auditory system of Cx43 mutant mice is more susceptible to insult upon exposure to loud 
noise. We discovered that although Cx43I130T/+ mutant mice had normal hearing which 
persisted in mature adult mice and after a loud noise auditory insult, Cx43G60S/+ mutant mice 
had severe hearing loss suggesting that hearing impairment is a result of severe loss of Cx43 
function. 
4.2. Materials and methods 
4.2.1. Animals 
Heterozygous mice harbouring the Cx43 I130T mutation (generously obtained from Glenn 
Fishman) were created as previously described [44] and were bred on a C57BL/6 background 
and backcrossed in house for over 6 generations. Both male Cx43I130T/+ mutant and WT 
littermate controls were used for our studies. Mutant mice were phenotyped by evident 
syndactyly of the digits, and all mice were genotyped. In addition, heterozygote mice carrying 
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the Cx43 G60S mutation (generously obtained from Janet Rossant) were created as previously 
described [46]. These mice were on a mixed C3H/HeJ and C57BL/6 background, and 
Cx43G60S/+ mutant mice used in these studies were compared to their WT littermate controls. 
All mice tested were male and 2-3 months of age unless otherwise stated. Mice were housed 
in the animal care facilities at the University of Western Ontario, and maintained on a 12/12-
hour light/dark cycle and fed ad libitum. All experiments were approved by the Animal Care 
Committee at the University of Western Ontario.  
4.2.2. Ribonucleic acid extraction and reverse-transcription polymerase chain 
reaction 
Following euthanasia by CO2, cochleae were dissected from mice and flash-frozen in liquid 
nitrogen. Ribonucleic acid (RNA) was extracted from tissues using a combination of Trizol 
and a Qiagen RNeasy mini kit as was previously described [49]. A NanoDrop 
spectrophotometer was used to measure the absorbance of RNA and a one-step reverse 
transcription-polymerase chain reaction (RT-PCR) was performed using an RT-PCR Qiagen 
kit. The PCR profile was as follows: 50°C for 30min, 95°C for 15min, 94°C for 30s, 64°C for 
30s, and 72°C for 1 min for 30 cycles. Primers used were as follows: Cx43 specific primers 
(forward: 5’ -ACAACAAGCAAGCCAGCGAG-3’ and reverse: 5’ -
TCGTCAGGGAAATCAAACGG-3’), Cx26 specific primers (forward: 5’ -
CCGTCTTCATGTACGTCTTTTACAT-3’ and reverse: 5’ -
ATACCTAACGAACAAATAGCACAGC-3’) and Cx30 specific primers (forward: 5’ -
GGCCGAGTTGTGTTACCTGCT-3’ and reverse: 5’ -TCTCTTTCAGGGCATGGTTGG-
3’). 18S ribosomal ribonucleic acid (rRNA) was used as a housekeeping gene (forward: 5’ -
GTA ACCCGTTGAACCCCATT-3’ and reverse: 5’ -CCATCCAATCGGTAGTAGCG-3’). 
The amplified products were run on a 2% agarose gel with ethidium bromide for visualization.  
4.2.3. Quantitative RT-PCR 
Following euthanasia by CO2, cochleae were dissected from mice and flash-frozen in liquid 
nitrogen. RNA was extracted and converted to cDNA as previously described [49]. Two-step 
quantitative PCRs (qPCRs) were performed using a SYBR green PCR master mix by Life 
Technologies in order to quantify Cx43, Cx26, and Cx30 expression. The PCR protocol for all 
primers were as follows: 50°C for 2 min, 95°C for 2 min, 95°C for 5s, 60°C for 15s, followed 
by a melt curve. The same primers as mentioned above were used for qPCR and transcripts 
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were normalized to 18S rRNA. Normalized mRNA expression levels were analyzed using the 
delta delta CT method which was calculated using BioRad Software. A WT sample was set as 
the control for all calculations.  
4.2.4. Immunoblotting 
Following euthanasia by CO2, a litter of mice (approximately 6-10 cochleae) were dissected 
and pooled together (due to small tissue sizes) for one lysate sample and stored at -80°C. 
Cochleae were crushed with a mortar and pestle with liquid nitrogen as previously described 
[49]. Tissues were solubilized in RIPA buffer (50mM Tris-HCL, 150mM NaCl, 1% TritonX-
100, 13mM deoxycholic acid, 0.1% SDS) and 30 µg of lysate were run on 10% polyacrylamide 
gels using SDS-PAGE and transferred to nitrocellulose membranes using an iBlot transfer 
apparatus (Invitrogen). Membranes were blocked with 3% bovine serum albumin (BSA) in 
PBS-Tween (1X phosphate buffered saline, 0.05% Tween 20) for 1 hr. Blots were probed 
overnight with anti-rabbit Cx43 (1:750, Sigma, catalog#C6219) and anti-mouse GAPDH 
(1:10000 dilution, Chemicon, catalog#MAB374) antibodies. Blots were then washed and 
stained with mouse AlexaFluor 680 secondary antibody (1:5000 dilution, Life Technologies) 
for Cx43 and rabbit IRdye800 (1:5000, Rockland) for GAPDH for 2 hours. Membranes were 
visualized with an Odyssey infrared imaging system (LiCor). Quantitative analysis was 
performed using Odyssey software to assess the amount of Cx43 total protein expression in 2-
3-month-old mice. GAPDH was used as a loading control and a reference protein for 
quantitative analysis.  
4.2.5. Immunofluorescent labelling  
Following dissections of cochleae, a small incision was made in the cochlear bone near the 
apical turn and 4% paraformaldehyde (PFA) was perfused through both the round and oval 
windows of the cochlea. Cochleae were fixed in 4% PFA overnight at 4°C, then subsequently 
washed with PBS. Cochleae were then decalcified in 4% EDTA for 3 days and upon full 
decalcification were immersed in 30% sucrose overnight for cryopreservation of the tissue. 
Each pair of cochleae was embedded in an agarose solution, flash frozen, and allowed to 
acclimate in the cryostat at -25°C. Sections were cut at 18 µm thickness and stored at -20°C 
until use. Slides were blocked and permeabilized for 1 hr in 3% BSA+ 0.02% Triton-X 100 
solution. Subsequently, slides were incubated with primary antibodies in 4°C overnight. These 
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antibodies included; anti-rabbit Cx43 (1:750, Sigma, catalog#C6219), anti-mouse CNPase 
(1:200, Millipore, catalog#MAB326), anti-mouse GFAP (1:200, Sigma, catalog#63893), anti-
rabbit myosin VI (1:200, Proteus Biosciences, catalog#25-6791), anti-mouse CtBP2 (1:200, 
BD Transduction laboratories, catalog#612044), anti-mouse myelin basic protein (1:200, 
Abcam, catalog#62631), and anti-rabbit beta III tubulin (1:400, Abcam, catalog#18207). Slides 
were then washed and incubated with a fluorescent conjugated secondary antibody as well as 
phalloidin (1:400, Invitrogen, catalog#A12379) for 1 hr following a nuclear Hoechst stain. 
Slides were then mounted and confocal immunofluorescent images were acquired using an 
LSM800 Zeiss confocal microscope.  
4.2.6. Hearing assessment with the auditory brainstem response (ABR) 
Hearing levels were determined using the ABR technique, which measures the electrical 
activity in the brainstem evoked by the repeated presentation of a given acoustic stimulus to 
ultimately assess hearing sensitivity. Five individual acoustic stimuli were used in our studies 
which allowed us to test auditory function at various regions along the cochlea which code for 
different sound frequencies. These stimuli included a broadband click stimulus which 
comprises the 1-10 kHz frequency region of the cochlea, and four tonal specific stimuli of 4-, 
8-, 16-, and 24 kHz in order to assess both broadband as well as tonal specific frequencies. In 
this manner, the low to mid-frequency ranges spanning the apical and middle turns of the 
cochlea would be tested. A detailed description of the experimental procedures for ABR 
recordings was previously described [49]. Briefly, mice were deeply anaesthetized with 
ketamine (100 mg/kg) and xylazine (10 mg/kg) administered via intraperitoneal injections, and 
electrical activity was recorded through subdermal electrodes placed at the vertex (active 
electrode), mastoid of the stimulated ear (reference electrode) and on the mid-back (ground 
electrode). Mice were maintained at ~37°C on a digital homeothermic heating pad throughout 
the duration of the experiment. For ABR waveform analysis, BioSig software program was 
used to measure the amplitudes and latencies of 90 dB sound pressure level (SPL) click stimuli 
for each wave and each mouse group tested. 
4.2.7. Noise Exposures 
For a separate cohort of mice at one month of age, an initial ABR was followed immediately 
by a loud 12 kHz tonal stimulus at 115 dB SPL bilaterally for exposure in both ears for a one 
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hour time period as has been previously described [49]. During the procedure, mice were 
deeply anaesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), while noise 
exposures were performed in a sound attenuated chamber. Immediately following noise 
exposure, mice were reassessed with a second ABR to confirm elevation of thresholds at high 
frequencies following noise exposure. Mice were then administered antipamezole (1 mg/kg) 
to reverse the effects of anaesthesia and allowed to recover in their home cages. One week after 
the noise exposure, a third and final ABR was performed to determine the extent of permanent 
hearing damage incurred by the loud noise exposure.  
4.2.8. Organotypic cochlear cultures 
Organotypic cochlear explant cultures were prepared from the cochleae of postnatal day 1 to 3 
pups and grown in MatTek dishes with glass coverslip as has been described [50]. Mouse pups 
were sacrificed by cervical dislocation and were surface sterilized by immersion in 80% 
ethanol for 10 mins. The heads were removed and placed in Leibovitz L-15 medium 
(Invitrogen) where they were bisected midsagitally. The cochlear capsule was removed 
followed by the stria vascularis leaving the organ of Corti and the epithelium. The explants 
were then plated in a MatTek dish onto a 14 mm diameter round glass coverslip that was coated 
with Cell Taq (Corning) for adhesion. Coverslips were immersed in 150 µL DMEM/F12 
medium supplemented with 5% FBS (Invitrogen). Cultures were incubated at 37°C and 5% 
CO2 for approximately 24 hrs. Cochlear cultures were fixed with 4% PFA, blocked for one 
hour with 3% BSA+ 0.2% Triton-X 100 and subsequently incubated with a myosin VI antibody 
(1:200, Proteus Biosciences) overnight at 4°C. Alexa Fluor secondary antibody (1:1000, 
Invitrogen) was added to reveal labelling in addition to an Alexa Fluor-conjugated phalloidin 
stain to visualize hair cell stereocilia. In addition, cultures were subjected to a fluorescently 
labelled dye, FM1-43, that is readily taken up by hair cells through the mechanoelectrical 
transduction channel. Cultures were loaded with FM1-43 dye for 30 seconds and were 
subsequently fixed with 4% PFA then washed and mounted. Cultures were imaged using a 
Zeiss LSM800 high-resolution confocal microscopy. Images were acquired using a 25X 
objective lens, averaged 4 times, where 20 individual slices were taken and merged together 
for a an averaged image. 
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4.2.9. Statistical Analysis 
Two-tailed independent unpaired student’s t-test were used for comparisons of connexin 
expression in qPCR as well as in Western blots for Cx43 between WT and Cx43I130T/+ and WT 
and Cx43G60S/+ mice. Two-way analysis of variance (ANOVA) with Sidak’s post hoc tests 
were used to compare different cohorts in ABR threshold analysis, amplitudes and latencies of 
ABR waveform analysis, hair cells counts and ABR thresholds for noise exposure analysis at 
each individual stimuli.  
4.3. Results 
4.3.1. Cx43 mRNA transcript is expressed in the cochlea with no evidence of 
Cx26 or Cx30 compensation in Cx43 mutant mice 
To confirm that Cx43 is expressed specifically in the cochlea, we used reverse transcriptase 
quantitative real-time polymerase chain reaction (qRT-PCR) to determine the level of Cx43 in 
the cochlea of 2-3-month-old Cx43I130T/+, Cx43G60S/+ mutant mice and their respective age and 
sex matched littermate controls. We found that Cx43 mRNA transcripts were similarly 
expressed in cochleae of Cx43I130T/+, Cx43G60S/+ mutant mice and their WT littermate controls 
when normalized to 18S rRNA (Figure 4.S1A,B). Interestingly, both Cx26 and Cx30 mRNA 
transcripts were similarly expressed in cochleae of WT and Cx43 mutant mice suggesting no 
evidence of Cx26 or Cx30 compensation in Cx43I130T/+ or Cx43G60S/+ mutant mice at the mRNA 
level (Figure 4.S1C-F). 
4.3.2.  Total Cx43 protein levels is lower in the cochleae of Cx43G60S/+ mutant 
mice 
Total Cx43 protein levels were analyzed in cochlear lysates obtained from dissected whole 
cochleae at various postnatal time points (postnatal day 4 (P4), P8, P14, and P30, and P60-
P90). Both strains of WT mice had a high abundance of total Cx43 protein expression at all 
developmental time points with both phosphorylated (P1/P2) and non-phosphorylated Cx43 
species (NP) present (Figure 4.1A, B). 
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Figure 4.1. Cx43 protein levels are reduced in Cx43G60S/+ mice. 
Western blots revealed that Cx43 is prevalent in the cochlea of all mice with mutant mice 
exhibiting variable amounts of the P1/P2 phosphorylated species (A, B). Total Cx43 levels in 
the cochleae were quantified at 2-3 months of age and there were no differences in Cx43I130T/+ 
mice compared to controls (C), but there was a significant decrease in Cx43G60S/+ mutant mice 
compared to their WT littermates (D). N=5 pooled cochlear samples for each genotype. 
GAPDH was used as a loading control for western blots. Independent student T-tests were 
performed, ****P<0.0001. P= postnatal. NP = not phosphorylated; P1/P2 = phosphorylated 
species of Cx43. 
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Figure 4.1. 
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Cx43I130T/+ mutant mice appeared to have decreased Cx43 compared to their WT counterparts 
at all developmental time points; however, this difference was not significant when quantified 
for P60-P90 mice (Figure 4.1C). Cx43G60S/+ mutant mice had an apparent reduction in Cx43 in 
the cochleae at every developmental time point and a significantly lower level of total Cx43 
compared to wildtype littermates at the P60-P90 time point (Figure 4.1B,D).  
4.3.3. Cx43 is localized to cells of the cochlear nerve region 
A clear understanding of the localization profile of Cx43 along the auditory tract remains 
controversial. In an attempt to resolve this issue, cochlear cross sections from wildtype and 
mutant mice were immunostained for Cx43. As might be expected, there was no detectable 
Cx43 (absence of red staining) in inner ear hair cells which were demarcated by phalloidin 
staining of actin-rich stereocilia (green, Figure 4.2A,B). Little Cx43 (denoted by red) was 
detected in the spiral ganglion neurons or in satellite cells surrounding the neurons, labelled by 
CNPase (green) (Figure 4.2C). Farther along the auditory pathway, Cx43 was highly expressed 
in resident cells of the cochlear nerve region within the central modiolus, where all the spiral 
ganglion neurons are bundled together (Figure 4.2D). Upon higher level imaging, Cx43 was 
found in distinct gap junction plaques in areas surrounding GFAP-positive cells, an astrocytic 
glial cell marker (green) (Figure 4.2E, F, arrows). Cx43 gap junctions were also found between 
the cell processes which formed a “glial- like” syncytium in the cochlear nerve region (Figure 
4.2F). There was a noticeable reduction of Cx43 gap junctions in the cochlear nerve region of 
both mutant mice (Figure 4.2E,F).  
4.3.4. Cx43G60S/+ mutant mice have severe hearing loss and auditory 
brainstem deficits 
To assess whether hearing in the mutant mice is directly influenced by the extent of Cx43 
function, we utilized the auditory brainstem response (ABR) technique to measure hearing 
thresholds (i.e., hearing sensitivity) in response to various acoustic stimuli. Firstly, we 
administered a broadband click stimulus to the animals, which activates several regions of the 
cochlear sensory epithelium and thus provides an overall measurement of hearing sensitivity. 
Secondly, we played specific tonal frequencies (4, 8, 16 and 24 kHz), that activate hair cells in 
specific regions of the cochlea, to give an indication of where along the sensory epithelium any 
dysfunction is present. 
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Figure 4.2. Cx43 is highly expressed in select cells found in the cochlear nerve. 
Immunofluorescent images revealed that Cx43 is not expressed in the cochlear duct region 
(red=Cx43, green= phalloidin staining actin-rich stereocilia) (A) or in areas surrounding hair 
cells of the organ of Corti (B). There was little to no detection of Cx43 in the spiral ganglion 
neurons, red=Cx43, green=Schwann cells (C). Scale bars = 20µm. Cx43 was found in the 
modiolus region of the cochlea (red=Cx43, blue=nuclei) (D) and was localized amongst 
GFAP-positive cells (green=GFAP, red=Cx43, blue=nuclei) (E, F). OC= organ of Corti, SGN= 
spiral ganglion neurons, CN= cochlear nerve. Dashed line in (D) delineates the glial juncture 
of the cochlear nerve. Dashed box in (E) delineated area zoomed in (F). Arrows in (F) represent 
examples of Cx43 gap junction plaques in the cochlear nerve region. Scale bars = (A-C) 20µm 
(D) 100µm, (E, F) 20µm. 
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Figure 4.2. 
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Representative examples of an ABR trace recording from WT and Cx43I130T/+ mutant mice 
showed similar waveform characteristics and thresholds in response to a click stimulus at 
decreasing sound intensity levels (90 to 30 dB sound pressure level, SPL; Figure 4.3A). 
However, Cx43G60S/+ mutant mice had different waveform profiles including decreased ABR 
amplitudes (indicating less synchronized neural firing in the auditory brainstem relays), and 
increased thresholds (i.e. worse hearing) compared to their WT littermate controls (Figure 
4.3B). Averaged ABR thresholds were similar for all stimuli tested in WT and Cx43I130T/+ 
mutant mice at 2-3 months of age (Figure 4.3C). Normal hearing in Cx43I130T/+ mutant mice 
persisted in older mice at 6 months of age, albeit with an increase in ABR thresholds at higher 
frequencies, consistent with expected age-dependent high-frequency hearing loss due to their 
C57BL/6 background [51-53] (Figure 4.3E). Although hearing remained intact in Cx43I130T/+ 
mutant mice, averaged ABR thresholds for all stimuli tested were significantly increased in 
Cx43G60S/+ mutant mice compared to their WT littermate controls at both 1 and 2-3 months of 
age (Figure 4.3D,F) indicating that these mutant mice had severe hearing loss. ABR thresholds 
for Cx43G60S/+ mutant mice ranged from approximately 60-80dB SPL compared to 20-40dB 
SPL for WT littermate controls across all stimuli tested, showing a 40dB elevation in hearing 
thresholds (i.e., worsened hearing) of Cx43G60S/+ mutant mice compared to their WT controls. 
Collectively, these data show that although Cx43I130T/+ mutant mice have normal hearing, 
Cx43G60S/+ mutant mice have severe hearing loss. 
In addition to measuring hearing sensitivity, ABR waveform morphologies provide an 
indication of the integrity of the ascending auditory pathway, where waves I-V correspond 
with the successive relay centers (i.e., cochlear nerve, cochlear nucleus, superior olivary 
complex, lateral lemniscus, and interior colliculus, respectively). In order to examine whether 
Cx43 mutant mice had any defects in specific auditory brainstem regions, we analyzed the 
amplitudes and latencies of the loudest (90dB SPL) click ABR waveforms to assess neural 
synchrony, where larger amplitude represents more synchronous neural firing, and latency 
represents the speed of neurons firing, respectively.  
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Figure 4.3. Cx43G60S/+ mutant mice exhibit severe hearing loss. 
Representative examples of a click stimulus for Cx43I130T/+, Cx43G60S/+, and their respective 
WT littermate controls overlaid together (A, B). Mean ABR thresholds of all stimuli of 
Cx43I130T/+ and Cx43G60S/+ mutant mice and their WT littermate controls (C-F). Cx43G60S/+ 
mutant mice had significantly elevated ABR thresholds (i.e. worse hearing) at both 1 and 2-3 
months of age compared to their WT littermate controls, two-way repeated measures ANOVA, 
***P<0.001, ****P<0.0001 (D, F). WT and Cx43I130T/+ mutant mice: N= 8 mice for 2-3 
months and N=6 mice for 6 months in each genotype. WT and Cx43G60S/+ mutant mice: N=6 
for 1 month and N=8 for 2-3- months in each genotype. Bars represent mean ± SE. 
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Figure 4.3. 
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Cx43I130T/+ mutant mice had similar ABR amplitudes and latencies as WT controls (Figure 
4.4A,C). Interestingly, Cx43G60S/+ mutant mice had significantly decreased ABR wave 
amplitudes but no difference in latencies, suggesting Cx43-linked defects in neural synchrony 
and/or firing at those auditory brainstem regions but not conduction speeds (Figure 4.4B,D). 
Taken together, these results suggest that although Cx43I130T/+ mutant mice do not have 
auditory brainstem region deficits, Cx43G60S/+ mutant mice exhibit sensorineural hearing loss.  
4.3.5. Hearing loss in Cx43G60S/+ mice is not due to reduced hair cell number 
or functional loss  
Given that loss of hair cell number is a common cause of hearing impairment, we next assessed 
whether hearing loss in Cx43G60S/+ mice was due to inefficient development of the sensory 
epithelium. To this end, we cultured the organ of Corti from WT and Cx43 mutant pups (P0-
P3) to visualize and count the number of hair cells. Representative images of organotypic 
cochlear cultures from WT and Cx43 mutant mice in each turn of the cochlea (apical, mid-
apical, basal and mid-basal) showed that hair cells were intact in all mice as visualized with 
the hair cell marker, myosin VI (green), and the stereocilia marker, phalloidin (red) (Figure 
4.5A). When the number of outer and inner hair cells were quantified from cochlear cultures 
there was no hair cell loss evident in Cx43I130T/+ or Cx43G60S/+ mutant mice in any of the 
cochlear regions (Figure 4.5B).  
Hair cell activation occurs via the deflection of hair-like stereocilia on the apical surface of 
hair cells in response to sound-induced vibration of the sensory epithelium (organ-of-Corti). 
The deflection causes the opening of mechanotransducer (MET) channels that allows the influx 
of cations including K+, of which the concentration in endolymph is extremely high (150 mM). 
This leads to depolarization of hair cells and consequent calcium uptake and neurotransmitter 
release. Taking advantage of this mechanism, we investigated whether hair cells in Cx43G60S/+ 
mice were functional by exposing cochlear cultures to a MET channel-permeable, fluorescent 
FM1-43 dye. If MET channels are functional, the dye would enter hair cells and fluoresce 
green. Representative low (Figure 4.S2A) and high (Figure 4.S2B) resolution images revealed 
that the rows of inner and outer hair cells of both Cx43 mutant and WT mice were able to take 
up the FM1-43 dye. Taken together, organotypic cochlear cultures revealed that hearing loss 
in Cx43G60S/+ mutant mice is not due to hair cell damage in early postnatal development. 
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Figure 4.4. Amplitudes and latencies of all five ABR waveforms were analyzed for a 
90dB SPL click stimulus. 
Cx43I130T/+ mutant mice had similar ABR wave amplitudes (neural firing/synchrony) and 
latencies (neural conduction speeds) for all five ABR waves compared to WTs (A, C). 
However, Cx43G60S/+ mutant mice had significantly decreased ABR wave amplitudes 
compared to WTs (B), two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001), 
although the ABR wave latencies remained the same (D). N=8 mice per each cohort of each 
genotype. Bars represent mean ± SE. 
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Figure 4.4.  
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Figure 4.5. Cx43G60S/+ mutant mice do not exhibit postnatal hair cell loss in cochlear 
cultures. 
Representative confocal images of hair cell staining in each genotype of mice in four different 
regions of the cochlea representing different frequency ranges; Basal- high frequency, Mid-
Basal- Mid-high frequencies, Mid-Apical- Mid-low frequencies, and Apical- Low frequencies 
(A). Hair cell bodies were stained with myosin VI (green) and stereocilia of hair cells were 
stained with phalloidin (red). When the number of outer and inner hair cells were quantified 
for each cochlear region, there were no differences found in either Cx43 mutant mice compared 
to their WT littermate controls (B). Images were acquired on a 25x lens from 20 individual 
stacked slices (from the top to bottom span of the culture) and compiled to generate one merged 
image. OHC= outer hair cells, IHC= inner hair cells. Blue= nuclei. Scale bars = 50µm. 
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Figure 4.5. 
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Although cochlear cultures from P0-P3 pups revealed that Cx43G60S/+ mutant mice did not have 
hair cell loss, hair cells at this stage are still immature and are not fully developed until ~P14. 
Since Cx43G60S/+ mutant mice exhibited hearing loss at both 1 and 2-3 months of age, we 
assessed whether there was hair cell loss in adult (2-3 month-old) mutant mice. Staining for 
hair cell markers, myosin VI and actin, in whole mount cochlear epithelium preparations of 
adult cochleae from the apical turns showed no evidence of hair cell loss, and the hair cells 
retained normal morphological appearances in Cx43G60S/+ mutant mice (Figure 4.6A). Further, 
to examine the structural integrity of the synaptic interface between the inner hair cells and the 
spiral ganglion neurons, we stained adult whole mount sections with myosin VI to visualize 
hair cells, and CtBP2, a molecular marker expressed in ribbon synapses of hair cells that 
promotes rapid release of neurotransmitters to the spiral ganglion neurons. These dense ribbon 
synapses are essential for propagation of electrical signals to the brainstem, and loss of such 
markers as CtBP2 can lead to hearing loss. Inner hair cells of Cx43G60S/+ mutant mice appeared 
to have a similar number of CtBP2-positive synapses as controls suggesting no shortages in 
the innervation of inner hair cells (Figure 4.6B).  
4.3.6. Hearing loss in Cx43G60S/+ mice is not due to any evident spiral 
ganglion neuron degeneration or demyelination in the cochlear nerve region  
Since there was no evidence of hair cell loss in the mutant mice, we next looked at spiral 
ganglion neuron morphology. There was no evidence of neuronal loss in Cx43G60S/+ mutant 
mice as evidenced by immunofluorescent labeling of beta III tubulin, a neuronal marker, 
showing similar staining patterns in both WT and mutant mice (Figure 4.7A). Further, we 
examined if Cx43G60S/+ mutant mice presented any evidence of differential expression of 
myelin in the modiolus region using a marker of myelin, myelin basic protein. The cochlear 
nerve regions in both WT and Cx43G60S/+ mutant mice had abundant expression of myelin basic 
protein (Figure 4.7B,C), however, whether there is more intricate disarrangement of myelin 
within the cochlear nerve region of Cx43G60S/+ mutant mice remains unknown. 
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Figure 4.6. Hair cells of Cx43G60S/+ mutant mice remain intact in adult mice. 
Hair cells dissected from the apical region of adult (2-3 month-old mice) cochleae labeled with 
myosin VI (green) and phalloidin (red) revealed that hair cells were intact (A). Similarly, adult 
Cx43G60S/+ mutant mice did not exhibit hair cell loss (A). Adult whole mounts were also stained 
for hair cell-specific ribbon synapses using antibodies that target CtBP2 (red) (B). Arrows 
indicate individual synapses that can be visualized. OHC= outer hair cells, IHC= inner hair 
cells. Scale bars = 10µm. 
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Figure 4.6. 
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Figure 4.7. Spiral ganglion neurons remain intact with no evidence of spiral ganglion 
neuron degeneration or demyelination of the cochlear nerve in Cx43G60S/+ mutant mice. 
Immunofluorescent confocal images of spiral ganglion neurons of WT and Cx43G60S/+ mutant 
mice labeled for beta-tubulin (neurons = green) and CNPase (Schwann cells = red) (A). 
Representative images of cochlear cross sections in WT and Cx43G60S/+ mutant mice (B). 
Higher magnification images revealed abundant myelin, stained with myelin basic protein 
(green) in the cochlear nerve region (C). Note that Cx43 (red) is far less abundant in the 
cochlear nerve region of mutant mice compared to littermate controls (B, C). OC= organ of 
Corti, SGN= spiral ganglion neurons, CN= cochlear nerve. Scale bars = (A) 20µm, (B) 
100µm, and (C) 20µm.  
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Figure 4.7. 
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4.3.7. WT and Cx43I130T/+ mutant mice have similar susceptibility to noise-
induced hearing loss  
To examine whether Cx43 plays a role in noise-induced hearing loss, we delivered a 12 kHz 
tonal stimulus at 115 dB SPL for 1 h to Cx43I130T/+ mutant mice and their WT littermate 
controls. Since reduced expression of Cx26, a known connexin family member that is required 
for hearing, has been shown to sensitize mice to noise-induced hearing loss, we postulated that 
mutant mice with reduced Cx43 function would be more susceptible to loud noise-induced 
hearing loss if Cx43 played a central role in this process. Hearing testing was measured using 
the ABRs at three separate time points; (1) baseline; (2) immediately after loud noise exposure; 
and (3) one week after noise exposure. While ABR thresholds remained similar in the low 
frequencies (Figure 4.8A-C), as expected, thresholds were elevated immediately after noise-
exposure in both WT and Cx43I130T/+ mice at the high (16- and 24 kHz) frequencies (Figure 
4.8D,E). With the exception of the broadband click stimulus which changed only by ~10%, 
there were no differences in ABR thresholds between WT and Cx43I130T/+ mutant mice one 
week after noise-exposure (Figure 4.8A-E). Importantly, WT and Cx43I130T/+ mutant mice 
recovered to the same degree 7 days after noise-exposure at the high frequency stimuli, where 
the chosen noise-exposure preferentially damaged the peripheral auditory system (i.e., 
thresholds were greater at the high versus the low frequency stimuli). Thus, upon challenging 
the auditory system with a loud noise exposure, both WT and Cx43I130T/+ mutant mice have 
similar susceptibility to noise-induced hearing loss. 
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Figure 4.8. WT and Cx43I130T/+ mutant mice have similar susceptibility to noise-induced 
hearing loss. 
Noise exposure (NE) increased ABR thresholds immediately after NE (Post NE) for all stimuli 
tested, confirming auditory damage in both WT and Cx43I130T/+ mutant mice (A-E). The 
highest ABR thresholds post NE were found at the higher frequency stimuli (D) 16kHz and 
(E) 24kHz tones. There were no differences between the two groups at the higher frequency 
stimuli 7 days after NE (D, E). Two-way repeated-measures ANOVAs with a post hoc Sidak’s 
test were performed for each individual stimulus, *P<0.05. N=6 for both WT and Cx43I130T/+ 
mice. Bars represent mean ABR threshold ± SE.  
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Figure 4.8. 
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Figure S 4.1. Connexin mRNA transcripts are expressed in the cochlea at similar levels 
in WT and mutant mice. 
Cx43 is expressed in the cochlea of both Cx43 mutant mice as well as their wildtype (WT) 
littermate controls (A, B). There was no evidence of compensation by Cx26 or Cx30 mRNA 
transcripts in Cx43 mutant mice (C-F). Gels presented reflect RT-PCR and graphs represent 
qPCR where mRNA transcript expression were quantified. 18S rRNA was used as a reference 
gene. Independent student T-tests were used for each group, N=4, n=12 for Cx43I130T/+ and 
N=7, n=21 for Cx43G60S/+ cochleae for each genotype in each qPCR experiment. Points on 
graph represent mean of triplicates for each biological sample (i.e., mean of 4 and 7 for 
Cx43I130T/+ and Cx43G60S/+, respectively. Bars represent ±SEM of biological samples (i.e., 4 
and 7). 
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Figure S 4.1. 
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Figure S 4.2. Hair cells in control and mutant mice have functional mechanoelectrical 
transducer channels. 
Representative examples of FM1-43 dye uptake into hair cells in Cx43I130T/+, Cx43G60S/+ 
mutant mice and their WT littermate controls (A). Arrow indicates location of hair cells, which 
have taken up fluorescently labelled dye that is shown in green. Higher magnifications of FM1-
43 dye-labeled hair cells revealed fluorescent dye within the cytoplasm of the hair cell. (B). 
Images were acquired using a confocal microscope equipped with a 10X objective lens. Six 
individual tiled images were seamlessly compiled together into a montage. OHC= outer hair 
cells, IHC= inner hair cells. Scale bars=200µm in (A) and 20µm in (B).  
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Figure S 4.2. 
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4.4. Discussion 
It has been known for some time that Cx26 and Cx30 are essential for auditory function as 
mutations in the genes encoding both of these connexins are causal of hearing loss. The role 
of Cx43 in hearing is far less clear although this connexin has been reported to be expressed at 
defined locations along both the peripheral and central auditory regions [25, 28, 30, 31, 54]. 
Furthermore, two mutations in the gene encoding Cx43 (GJA1), L11F and V24A, have been 
identified in a cohort of patients with non-syndromic hearing loss providing a putative link 
between Cx43 and hearing loss [37]. To ascertain whether Cx43 contributes to hearing, we 
used two genetically-modified mouse lines that have been classically used to investigate the 
role of Cx43 in the developmental disorder known as oculodentodigital dysplasia (ODDD). 
We found that Cx43I130T/+ mutant mice, which have been shown in other cell lines and tissue 
to retain ~50% of total Cx43 gap junction function [44], have normal hearing which persisted 
in middle aged mature mice. However, Cx43G60S/+ mutant mice, which have been shown to 
have ~20% Cx43 function in other cell types and tissues [46], exhibit severe hearing loss and 
auditory brainstem (where Cx43 is expressed) neural firing deficits. Intriguingly, hearing loss 
was not attributed to loss of hair cell number or function suggesting the defect lies downstream 
of the organ of Corti, i.e., within the central neural pathway. In challenging the auditory system 
with exposure to a loud noise, Cx43I130T/+ mutant mice exhibited similar susceptibility to 
hearing impairment as their wildtype littermate controls, thereby minimizing a possible role of 
Cx43 in noise-induced hearing loss. Taken together, this study suggests that Cx43 is involved 
in the normal function of the auditory system. 
Cx43 is the most ubiquitously expressed connexin family member and it has been linked to 
ODDD, a human disease that is inherited in mostly an autosomal dominant manner [41]. 
Patients with ODDD exhibit many different symptoms including; craniofacial bone 
abnormalities, small eyes, enamel loss, and fusion of soft tissue digits [41, 42]. In rare cases, 
patients can also exhibit neurological deficits and hearing loss, which has been found in ~7% 
of reported ODDD cases [42]. Hearing loss in ODDD patients has been mostly attributed to 
conductive hearing loss, which is caused by abnormalities in either the outer or middle ear, 
where sound cannot adequately reach the cochlea, while others were reported to be due to 
central auditory deficits and a few remain idiopathic [42]. However, it is currently unknown 
why some patients with ODDD exhibit hearing loss while others do not and whether this is 
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regulated by the functional status of Cx43. Thus, to examine Cx43 in the auditory system we 
repurposed two different human disease-linked mutant mouse models of ODDD, Cx43I130T/+ 
and Cx43G60S/+, that were previously used to study ODDD in a variety of tissues and organs 
[44-48]. These two Cx43 mutants have distinct effects on Cx43 function. For example, when 
expressed alone in gap junction-deficient N2A or HeLa cells, the I130T mutant maintains 
residual gap junction channel function [43, 45] while the G60S mutant is functionally dead 
[45, 46, 55]. However, when the same mutants are expressed in cells that co-express wild-type 
or endogenous Cx43, the functional levels of total Cx43 channels are consistently reduced to 
~50% normal (I130T) or ~20% normal (G60S) reflecting their dominant behavior on Cx43 
[44-48, 56, 57]. Thus, although Cx43-based GJIC function has not been examined specifically 
in the auditory system (due to inaccessibility of the auditory tract for GJIC studies), we can 
extrapolate that the loss of Cx43 function in both mutant mice within Cx43 expressing cells of 
the auditory system should be similar to what has been previously reported. Therefore, using 
these two different mutant mice with both mild and severe loss of Cx43-based GJIC, we were 
able to assess how the level of functional Cx43 impacts hearing. 
To our knowledge, only one study in mice has attempted to assess the role of Cx43 in hearing 
and they found that 3-4 month-old Cx43+/- mice had comparable hearing competence to 
controls with a modest decrease in hearing capability in 10 month old Cx43+/- mice [31]. These 
findings are consistent with adult Cx43I130T/+ mice that did not have any significant hearing 
impairments probably due to the fact that they also retained at least 50% normal Cx43 function. 
However, Cx43G60S/+ mutant mice harbouring only ~20% Cx43-based GJIC had severe hearing 
loss which was found to be ~60dB across all sound frequencies. Hearing loss in Cx43G60S/+ 
mutant mice was accompanied by decreases in all ABR waveform amplitudes which indicate 
decreased neural synchrony and/or firing of downstream auditory brainstem regions, where 
wave I represents the cochlear nerve activity and the subsequent waves (II-V) represent 
electrical activity in the subsequent relay nuclei of the central auditory pathway [58]. In this 
manner, reductions of neural synchrony and/or firing could lead to inadequate transmission of 
auditory signals to the central auditory system. This finding suggests that Cx43 is involved in 
proper firing of neurons within the auditory brainstem nuclei as mice with severe loss of Cx43 
function exhibited significantly decreased amplitudes. A previous study reported a similar 
phenotype in Cx29-/- mice, where they had severe hearing loss and distorted ABR wave I 
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amplitudes [59]. Interestingly, Cx29 is expressed in the myelinating Schwann cells of the spiral 
ganglion neurons, whose axons are bundled together to form the cochlear nerve (i.e. 
represented by the ABR wave I). Upon further analysis, it was found that hearing loss and 
cochlear nerve defects in Cx29-/- mice was due to demyelinated auditory nerve fibers in the 
spiral ganglion neurons [59]. Thus, the authors speculated that hearing loss in Cx29-/- mice was 
due to auditory neuropathy spectrum disorder, which is hearing loss in the presence of intact 
hair cells within the peripheral auditory system, but where there is abnormal transmission of 
sound conduction through the auditory nerve and to the brain within the central auditory 
system. Another gene linked to auditory neuropathy is Cx32, where mutations in the gene 
encoding Cx32 cause X-linked Charcot-Marie-tooth disease (CMTX). In the auditory system, 
Cx32 is expressed in the stria vascularis [60] and in the cochlear nerve region near the glial 
juncture [59], where we have also found Cx43 to be expressed. Patients with CMTX also 
exhibit hearing loss in some cases, which has been attributed to both cochlear and neural 
auditory pathologies [61, 62]. Thus, Cx29, Cx32, and Cx43-induced hearing loss appear to 
manifest from abnormal transmission of sound to the higher-order centers of the auditory 
pathway, consistent with auditory neuropathy spectrum disorder.  
To further elucidate the mechanism of hearing loss in Cx43G60S/+ mutant mice, we examined 
Cx43 expression and cell/tissue integrity using a top-bottom approach of the auditory tract 
from the peripheral auditory system including the morphology of the cochlea, to the status of 
hair cells and spiral ganglion neurons, to the cochlear nerve region, and finally to the first part 
of the central auditory system. First, at the level of the cochlea, we found that Cx43G60S/+ mutant 
mice did not exhibit hair cell loss, and these cells remained functional as assessed via FM1-43 
dye uptake through MET channels that are essential for proper depolarization of hair cells. 
Upon examination of hair cells in 2-3 month-old adult mice, it was evident that the mechanism 
of hearing loss in Cx43G60S/+ mice was not due to mature hair cell loss in animals. Likewise, 
farther along the auditory tract, there was no evidence of spiral ganglion neuron degeneration 
in Cx43G60S/+ mutant mice compared to WTs. Finally, we found that Cx43G60S/+ mutant mice 
had significantly decreased ABR wave amplitudes in all five waves suggesting that neural 
synchrony is altered in the auditory brainstem regions where we and others [31] have shown 
Cx43 to be expressed. Decreases in the first ABR wave have been previously associated with 
auditory nerve fibre reductions which can lead to hearing loss [63]. However, Cx43G60S/+ 
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mutant mice did not exhibit any differences in inner hair cell synapses as was revealed by 
CtBP2 staining of ribbon synapses. Due to the presence of an intact organ of Corti, the lack of 
hair cell loss, and the high abundance of Cx43 in the cochlear nerve, it is likely that the 
mechanism of hearing loss in Cx43G60S/+ mice is due to auditory brainstem neural deficits and 
is occurring downstream of the organ of Corti. Due to the abundant expression of Cx43 gap 
junction plaques in the cochlear nerve region and the decreased ABR wave amplitudes, the 
most probable mechanistic site of hearing loss in Cx43G60S/+ mutant mice is in the cochlear 
nerve region. 
In the auditory tract of young guinea pigs, rats and humans, Cx43 has been found in the satellite 
glial cells of the spiral ganglion neurons [27, 28, 54]. In mice, a study showed that Cx43 was 
weakly expressed in the immature sensory epithelium until postnatal day 8 when Cx43 became 
exclusively localized to the cochlear bone [30]. Recently, Cx43 has also been described in mice 
in the modiolus region of the cochlea as well as the higher auditory brainstem relays [31]. The 
current study showed that Cx43 is found in gap junctions within the cochlear nerve region and 
surrounding astrocytic processes. This Cx43 localization pattern has also been shown in the 
brain where it is expressed amongst astrocytic processes that produce a glial syncytium 
network enabling a conduit for glial cell communication [64, 65]. The proposed role of Cx43 
in these networks is to clear out waste materials such as excess neurotransmitter and potassium 
ions, allow the passage of metabolites and ions from capillaries to neurons, as well as to recycle 
metabolites and ions that are important in normal neuronal homeostasis within the brain [32, 
66, 67]. For example, one of the most prevalent roles of Cx43 in astrocytes of the brain is 
potassium buffering and clearance where it is proposed to shuttle potassium ions from areas of 
high concentration to areas of low concentration in the brain to redistribute these excess ions 
arising from neural activity [68, 69]. In this manner, Cx43 maintains homeostasis and alleviates 
toxicity as well as the buildup of unwanted ions in the brain. Therefore, due to the prevalence 
of Cx43 around glial cells in the cochlear nerve regions and the decreased neural output of the 
auditory brainstem regions, we propose that Cx43 may be playing a similar role in the cochlear 
nerve region. More specifically, Cx43 gap junctions in this region can assist in maintaining ion 
homeostasis and dissipation of potentially harmful molecules such as overexposure to 
potassium ions or glutamate neurotransmitters, which have both been shown to cause hearing 
damage [70]. These Cx43 based gap junction channels would provide communication in glial 
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cells of the cochlear nerve region and in turn could shuttle K+, glutamate, and other ions and 
neurotransmitters from areas of high to low concentrations to maintain proper cellular 
homeostasis within this auditory region, similar to the role of Cx43 in astrocytes of the brain. 
In turn, lack of efficient Cx43-based GJIC in astrocytes in the cochlear nerve could impede 
further conduction of auditory signals throughout subsequent brainstem relays.  
Although studies have suggested a link between Cx43 and hearing its involvement in noise-
induced hearing loss is unknown. Both Cx26 and Cx30 are thought to play a role in the active 
transport of sodium and potassium within the cochlea and [7] both Cx26 and Cx30 protein 
levels were significantly decreased after noise exposure [38]. In addition, when Cx26 was 
conditionally knocked down at postnatal day 18, mice exhibited more pronounced noise-
induced hearing loss than their wild type counterparts [39]. In the present study we sought to 
investigate the potential contributions of Cx43 to noise-induced hearing loss. When we 
challenged the auditory system of Cx43-compromised (~50% normal Cx43 function) 
Cx43I130T/+ mutant mice with an acute loud noise, we found that there was no increase in 
susceptibility to noise trauma, or recovery, when compared to littermate controls, unlike what 
has been shown for Cx26. The relative differences in the impact of noise-exposure of these 
two different connexins may give us novel insights into their relative roles within the auditory 
tract. This suggests that Cx43 is not likely linked to noise-induced hearing loss as might be the 
case for Cx26.  
4.5. Conclusions 
In summary, it is well known that mutations in genes encoding connexin family members (such 
as Cx26 and Cx30) lead to mild, moderate, and severe hearing loss [19-24]. Here, we have 
identified that Cx43G60S/+ mutant mice that retain only ~20% normal Cx43 function exhibit 
severe hearing loss and central auditory deficits, thereby expanding the list of connexin family 
members linked to hearing loss. We propose that Cx43 is essential in the propagation of sound 
from the cochlear nerve to the higher-order auditory regions, and thus, a loss of Cx43-based 
GJIC results in abnormal transmission of sound conduction, similar to what is seen in auditory 
neuropathy spectrum disorders. Furthermore, we have found that a 50% reduction of Cx43 
does not appear to play a role in noise-induced hearing loss in mice. Taken together, we have 
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identified Cx43 function as being critically important in hearing, which may explain why some 
ODDD patients harbouring Cx43 mutants have the additional morbidity of hearing loss.  
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Chapter 5 : Cisplatin-induced ototoxicity in organotypic cochlear 
cultures occurs independent of gap junctional intercellular 
communication 
 
 
 
Cisplatin is a very effective chemotherapeutic agent used to treat cancers, however, it causes 
hearing loss in the majority of patients. In this chapter, we use two different models to ablate 
Cx43 function in inner ear derived cultures and assessed whether decreasing GJIC impacts 
cisplatin-induced ototoxicity. 
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5.1. Introduction 
Connexins, the protein subunits that form gap junction channels, allow for the passage of 
members of the metabolome up to 1kDa in size, establishing a form of cellular signaling called 
gap junctional intercellular communication (GJIC) [1,2]. Mounting evidence suggests that 
connexin hemichannels where cochlear cells communicate with the extracellular milieu also 
serve important functions [3]. Gap junctions are essential to maintain proper tissue homeostasis 
as evidenced by nearly 30 distinct diseases that are associated with connexin gene mutations, 
with hearing loss being the most frequently occurring impairment [4]. Clinically, mutations 
and/or deletions in GJB2 (encoding Cx26) and/or GJB6 (encoding Cx30) are responsible for 
nearly 50% of congenitally acquired hearing loss with approximately 135 different mutations 
in GJB2 causing hearing loss [4,5]. 
Spontaneous activity in the cochlea depends upon ATP and calcium release, suggesting a 
critical role for connexins in cochlear development [3,6]. The necessity of connexins in the 
development of the organ of Corti (i.e. the sensory epithelium in the cochlea) is revealed from 
the use of Cx26 conditional knock-out mice where hair cell loss and underdevelopment of the 
organ of Corti leads to hearing loss [7–9]. Complementary studies using tamoxifen-induced 
Cx26 knock-down mice revealed that Cx26 was a key regulator in early cochlear development. 
Indeed, knocking down Cx26 in early postnatal stages resulted in severe hearing loss, 
malformation of the cochlea, and defects in supporting cells [10–13].  
The localization and expression pattern of Cx43 in the cochlea remains controversial but Cx43 
has been reported to be expressed at distinct developmental time points in the organ of Corti 
[14–16], spiral limbus [17], spiral ganglion neurons [18–20], cochlear lateral wall [21], 
cochlear nerve, and auditory brainstem tract [22]. In keeping with a key role for Cx43 in 
hearing, we previously showed that the severe loss of Cx43 function led to hearing loss [23], 
suggesting that Cx43 plays an important role in the development and/or function of the auditory 
pathway. That said, it remains unclear if dysregulated Cx43 status during development 
influences the susceptibility of cochlear cells to drug-induced cell death and hearing loss.  
One of the most effective and commonly used chemotherapy drugs to treat solid malignant 
tumours in both children and adults is cisplatin (cis-diamminedichloroplatinumII) [24]. 
Although commonly used, it causes hearing loss in approximately 75-100% of patients [25]. 
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In most cases, cisplatin-induced hearing loss is permanent, and often progressive. Notably, 
approximately 60-80% of children who are treated with cisplatin will develop significant 
hearing loss [26], which can hinder their cognitive and speech skills throughout development 
[27]. Within the cochlea specifically, animal models have shown that cisplatin causes damage 
to the stria vascularis, spiral ganglion neurons, and hair cells [28]. Given that supporting cells 
of the organ of Corti have some of the largest and most active gap junctions found in the human 
body [29], it has been proposed that these channels may facilitate the spread of toxic death 
signals to adjoining cells amplifying cell death in a process called the bystander effect [30]. 
Others have argued that the bystander effect acts as a “Good Samaritan” by diluting the effect 
of toxins which protects the organ of Corti from increased damage [30]. To address the cellular 
mechanisms of cisplatin-induced ototoxicity, we utilized organ of Corti cultures that retain the 
three-dimensional aspects and architecture of this sensory organ in addition to a well-known 
immortalized cochlear cell line, HEI-OC1, which resembles cochlear progenitor cells [31].  
The aims of this study were threefold. We first used organotypic cochlear cultures from two 
Cx43 mutant mice which harbor either a moderate (Cx43I130T/+) or severe (Cx43G60S/+) loss of 
Cx43 function to determine the impact of reduced GJIC on cisplatin-induced ototoxicity. 
Secondly, we co-administered a gap junction blocker with cisplatin to determine whether 
blocking all cochlear gap junctions alters susceptibility to cisplatin-induced ototoxicity. 
Thirdly, we used control and Cx43 knockout HEI-OC1 cochlear-derived cells to evaluate the 
cellular mechanisms underpinning cisplatin-induced ototoxicity.  
5.2. Materials and methods 
5.2.1. Mice 
Heterozygous mice harboring the Cx43 I130T mutation (generously obtained from Glenn 
Fishman, New York University School of Medicine, New York, NT, USA) were created as 
previously described [32] and were bred on a C57BL/6 background and backcrossed in house 
for over six generations. Heterozygous mice harboring a Cx43 G60S mutation (generously 
obtained from Janet Rossant, The Hospital for Sick Children, Toronto, ON, Canada), were 
created as previously described and [33] were bred on a C3H/HeJ and C57BL/6 mixed 
background and backcrossed in house on a C3H background for over six generations. Both 
mutant mice were compared to their wild type (WT) littermates for all experiments and both 
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male and female neonatal pups were used. WT C3H mice were used for all experiments where 
carbenoxolone was employed as a gap junction blocker. Mice were housed in the animal care 
facilities at the University of Western Ontario and maintained on a 12-h-light-12-h-dark cycle 
and fed ad libitum. All experiments were approved by the Animal Care Committee at the 
University of Western Ontario.  
5.2.2. Organotypic cochlear cultures 
Organotypic cochlear cultures were prepared from the cochleae of postnatal day 0-3 (P0-P3) 
pups of both sexes, combined, and maintained in glass bottom dishes as was previously 
described [23]. Briefly, mouse pups were sacrificed by decapitation and sterilized in 80% 
ethanol for 10 minutes and dissected in ice-cold Leibovitz-L15 media (Invitrogen, 
catalog#11415-064). The epithelium of the organ of Corti was removed and the explants were 
plated in a glass bottom dish coated with Cell Tak (Corning; catalog#CB40240) to enhance 
adhesion to the substrate. Cultures were immersed in 200µL Dulbecco’s Modified Eagle’s 
Medium (DMEM)/F12 medium supplemented with 5% fetal bovine serum (FBS) (Invitrogen), 
and 100µg/mL ampicillin. Cultures were incubated at 37ºC and 5% CO2 overnight after 
dissection to ensure proper adhesion. Subsequently, cultures were treated with either regular 
media or 20µM cisplatin, 100µM carbenoxolone (CBX), or a combination of 20µM cisplatin 
+ 100µM CBX for a total of 48 hours prior to fixing with 4% paraformaldehyde (PFA). Media 
was replaced every 24 hours for all respective treatments. 
5.2.3. Immunofluorescence labelling  
Fixed cell cultures were blocked and permeabilized in either a 3% bovine serum albumin 
(BSA) + 0.1% TritonX-100 (HEI-OC1 cells) or 3% BSA+ 0.2% Triton X-100 (organotypic 
cochlear cultures) solution for one hour. Subsequently, cell cultures were incubated at 4ºC 
overnight with primary antibodies, with the exception of antibodies to cleaved caspase-3 which 
was incubated for two hours at room temperature. These antibodies included; rabbit anti-Cx30 
(1:400, Thermo-Fisher, catalog#71-2200), mouse anti-Cx26 (1:400, Thermo-Fisher, 
catalog#33-5800), rabbit anti-Cx43 (1:500, Sigma, catalog#C6219), rabbit anti-MyosinVI 
(1:200, Proteus Biosciences, catalog#25-6791), rabbit anti-cleaved caspase-3 (1:1000, Sigma, 
catalog#C9598), mouse anti-protein disulfide isomerase (PDI) (1:500, Assay Designs, 
catalog#SPA-891), and anti-BiP (1:1000, Sigma Aldrich, catalog# G8918). Cell cultures were 
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washed and incubated with fluorescent-conjugated secondary antibodies for one hour followed 
by a nuclear Hoechst 33342 stain. Cultures were additionally stained with phalloidin (1:400, 
Invitrogen, catalog#A12379). HEI-OC1 cells were mounted on a glass slide with airvol. A 
Zeiss LSM800 confocal microscope was used to acquire Z-stacks and high resolution Airyscan 
images. For all quantifications performed on organotypic cochlear cultures (i.e. hair cell counts 
and cleaved caspase 3 positive hair cell counts), the experimenter was blinded to treatment 
group, genotype, and cochlear region when counting. N values for each are described in figure 
legends.  
5.2.4. Co-localization and particle analysis  
Fixed cell cultures were blocked and permeabilized in either a 3% bovine serum albumin 
(BSA) + 0.1% TritonX-100 (HEI-OC1 cells) or 3% BSA+ 0.2% Triton X-100 (organotypic 
cochlear cultures) solution for one hour. Subsequently, cell cultures were incubated at 4ºC 
overnight with primary antibodies, with the exception of antibodies to cleaved caspase-3 which 
was incubated for two hours at room temperature. These antibodies included; rabbit anti-Cx30 
(1:400, Thermo-Fisher, catalog#71-2200), mouse anti-Cx26 (1:400, Thermo-Fisher, 
catalog#33-5800), rabbit anti-Cx43 (1:500, Sigma, catalog#C6219), rabbit anti-myosinVI 
(1:200, Proteus Biosciences, catalog#25-6791), rabbit anti-cleaved caspase-3 (1:1000, Sigma, 
catalog#C9598), mouse anti-protein disulfide isomerase (PDI) (1:500, Assay Designs, 
catalog#SPA-891), and anti-BiP (1:1000, Sigma Aldrich, catalog# G8918). Cell cultures were 
washed and incubated with fluorescent-conjugated secondary antibodies for one hour followed 
by a nuclear Hoechst 33342 stain. Cultures were additionally stained with phalloidin (1:400, 
Invitrogen, catalog#A12379). HEI-OC1 cells were mounted on a glass slide with airvol. A 
Zeiss LSM800 confocal microscope was used to acquire Z-stacks and high resolution Airyscan 
images. For all quantifications performed on organotypic cochlear cultures (i.e. hair cell counts 
and cleaved caspase 3 positive hair cell counts), the experimenter was blinded to treatment 
group, genotype, and cochlear region when counting. N values for each are described in figure 
legends.  
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5.2.5. Fluorescence recovery after photobleaching (FRAP) 
Control and drug-treated organotypic cochlear cultures were incubated for 48 hours. Cultures 
were then washed with phosphate-buffered saline (PBS) and incubated for five minutes at room 
temperature in 2µM calcein-AM dye (Invitrogen, catalog#3100-MP) in DMEM/F12 medium. 
Cultures were next washed twice with PBS and fresh DMEM/F12 medium was added. Dye 
loaded cultures were placed in a live cell incubation chamber (37°C, 5% CO2) under a Zeiss 
LSM 800 confocal microscope. To assess the level of gap junction function, both the outer 
sulcus and inner sulcus regions of organotypic cultures were selected for FRAP analysis. One 
outer sulcus cell that was adjacent to at least three other cells was photobleached and the 
recovery of fluorescence into the photobleached cell was examined every 10 seconds for eight 
minutes. Defined regions (288.5µm2 in diameter) of the tightly packed cells of the inner sulcus 
region were photobleached and fluorescence recovery to the photobleached region was 
determined as described above. The intensities of fluorescence were measured in ImageJ and 
the percent recovery was calculated as; (Fx-FP/FI) x 100, Fx= fluorescence at each time point, 
FP= fluorescence after photobleaching, and FI= initial fluorescence before photobleaching. 
Area under the curve of a linear regression analysis was calculated using GraphPad Prism 6.  
5.2.6. Cell culture and reagents 
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were kindly provided by Dr. Kalinec 
(House Ear Institute, Los Angeles, CA). HEI-OC1 cells were grown in high glucose DMEM 
supplemented with 10% FBS and 2mM L glutamine and incubated in permissive conditions 
(33°C, 10% CO2). Once HEI-OC1 cells reached 80% confluency they were treated with 
various doses of cisplatin (Sigma-Aldrich, catalog#PHR1624) or saline as a vehicle control 
(referred to as untreated) for 24 or 48 hours. Positive controls for the induction of apoptosis in 
HEI-OC1 cells were treated with 1uM staurosporine (Sigma, catalog#S6942) for two hours. 
Positive controls for the induction of ER stress in HEI-OC1 cells were treated with 2uM 
Thapsigargin (Sigma, catalog#T9033) for four hours.  
5.2.7. CRISPR-Cas-9 gene ablation 
HEI-OC1 cells were transiently transfected using the MIRUS-LT1 transfection reagent with 
the pSpCas9(BB)-2A-GFP plasmid (PX458, Addgene, Cambridge, MA, USA) which encodes 
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for the Cas9 protein along with a cloning backbone for a single guide RNA (sgRNA). sgRNAs 
were designed targeting the sole exon of the GJA1 gene (encoding Cx43) to induce in/del 
mutations in GJA1, rendering the gene functionally ablated. Two gRNAs were designed using 
the Sanger Institute CRISPR finder (http://www.sanger.ac.uk/htgt/wge/) and are predicted 
to exhibit extremely low to zero exonic off-targets (mouse GJA1: Sanger sgRNA ID: 
324658622 (5’- CGCTGTAACACTCAACAACC-3’) and Sanger sgRNA ID: 324658605 (5’- 
AAGCCTACTCCACGGCCGGA-3’)). After transfection, GFP-expressing HEI-OC1 cells 
were sorted using fluorescence-activated cell sorting (FACS) and individual clones were 
examined for Cx43 ablation. Cx43 protein levels were assessed via Western blotting and 
immunofluorescence. A minimum of two different CRISPR clones were used in all subsequent 
experiments. Cx43-ablated HEI-OC1 cells will be hereafter referred to as Cx43 KO cells. 
5.2.8. WST-1 assay 
Cell viability was analyzed using the WST-1 assay (Sigma, catalog# 5015944001). HEI-OC1 
cells were plated at a density of 1x104 cells (low density) or 3x104 cells (high density) in each 
well of a 96 well dish and incubated overnight. HEI-OC1 cells were treated with the intended 
concentration of cisplatin in triplicate for 24 or 48 hours. HEI-OC1 cells were then treated with 
1:10 dilution of WST-1 in fresh media for two hours. Wells with no cells or media only were 
used as a negative control. The optical density of each sample was measured using a 
spectrophotometer reader at 450nm and a reference wavelength at 630nm. Cell viability was 
determined by subtracting the reference absorbance, and the optical density of the negative 
control from each sample. Cell viability was then measured as a percentage of the cell viability 
of cells treated with saline, denoted as 100%. 
5.2.9. Immunoblotting 
Control or drug-treated HEI-OC1 cells were washed with PBS and lysed using 1x IP lysis 
buffer ((2x IP lysis buffer (2 % Triton X-100, 330mM NaCl, 20mM Tris, 2mM EDTA, 2mM 
EGTA, 1 % NP-40, pH 7.4), containing 1 tablet complete mini protease inhibitor cocktail 
(Sigma-Aldrich), 1:100 sodium fluoride (Millipore Sigma, catalog# SX0550-1) and 1:100 
sodium orthovanadate (Sigma, catalog# S6508) phosphatase inhibitors in PBS. Once protein 
concentrations were measured, equal amounts of protein were resolved using SDS-PAGE 
(10% or 12% polyacrylamide gel) and were transferred to a nitrocellulose membrane using an 
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iBlot transfer system. Membranes were probed overnight with primary antibodies in 3% BSA 
dissolved in PBS Tween (0.05% Tween 20) unless indicated otherwise. Primary antibodies 
included: mouse anti-GAPDH (1:5000, EMD Millipore, catalog# MAB374), rabbit anti-Bax 
(dissolved in Tris-buffered saline (TBS) Tween, 1:1000, Cell Signaling, catalog#2772), and 
rabbit anti-BiP (1:1000, Sigma Aldrich, catalog# G8918). Membranes were then washed with 
PBS or TBS Tween and incubated with Alexa Fluor 680-conjugated anti-rabbit-IgG secondary 
antibody (1:5000, Life Technologies, catalog#A21057) or IRdye800-conjugated anti-mouse-
IgG antibody (1:5000, Rockland, catalog#611-132-002) for one hour. Protein signals were then 
visualized using an Odyssey infrared imaging system (LiCor) and the intensity of the bands 
were quantified using Odyssey software. Protein expression was normalized to the loading 
control GAPDH.  
5.2.10. Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was extracted from samples using RNeasy Mini Protocol for Isolation of Total 
RNA from Animal Cells (Qiagen, catalog# 74106) and converted to cDNA using the High 
Capacity cDNA Reverse Transcription Kit (ThermoFisher, catalog#4368814). Quantitative 
real-time polymerase chain reaction (qRT-PCR) was performed using PowerUp SYBR Green 
Master Mix (Life Technologies, Cat# A25742) and the cycle conditions for each primer 
consisted of: 50°C for 2 min, 95°C for 2 min, 95°C for 5 s, 60°C for 15 s for 40 cycles, followed 
by a melt curve. The following primers were used: 18s rRNA, the house keeping gene (forward, 
5’- GTAACCCGTTGAACCCCATT; reverse, 5’-CCATCCAATCGGTAGTAGCG), 
manganese superoxide dismutase (MnSOD) (forward, 5’- GGCCAAGGGAGATGTTACAA; 
reverse, 5’- CCTTGGACTCCCACAGACAT), glutathione peroxidase (GPx1) (forward, 5’ - 
GTCCACCGTGTATGCCTTCT; reverse 5’ -CCTCAGAGAGACGCGACATT), catalase 
(forward, 5’- GGAGGCGGGAACCCAATAG; reverse, 5’- 
GTGTGCCATCTCGTCAGTGAA, Bcl-2 (forward, 5’ –CCTGTGGATGACTGAGTACC; 
reverse, 5’-GAGACAGCCAGGAGAAATCA), Bax (forward, 5’ – 
GTTTCATCCAGGATCGAGCA; reverse, 5’-CATCTTCTTCCAGATGGTGA). WT was set 
as a control and mRNA levels were normalized to 18s rRNA and measured using the ΔΔCT 
method. 
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5.2.11. Statistical analysis 
Two-way analysis of variance (ANOVA) followed by Tukey’s post hoc tests were used for 
hair cell counts, cell viability, cleaved caspase 3 staining, mRNA and protein analysis, and gap 
junction particle analysis at each individual cochlear region (i.e. apical, middle, and basal). A 
one-way ANOVA followed by Tukey’s post hoc tests were performed for analyzing cleaved 
caspase 3 staining of organotypic cochlear cultures, and Pearson’s correlation co-efficient of 
each cochlear region. A regression line analysis was performed for percent of dye recovery 
which was used to generate the area under the curve. Additional one-way ANOVAs followed 
by Tukey’s post hoc tests were performed for HEI-OC1 cell experiments and are denoted in 
figure legends. All statistical analysis was performed using GraphPad Prism 6.  
5.3. Results 
5.3.1. Cx26 and Cx30 are abundantly expressed in the inner ear while Cx43 
is detected at low levels 
To assess the connexin content of organotypic cochlear cultures from Cx43 mutant and WT 
littermate mice, cultures were immunolabeled for Cx26 and Cx30. High levels of Cx26 and 
Cx30 protein were found in Kolliker’s organ supporting cells of the cochlea (Figure 5.1A,B). 
Of note, there were no detectable changes in the distribution or levels of Cx26 or Cx30 in either 
Cx43 mutant mice compared to their respective WT littermates (Figure 5.1A,B). In all cases, 
both Cx26 and Cx30 appeared to be more predominantly found in the apical (low-frequency) 
regions compared to the basal (high-frequency) regions (Figure 5.1).  
To examine the localization of Cx43 in the cochlea, Cx43 immunofluorescence labelling was 
performed on cross sections from young WT and mutant mice (P0 and P4) as well as 
organotypic cochlear cultures from WT mice. Low magnification confocal images of P0 and 
P4 cochleae revealed no Cx43 gap junctions in the organ of Corti (Figure 5.2A). Higher 
magnification confocal images also revealed no evidence for Cx43 in the organ of Corti, inner 
sulcus, or spiral limbus regions (Figure 5B).  
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Figure 5.1. Cx26 and Cx30 are highly expressed in supporting cells of organotypic 
cochlear cultures. 
 (A) Representative confocal images of Cx26 and Cx30 distribution in organotypic cochlear 
cultures from WT and Cx43I130T/+ mutant mice denoting the apical (low-), middle (mid-), and, 
basal (high frequency) regions. (B) Representative confocal images of Cx26 and Cx30 
distribution in organotypic cochlear cultures of WT and Cx43G60S/+ mutant mice. OHC= outer 
hair cell, IHC= inner hair cell. Cx30 is denoted in green, Cx26 is in red, phalloidin labelling 
hair cell stereocilia is in white, and Hoechst nuclear stain is in blue. Scale bars =20µm.  
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Figure 5.1 
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Figure 5.2. Low but detectable amount of Cx43 are expressed in organotypic cochlear 
cultures. 
 (A) 3D reconstruction of consecutively stacked confocal images of cochleae obtained from 
Cx43I130T/+ mutant mice and their WT littermates (P0 and P4). (B) Higher magnification 
images of specific cochlear regions of WT P4 cochleae. (C) Stacked confocal images of 
organotypic cochlear cultures from WT mice. (D) Schematic diagram representing the 
localization and relative expression levels of cochlear connexins in organotypic cochlear 
cultures. Cx43 is denoted in green, Cx26 is in red, phalloidin is in white, and Hoechst nuclear 
stain is in blue. Orange arrowheads indicate areas of gap junction plaques. Scale bars =10µm. 
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Figure 5.2.  
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However, detectable Cx43 expression was found in the cochlear lateral wall region and in 
supporting cells of Kolliker’s organ within organotypic cochlear cultures with higher 
expression in the inferior region of Kolliker’s organ (Figure 5.2B,C). A diagrammatic 
representation of the relative distribution patterns of Cx26, Cx30, and Cx43 in organotypic 
cochlear cultures is outlined (Figure 5.2D).  
5.3.2. Cisplatin causes hair cell death in Cx43 mutant mice and their WT 
littermates 
Since we know that low levels of Cx43 are present in distinct regions of the organ of Corti, 
specifically the cochlear lateral wall, and we hypothesize that Cx43 is important in the 
development of the organ of Corti, we wanted to determine if organotypic cultures from Cx43 
mutant mice have differential susceptibility to cisplatin-induced hair cell loss. First, 
organotypic cochlear cultures from control and Cx43I130T/+ mutant mice were treated with 20 
µM cisplatin for 48 hours and hair cells were immunolabeled for the hair cell body marker, 
MyosinVI, and phalloidin to visualize the hair cell stereocilia. There was no evidence of hair 
cell loss in untreated organotypic cochlear cultures from Cx43I130T/+ mutant mice (Figure 
5.3A). However, there was a significant decrease in the number of outer hair cells in all 
cochlear regions in cisplatin-treated cultures (Figure 5.3B). Notably, there were no differences 
between WT and Cx43I130T/+ mutant hair cell loss after cisplatin treatment (Figure 5.3B). To 
further examine whether a severe loss of Cx43 function led to differential hair cell death, 
organotypic cultures from control and Cx43G60S/+ mutant mice were treated with cisplatin. 
Cisplatin treatment caused a significant loss of outer hair cells, however, there were again no 
differences between WT and mutant cisplatin-treated organotypic cultures (Figure 5.3C). 
5.3.3. Cisplatin induces regional changes in apoptosis in organotypic 
cochlear cultures from Cx43G60S/+ mutant mice  
One of the most common mechanisms by which cisplatin causes damage to the inner ear is 
through apoptosis. To examine whether reduced Cx43 function regulates the level of apoptosis, 
immunofluorescent staining of cleaved caspase 3 (CC3), a marker of late apoptosis, was 
examined. In untreated cultures, no CC3-positive hair cells were found, however, after 
cisplatin treatment CC3-positive hair cells were readily identified indicative of apoptosis 
(Figure 5.S1A,B).  
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Figure 5.3. Cisplatin causes hair cell loss in organotypic cochlear cultures from WT and 
Cx43I130T/+ mutant mice. 
 
(A) Representative confocal images of organotypic cochlear cultures from WT and Cx43I130T/+ 
mutant littermate mice either untreated or treated with 20µM cisplatin for 48 hours. MyosinVI 
was immunolabeled to denote the hair cell body (green), phalloidin staining was used to 
demarcate actin (red), and Hoechst staining was used to locate the position of the nuclei (blue). 
(B) Quantitative analysis of hair cell counts in apical, middle, and basal regions of Cx43I130T/+ 
and WT littermate mouse cultures, either untreated or treated with 20µM cisplatin. N values; 
WT untreated= 4, WT cisplatin= 5-6, Cx43G60S/+ untreated= 5, Cx43G60S/+ cisplatin= 4-5. (C) 
Quantitative analysis of hair cell counts in apical, middle, and basal regions of cultures for 
Cx43G60S/+ mutant mice and WT littermates. N values; WT untreated= 4-6, WT cisplatin= 3-4, 
Cx43G60S/+ untreated= 3-5, Cx43G60S/+ cisplatin= 3-6. OHC= outer hair cell, IHC= inner hair 
cell. Means represent mean ± standard error. Scale bars= 20µm. Two-way ANOVAs were 
performed for each cochlear region with a subsequent Tukey’s post hoc test. *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 5.3. 
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In all regions there was a significant increase in the number of CC3 positive hair cells in 
cisplatin-treated WT cultures (Figure 5.S1A,B), however, there were no differences in the 
number of CC3-positive hair cells between WT and Cx43I130T/+ mutant mice (Figure 5.S1A B). 
Similarly, the number of CC3-positive hair cells were significantly increased after cisplatin 
treatment in WT and Cx43G60S/+ mutant mice (Figure 5.4A,B). Intriguingly, cisplatin-treated 
cultures from Cx43G60S/+ mutant mice had a significant increase in CC3-positive hair cells in 
the middle turn compared to cisplatin treated WT littermates (Figure 5.4A,B).  
5.3.4. Cx43 KO HEI-OC1 cells have similar sensitivity to cisplatin as WT 
cells 
Dose controlled cisplatin treatments for 24 hours and 48 hours revealed that both WT and Cx43 
KO cells had greatly reduced cell viability (Figure 5.5A). After 24 hours of low dose (10 µM) 
cisplatin treatment, Cx43 KO cells were unaffected as compared to WT cells, however, this 
difference did not persist at higher cisplatin doses or at the 48 hour time point (Figure 5.5A). 
To assess whether the extent of gap junction formation may play a role in cisplatin-induced 
cell death, cells were plated at low density to minimize gap junction assembly. While the IC50 
was reduced by 50% when cells were plated at low density, there was no difference between 
WT and Cx43 KO cells (Figure 5.5A). The number of CC3-positive cells was significantly 
increased at both 15 µM and 30 µM cisplatin compared to untreated cells (Figure 5.5B,C). 
However, no differences in the number of CC3-positive cells were observed between WT and 
Cx43 KO cells (Figure 5.5C).  
5.3.5. Reduced Cx26 and Cx30 colocalization after cisplatin treatment of 
organotypic cochlear cultures 
To assess whether cisplatin alters cochlear connexin distribution, double-immunolabeling for 
Cx26 and Cx30 was performed on control and cisplatin-treated cochlear cultures from WT and 
Cx43G60S/+ mutant mice. Representative confocal images of the basal region revealed altered 
hair cell morphology, hair cell loss, and supporting cell expansion, particularly in the pillar 
supporting cells (arrowheads), after cisplatin treatment (Figure 5.6A). High resolution 
Airyscan confocal images from the Kolliker’s organ were acquired and Pearson’s correlation 
coefficient was performed to assess the spatial localization of both Cx26 and Cx30.  
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Figure 5.4. CC3 is preferentially upregulated in cochlear cultures obtained from 
Cx43G60S/+ mutant mice. 
(A) Representative confocal images of the apical, middle, and basal regions of organotypic 
cochlear cultures from WT and Cx43G60S/+ mice labelled for CC3 after being untreated or 
treated with 20µM cisplatin. CC3 is denoted in red, phalloidin in green, and nuclei in blue. (B) 
CC3- positive hair cells were quantified as hair cells labelled positive for CC3 and phalloidin. 
N values; WT untreated= 5, WT cisplatin= 5-6, Cx43G60S/+ untreated= 4, Cx43G60S/+ cisplatin= 
3. Means represent mean ± standard error. Scale bars= 20µm. One-way ANOVA’s were 
performed for each cochlear region and subsequently a post hoc Tukey’s test was performed. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Figure 5.4. 
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Figure 5.5. WT and Cx43-ablated HEI-OC1 cells both have reduced cell viability after 
cisplatin treatment. 
 (A) Cell viability of HEI-OC1 cells at 24 and 48 hours after cisplatin treatment. IC50s were 
calculated as the dose required to kill 50% of cells (B) Representative confocal images of CC3 
staining in control and cisplatin-treated cells. CC3 is denoted in red, and nuclei are in blue. 
Staurosporine-treated cells were used as a positive control. (C) Quantification of the percentage 
of CC3-positive cells showed a significant increase in the percentage of CC3-positive cells 
after cisplatin treatment. Bars represent mean ± standard error from four independent 
experiments comprised of two different Cx43 KO HEI-OC1 clones. N values; WT: N=4, 
Cx43KO: N=7. Scale bars= 10µm. Two-way ANOVA with Tukey’s post hoc test, *p<0.05, 
**p<0.01, ****p<0.0001.  
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Figure 5.5. 
 
 
24 Hours 48 Hours
A
B
C
WT Cx43 KO
15µM 
Cisplatin
30µM 
Cisplatin
Staurosporine
Untreated
CC3 CC3Merge Merge
WT
Cx43 
KO
CC3 Merge
0 10 25 50 100 200
0
50
100
150
Cx43 KO, IC50 73.5µM
*
Cisplatin Dose (µM)
%
C
el
l V
i a
bi
li t
y
WT, IC50 36µM
0 10 15 20 30 40
0
50
100
150
Cisplatin Dose (µM)
%
Ce
llV
ia
bi
lity
WT High Density, IC50 16.8µM
WT Low Density, IC50 7.9 µM
Cx43 KO High Density, IC50 15.7µM
Cx43 KO Low Density, IC50 8.5µM
WT Cx43 KO
0
5
10
15
20
25
Pe
rc
en
ta
ge
of
C
el
l s
Ex
pr
es
si
ng
C
l e
av
ed
C
as
pa
se
3
( %
) **
* *
**** Untreated
15µM Cisplatin
30µM Cisplatin
 210 
 
 
 
Figure 5.6. Cisplatin treatment alters the spatial location of hair cells, causes supporting 
cell expansion, and induces the reorganization of Cx26 and Cx30 gap junctions. 
(A) Representative confocal images of the basal region of organotypic cochlear cultures 
obtained from untreated and cisplatin-treated Cx43G60S/+ mutant mice and WT littermates. 
Orange arrows denote areas of Pillar cell expansion. (B) High magnification Airyscan images 
were acquired of the basal area from the inner sulcus region. Cx26 is denoted in red and Cx30 
is in green. (C) Pearson’s correlation coefficient was quantified in apical, middle, and basal 
regions of organotypic cultures to measure Cx26 and Cx30 co-localization. N values; WT 
untreated= 5-6, WT cisplatin= 3-5, Cx43G60S/+ untreated= 6-7, Cx43G60S/+ cisplatin= 4-6. 
Means represent mean ± standard error. Scale bars= 10µm. One-way ANOVA’s were 
performed for each cochlear region and subsequently a post hoc Tukey’s test was performed. 
*p<0.05. 
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Figure 5.6. 
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Cx26 and Cx30 were colocalized in untreated cultures within the basal region with a correlation 
coefficient of approximately 0.5, suggesting that 50% of Cx26 and Cx30 were co-localized 
(Figure 5.6B,C). 
After cisplatin treatment, Cx26 and Cx30 were predominantly found separated into their own 
distinct gap junction plaques as colocalization was significantly decreased (Figure 5.6B,C). 
Interestingly, both untreated and cisplatin-treated cultures from Cx43G60S/+ mutant mice had 
significantly decreased Cx26 and Cx30 colocalization compared to WT untreated cultures 
(Figure 5.6B,C). Particle analysis was performed to determine the average intensity, number 
of gap junction plaques, and the size of gap junction plaques in untreated and cisplatin-treated 
cultures. No differences were found in any of the parameters tested in untreated and cisplatin-
treated cultures (Figure 5.S2A-C).  
5.3.6. Carbenoxolone decreases Cx26 and Cx30 levels and GJIC in 
organotypic cochlear cultures 
We next took a pharmacological approach to determine if blocking all cochlear gap junction 
function would attenuate the effect of cisplatin-induced cell death. To confirm that 
carbenoxolone (CBX) blocked GJIC in WT organotypic cochlear cultures, fluorescence 
recovery after photobleaching (FRAP) was performed. As expected, supporting cells in the 
Kolliker’s organ region were well coupled via gap junctions as WT cultures recovered 
approximately 60% of their initial fluorescence intensity after photobleaching (Figure 5.7A,B). 
However, CBX treated cultures exhibited a greatly reduced fluorescence recovery (Figure 
5.7A,B). Cells from untreated cultures in the outer sulcus region of cochlear cultures were also 
well coupled, but to a lesser degree than cells of Kolliker’s organ region, as they recovered 
approximately 30% of their original fluorescence intensity (Figure 5.7A,B). A linear regression 
analysis of the slopes of the lines and assessment of the area under the curve of the linear 
regression all confirmed that CBX treatment significantly inhibited GJIC in both inner and 
outer sulcus regions (Figure 5.7A-C). To assess whether CBX treatment altered Cx26 and 
Cx30 levels, organotypic cultures were treated with 100 µM CBX, 20 µM cisplatin, or a 
combination of 100 µM CBX + 20 µM cisplatin.  
 
 213 
 
 
 
Figure 5.7. Carbenoxolone blocks calcein dye transfer in cochlear supporting cells. 
 (A) Representative images of prebleach, bleached, and dye recovery after photobleach of 
calcein fluorescence in untreated or CBX-treated cochlear culture regions. Dashed areas 
represent photobleached regions. The photobleached region of inner sulcus cells was 
288.5µm2. (B) Percentage of fluorescence recovery compared to baseline in the inner and outer 
sulcus regions of untreated or 100µM CBX-treated cochlear cultures. (C) Area under the curve 
for both inner and outer sulcus regions revealed that CBX was an effective inhibitor of dye 
transfer. N=3, n=6 in each group and for each region. CBX= carbenoxolone treated. Scale 
bars= 10µm. Linear regression analysis of slopes performed for each region and area, 
****p<0.0001.  
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Figure 5.7. 
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At low magnification of cultures treated with CBX, little immunolabeled Cx26 or Cx30 was 
detected as compared to the abundant signal found in untreated and cisplatin-treated cultures 
(Figure 5.S3A). Similarly, at higher magnification, supporting cells of the inner sulcus and 
outer sulcus regions expressed abundant amounts of Cx26 and Cx30 in both the untreated and 
cisplatin-treated groups, but both isoforms were undetectable after CBX treatment (Figure 
5.S3B).  
5.3.7. Blocking gap junctions does not alter cisplatin-induced hair cell death 
Since CBX was a found to be an excellent blocker of cochlear connexins we assessed if this 
caused a change in hair cell susceptibility to cisplatin-induced cell death. Representative 
images of hair cells revealed that CBX treatment did not induce cell death, but cisplatin alone 
or in combination with CBX was a potent inducer of hair cell death (Figure 5.8A). Specifically, 
hair cell counts revealed that when 20 µM cisplatin and 100 µM CBX were co-administered, 
there were no significant differences in hair cell number compared to cisplatin treatment alone 
(Figure 5.8B). Thus, blocking gap junctions in cochlear organotypic cultures does not affect 
cisplatin-induced hair cell loss.  
5.3.8. WT and Cx43 KO HEI-OC1 cells undergo different mechanistic routes 
leading to cisplatin-induced cell death 
To examine the mechanisms of action of cisplatin-induced cell death in gap junction competent 
and deficient HEI-OC1 cells, markers of reporter proteins for intrinsic mitochondrial cell death 
and endoplasmic reticulum (ER) stress were assessed. First, to assess whether WT or Cx43 KO 
cells have differential susceptibility to reactive oxygen species (ROS) accumulation, mRNA 
expression of antioxidant enzymes were examined. A series of antioxidants including: 
manganese superoxide (MnSOD), catalase, and glutathione peroxidase (GPx1) were 
significantly increased after 15 µM and/or 30 µM cisplatin treatment for 48 hours in Cx43 KO 
but not in WT cells (Figure 5.S4A). To implicate a role for the mitochondrial pathway, the Bax 
(pro-apoptotic) and Bcl-2 (anti-apoptotic) mRNA ratio was elevated in both cell lines with 
more profound upregulation in WT HEI-OC1 cells, suggesting enhanced mitochondrial 
dysfunction. In addition, western blots showed that Bax protein expression in WT HEI-OC1 
cells was significantly increased after treatment with 15 µM cisplatin, however no differences 
were found in Cx43 KO cells (Figure 5.S4B,C).  
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Figure 5.8. Blocking gap junctions does not impact cisplatin-induced hair cell loss. 
(A) Representative confocal images of hair cells in WT cultures that were untreated or treated 
with 100µM carbenoxolone (CBX), 20µM cisplatin, or 100µM CBX and 20µM cisplatin 
(Cisplatin + CBX) for 48 hours. MyosinVI is denoted in green, phalloidin is in red, and nuclei 
are in blue. (B) Quantification of hair cell counts from all four treatment groups at the apical, 
middle, and basal regions. N values; untreated=4-7, CBX= 4-6, Cis= 4, Cis+ CBX= 3-5. OHC= 
outer hair cell, IHC= inner hair cell. Bars represent mean ± standard error. Scale bars= 20µm. 
Two way ANOVA’s and subsequent Tukey’s post hoc tests were performed for each region. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Figure 5.8.  
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To evaluate if ER stress is at the root of cisplatin-induced cell death, the expression of 
immunoglobulin protein (BiP), an ER chaperone protein upregulated during ER stress, was 
examined. Immunofluorescence revealed that BiP was readily detected after cisplatin treatment 
in both WT and Cx43 KO HEI-OC1 cells and was localized to the ER compartment as evident 
by colocalization with protein disulfide isomerase (PDI) (Figure 5.S5A). Western blots 
revealed that BiP was found in higher abundance in Cx43 KO but not WT cells after cisplatin 
treatment compared to untreated cells (Figure 5.S5B,C).  
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Figure S 5.1. Cleaved caspase 3 is upregulated after cisplatin treatment. 
(A) Representative confocal images of organotypic cochlear cultures labelled for cleaved 
caspase 3 (CC3) both in untreated and in 20 µM cisplatin treated cultures from Cx43I130T/+ 
mutant mice and WT littermates. CC3 is denoted in red, phalloidin is in green, and nuclei are 
in blue. (B) CC3-positive hair cells were quantified as hair cells labelled positive for CC3 and 
phalloidin. N values; WT untreated= 4-5, WT cisplatin= 5-7, Cx43I130T/+ untreated= 4, 
Cx43I130T/+ cisplatin= 4. Bars represent means ± SEM. Scale bars= 20 µm. One-way ANOVAs 
were performed for each cochlear region and subsequently a post hoc Tukey's test was 
performed. *p<0.5, **p<0.01, ***p<0.001. 
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Figure S 5.1. 
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Figure S 5.2.  Assessment of Cx26 and Cx30 levels in organotypic cochlear cultures 
after cisplatin treatment. 
Double-labeled immunofluorescence for Cx26 and Cx30 was performed in WT and Cx43G60S/+ 
mutant mice before and after cisplatin treatment. Particle analysis plugin on ImageJ was used 
to quantify the expression and number of gap junctions in the inner sulcus region of littermate 
mice. (A) Cx30 and Cx26 average intensity levels were analyzed in Cx43G60S/+ mutant mice 
and their WT littermates in control cultures and after 20μM cisplatin treatment for 48 hours. 
(B) The number of Cx30 and Cx26 gap junction plaques were quantified. (C) Average gap 
junction plaque size was quantified. N values; WT untreated= 5, WT cisplatin= 4, Cx43G60S/+ 
untreated=6-7, Cx43G60S/+ cisplatin= 3-4. Means represent mean ± standard error.  
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Figure S 5.2.  
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Figure S 5.3. Carbenoxolone reduced the number of Cx26 and Cx30 gap junctions in 
cochlear supporting cells. 
(A) Double-immunofluorescent labeling for Cx26 and Cx30 was performed on the basal region 
of organotypic cochlear cultures before and after carbenoxolone (CBX) and/or cisplatin 
treatment. (B) Higher magnification images of Cx30 and Cx26 in supporting cells of the inner 
sulcus region (C) outer sulcus region. Cx30 is denoted in green, Cx26 is in red, phalloidin is 
in white, and nuclei are in blue. Scale bars= 20μm.  
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Figure S 5.3. 
 
Untreated CBX Cisplatin Cisplatin + CBX
Inner 
Sulcus
Outer 
Sulcus
A
Cx30
Cx26
Phalloidin
B (C)
Cx30 Cx26 Merge
Untreated
CBX 
Cisplatin
Cisplatin + 
CBX
Cx30 Cx26 Merge
 225 
 
 
 
 
Figure S 5.4 Cx43-ablated HEI-OC1 cells have increased mRNA expression of 
antioxidant enzymes after cisplatin treatment. 
(A) Quantitative real time polymerase chain reaction (qRT-PCR) of antioxidant enzymes: 
manganese superoxide dismutase (MnSOD), catalase, and glutathione peroxidase (GPx1) from 
control and Cx43-ablated HEI-OC1 cells after cisplatin treatment. The ratio of proapoptotic 
Bax to anti-apoptotic Bcl-2 mRNA levels were also calculated. Bars represent mean ± standard 
error from four independent experiments comprised of two independent Cx43 KO clones. N 
values; WT: N=4, Cx43 KO: N=7.  (B, C) Western blot and quantification of Bax protein 
expression. GAPDH was used as a protein loading control. N values; WT: N=4, Cx43KO: 
N=5-7.  Two-way ANOVA with Tukey’s posthoc test, *p<0.05, **p<0.01, ***p<0.001.     
P<0.05 Represents one-way ANOVA and subsequent Tukey’s post hoc test performed.  
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Figure S 5.4.Cx43-ablated HEI-OC1 cells have increased mRNA expression of 
antioxidant enzymes after cisplatin treatment. 
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Figure S 5.5. HEI-OC1 cells lacking Cx43 preferentially undergo an ER stress response 
after cisplatin treatment 
 
(A) Representative confocal images of BiP expression and localization in WT and Cx43KO 
HEI-OC1 cells treated with saline, 15µM, or 30µM cisplatin for 48 hours. BiP is in green, PDI 
(an ER resident marker) is in red, and blue are nuclei. WT HEI-OC1 cells treated with 
thapsigargin, a known activator of ER stress were used as a positive control. (B) Western blot 
for BiP protein expression in untreated and cisplatin-treated cells. GAPDH was used as a 
loading control. (C) Quantification of BiP protein expression in cells treated with saline 
(untreated), 15µM, or 30µM cisplatin for 48 hours. Bars represent mean ± standard error from 
four independent experiments comprised of two independent Cx43 KO clones. N values; WT: 
N=3-4, Cx43KO: N=5-8. Scale bars=10µm. Two-way ANOVA, *p<0.05. P<0.05 represents 
one way-ANOVA followed by a Tukey’s post hoc test.  
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Figure S 5.5. HEI-OC1 cells lacking Cx43 preferentially undergo an ER stress response 
after cisplatin treatment 
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5.4. Discussion 
Cisplatin is one of the most effective and commonly used chemotherapeutic drugs to treat solid 
cancer tumors but causes hearing loss in approximately 75-100% of patients [25]. The 
reason(s) why this sensory organ is so highly susceptible to cisplatin damage is not entirely 
clear but may be related to the organ of Corti being highly enriched with gap junctions that 
mediate small molecule (potentially toxic) exchange between connecting cells. Related studies 
have shown that Cx43-mediated GJIC plays a bystander role in cancer cell lines where 
downregulating Cx43 leads to protection against cisplatin-induced cell death [34–36]. 
Although the role of Cx43 in hearing and its localization pattern in the cochlea remain 
controversial, we have shown for the first time that Cx43 is expressed in organotypic cochlear 
cultures of neonatal mice. Interestingly, both Cx26 and Cx30 expression were more 
pronounced in the apical (low frequency) region of organotypic cochlear cultures compared to 
the basal (high frequency) region, a finding that has also been reported in guinea pigs [37]. 
This is of particular interest due to the fact that hearing loss generally occurs primarily in the 
high frequency areas [38,39], a phenomenon that could be due to lowered Cx26 and Cx30 
expression within this region.  
Although Cx43 has been reported to exacerbate cisplatin-induced cell death, these studies have 
primarily been examined in cancer cell lines including: testicular [30,36], lung [34][40], 
ovarian, [34], prostate, and breast [41]. Recently, a study showed that although Cx43 increased 
cell death in cisplatin-treated testicular cancer cells, this effect was reversed in non-cancerous 
testicular cells where Cx43 downregulation led to enhanced cisplatin-induced cell death [30]. 
This suggests that Cx43 may play distinct roles with either propagation of death signals 
(bystander) or beneficial signals (Good Samaritan) in cisplatin treatment depending on the cell 
status. To further examine the role of Cx43 in cisplatin-induced ototoxicity, Cx43I130T/+ and 
Cx43G60S/+ mutant mice harboring a moderate and severe reduction of Cx43-mediated GJIC, 
respectively, were used. In the case of Cx43I130T/+ mutant mice, we have established that the 
expected level of Cx43-mediated GJIC is ~50% while Cx43G60S/+ mutant mice have only ~20% 
functional Cx43 [32,33]. We know that Cx43G60S/+ mice exhibit severe hearing loss, thereby 
linking Cx43 to hearing function [23]. Organotypic cochlear cultures from these mutant mice 
provide an ideal setting to assess Cx43 function on cisplatin-induced hair cell death. Clinically, 
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the plasma concentration range of cisplatin achieved during most cancer treatments is 
approximately 1.7 µM- 25 µM [42][43], thus concentrations used in our study are comparable 
to the clinical setting. We found that although cisplatin treatment caused significant outer hair 
cell loss compared to untreated cultures, neither mutant mouse showed any differences in hair 
cell loss compared to WT littermates. Interestingly, cultures from Cx43G60S/+ mutant mice had 
a significantly increased number of CC3-positive hair cells suggesting that these hair cells may 
be undergoing enhanced apoptosis possibly at a later time point due to the reduced level of 
functional Cx43 [32,33]. Cx43 KO HEI-OC1 cells had significantly higher cell viability 
compared to WT cells only when treated with 10 µM cisplatin for 24 hours, which is consistent 
with another report where the levels of Cx43 in HEI-OC1 cells were reduced using siRNA 
[44]. However, higher cisplatin concentrations eliminated this protection suggesting that 
cisplatin toxicity caused cell death irrespective of GJIC. Further supporting the notion that 
GJIC plays a minimal role in cisplatin-induced cell death, we found that pharmacological 
blockage of all gap junction channels with CBX had no effect on either resistance or sensitivity 
of organotypic cultured hair cells to cell death.  
Connexins are expressed in cochlear supporting cells and not in hair cells in vivo, [45–47], thus 
blocking gap junctions may not have a direct effect on cisplatin entry and/or propagation in 
hair cells themselves. Hair cells express many uptake transporters for cisplatin such as Ctr1, 
OCT1, and OCT2 [48–50], allowing cisplatin to directly enter hair cells. Two copper 
transporting ATPases, ATP7A and ATP7B mediate cisplatin efflux from cells and are 
expressed in pillar cells and hair cells, respectively [50]. Although hair cells are suggested to 
be the primary target of cisplatin, damage to supporting cells may also play a role in cisplatin-
induced cell death through indirect mechanisms. A previous study showed that after in vivo 
administration of cisplatin in rats, supporting cell morphology was altered prior to hair cell loss 
[51]; supporting our findings that altered architecture of the supporting cells may play a key 
role. It has been well documented that when the cochlea is injured, nearby supporting cells 
expand, extrude and eventually phagocytose the injured hair cells [52][53]. Cisplatin also 
disrupts the actin cytoskeleton in supporting cells where they form a “glial scar” to maintain 
the proper integrity of the sensory epithelium [53,54]. Taken together, these data suggest that 
although hair cell loss has been mostly documented as a consequence of cisplatin treatment, 
supporting cells in proximity to hair cells have altered morphology that may impact hair cell 
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death. In addition, architectural changes in supporting cells occur independent of Cx43-based 
GJIC suggesting the toxic or beneficial signals do not pass through the gap junction-rich 
supporting cells.  
In the cochlea, Cx26 and Cx30 have been shown to form heteromeric and/or heterotypic gap 
junction channels in most cochlear supporting cells [29][55][56]. Our study showed that 
cisplatin caused a reorganization of Cx26 and Cx30 in all organotypic cochlear cultures, 
reducing the number of hybrid gap junction channels which may give rise to distinct changes 
in the metabolome that can spread amongst the supporting cells, including propagation of cell 
death related toxic signals [57]. For example, a previous study showed that heteromeric 
Cx26/Cx30 cochlear channels had faster Ca2+ wave propagation than their homomeric 
counterparts [55]. Thus, we suspect that cisplatin alters the biochemical coupling status of 
cochlear supporting cells through the production of fewer heteromeric channels. 
Carbenoxolone (CBX) has been widely used as a non-specific gap junction blocker in many 
different tissues and cell lines including resident cells of the inner ear [58–62]. However, the 
mechanism of action remains unclear. In rat liver epithelial cells, CBX was shown to 
dephosphorylate Cx43, leading to a decrease in GJIC [63]. The current study showed that 
organotypic cochlear cultures treated with CBX had significantly decreased GJIC and Cx26 
and Cx30 protein expression, suggesting a novel mechanism of action for CBX in the inner 
ear. In support of our findings that connexin levels are reduced after CBX treatment, previous 
studies showed that CBX caused a decrease in Cx43 levels in the prefrontal cortex of rats [64], 
human glioma cells [65], and human cerebral endothelial cells [66]. In contrast, bovine aortic 
endothelial cells (BAECs) treated with CBX had elevated levels of Cx43 mRNA and protein 
[67]. To our knowledge our study is the first to show that CBX attenuates the protein levels of 
Cx26 and Cx30, suggesting a mode of action that may extend beyond blocking the function of 
gap junction channels.  
Cisplatin causes DNA damage leading to activation of various cell death pathways, including 
the intrinsic mitochondrial pathway via the permeabilization of the mitochondrial outer 
membrane and subsequent caspase activation [68]. This in turn generates ROS while depleting 
antioxidants, leaving cochlear cells unable to rapidly excrete toxins due to its anatomically 
closed structure [69]. The ER stress pathway, whereby a buildup of misfolded proteins causes 
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cellular dysfunction, has also been shown to be involved in cisplatin induced cell death [70]. 
To examine these pathways we evaluated the levels of various antioxidants, Bax (pro-apoptotic 
protein), and BiP (ER chaperone binding protein) as markers of mitochondrial apoptosis and 
ER stress, respectively. We showed that both WT and Cx43 KO cells underwent signature 
changes of the intrinsic mitochondrial pathway upon cisplatin treatment, albeit Cx43 KO cells 
had increased levels of antioxidant mRNA expression, possibly making them more resistant to 
ROS. In general, WT HEI-OC1 cells had significantly increased Bax protein expression (i.e. 
mitochondrial) whereas Cx43 KO HEI-OC1 cells had significantly increased BiP protein 
expression (i.e. ER) after cisplatin treatment. It is important to note that the cytoplasmic tail of 
Cx43 has been shown to bind Bax [71], and thus, WT HEI-OC1 cells may undergo enhanced 
mitochondrial dysfunction because they have the capacity to bind to Bax. Taken together, these 
data suggest that WT cells had enhanced mitochondria dysfunction while Cx43 KO cells 
favored an ER stress response pathway. 
5.5. Conclusions 
In summary, the current study sought to examine the role of GJIC in cisplatin-induced 
ototoxicity in two different cochlear relevant models. Collectively, we found that GJIC did not 
influence the amount of cisplatin-induced hair cell death but did cause alterations in cochlear 
supporting cell morphology and reorganization of Cx26 and Cx30 gap junctions. This is the 
first study to show that HEI-OC1 cells were highly sensitive to cisplatin-induced cell death 
regardless of the presence of Cx43, although the absence of Cx43 leads to more cisplatin-
induced ER stress. Future studies examining the roles of GJIC in cisplatin-induced ototoxicity 
in the in vivo inner should be evaluated to further understand the molecular processes involved. 
Overall, our studies are consistent with the notion that patients that harbor any one of several 
hundred connexin gene mutations are not at increased risk of cisplatin-linked hair cell loss and 
deafness than patients lacking these mutations. 
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6.1. Summary of main findings 
It has been known for nearly two decades that GJB2 and/or GJB6 gene mutations, encoding 
Cx26 and Cx30, respectively, cause a large proportion of congenitally acquired hearing loss 
[1,2]. Using a combination of five different genetically-modified mice, this thesis focuses on 
the importance of other related large-pore channels; Cx43, Panx1, and Panx3, in auditory 
function. In chapter 2, we show that both Panx1 and Panx3 are not involved in proper hearing 
function. In chapter 3, we used a double knock-out mouse to show that Panx1 and Panx3 were 
not compensating for one another in the auditory system. In chapter 4, we found that a severe 
but not moderate reduction of Cx43 gap junctional intercellular communication (GJIC) 
resulted in severe hearing loss where the defect was mapped to the higher-order auditory 
brainstem regions. In chapter 5, we found that GJIC did not influence the impact of cisplatin-
induced cell death in both organotypic cochlear cultures and cochlear relevant immortalized 
cells. Table 6.1. summarizes the main findings of this thesis. In this section I will further 
discuss how these findings are relevant to the molecular understanding of hearing with an 
emphasis on connexins and pannexins and the potential for therapeutic strategies to rescue 
hearing loss.  
6.1.1. Differential effects of pannexins on noise-induced hearing loss 
Hearing loss, including noise-induced hearing loss (NIHL), is highly prevalent and severely 
hinders an individual’s quality of life, yet many of the mechanisms that cause hearing loss are 
unknown [3,4]. Recently, the involvement of Cx channels in NIHL have been investigated; 
however, whether Panxs also play a role in this process has yet to be examined. As this thesis 
aimed to evaluate the roles of large pore channels in NIHL, we assessed hearing in globally 
ablated pannexin1 (Panx1-/-) and pannexin3 (Panx3-/-) knock-out mice at both baseline and 
after a loud noise-exposure. The Panx channel proteins, Panx1 and Panx3, are regionally 
expressed in many cell types along the auditory pathway, and mice lacking Panx1 in specific 
cells of the inner ear have been reported to exhibit hearing loss [5,6], suggesting a vital role 
for Panxs in hearing. We proposed that Panx1 and/or Panx3 null mice would exhibit severe 
hearing loss and increased susceptibility to noise-induced hearing loss. 
 
 
 242 
 
Table 6.1. Summary of main findings 
 Genetically 
Acquired 
Hearing Loss 
Noise-Induced 
Hearing Loss 
(NIHL) 
Cisplatin-
Induced 
Hearing Loss 
Panx1 Normal hearing 
when ablated 
Loss of Panx1 leads 
to similar NIHL as 
WT 
N/A 
Panx3 Normal hearing 
when ablated 
Loss of Panx3 leads 
to mild protection 
against NIHL 
N/A 
Cx43 Severe hearing loss 
when Cx43 function 
is less than 20%, but 
normal when 50% is 
maintained 
Reduction of Cx43 
function leads to 
similar NIHL as WT 
Reduced Cx43 
function does not 
lead to differential 
susceptibility to 
cisplatin-induced 
ototoxicity 
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Using the auditory brainstem response, we surprisingly found that Panx1-/- and Panx3-/- mice 
did not harbor hearing or cochlear nerve deficits. Furthermore, while Panx1-/- mice displayed 
no protection against loud noise-induced hearing loss, Panx3-/- mice exhibited enhanced 16- 
and 24 kHz hearing recovery seven days after a loud noise exposure (NE; 12 kHz tone, 115 dB 
sound pressure level for one hour). Interestingly, Cx26, Cx30, Cx43, and Panx2 were up-
regulated in Panx3-/- mice compared with wild-type and/or Panx1-/- mice, and assessment of 
the auditory tract revealed small but detectable morphological changes in the middle ear bones 
of Panx3-/- mice. It is unclear if these changes alone are sufficient to provide protection against 
loud noise-induced hearing loss. Contrary to what we expected, these data suggest that Panx1 
and Panx3 are not essential for baseline hearing in mice tested, but the therapeutic targeting of 
Panx3 may prove protective against mid-high-frequency hearing loss caused by loud NE. 
6.1.2. Double deletion of Panx1 and Panx3 affects skin and bone but not 
hearing 
To date, the use of single knock-out mouse models of both Panx1 and/or Panx3 have 
demonstrated their roles in skin development, bone formation, and auditory phenotypes [6–9]. 
Due to sequence homology between Panx1 and Panx3, when one Panx is ablated from germline 
cells, the other may be upregulated in a compensatory mechanism to maintain tissue 
homeostasis and function as has been demonstrated for skin, blood vessels, and the 
vomeronasal organ [7, 10-11]. To evaluate the roles of Panx1 and Panx3 in the skin, bone, and 
cochlea, we created the first Panx1/Panx3 double knock-out mouse model (dKO) where both 
isoforms were ablated. Profiling of the auditory system revealed that dKO mice did not exhibit 
hearing loss and were even slightly protected against noise-induced hearing damage at mid-
frequency regions, phenocopying what was found in Panx3-/- mice. Taken together, our 
findings suggest that Panx1 and Panx3 are expendable in the auditory system which is 
supported by other studies [12,13]. The expendability of Panx channels in the auditory system 
may be largely due to the fact that connexins are crucial for hearing and serve many functional 
similarities as Panx channels such as ATP release, Ca2+ wave propagation, and passage of 
small molecules and ions through the intracellular and extracellular space. 
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6.1.3. Mice harbouring an oculodentodigital dysplasia-linked Cx43 G60S 
mutation have severe hearing loss 
Given the importance of connexin43 (Cx43, encoded by GJA1) function in the central nervous 
system and sensory organ processing, we proposed that it would also be crucial in auditory 
function. In addition, since both Cx26 and Cx30 mutations are highly prevalent in congenitally 
acquired hearing loss, this raised the question as to whether Cx43 was also crucial in hearing. 
To that end, hearing was examined in two different mouse models of oculodentodigital 
dysplasia that globally express GJA1 mutations resulting in moderate or severe loss of Cx43 
function. Although Cx43I130T/+ mutant mice, with ∼50% Cx43 channel function, did not have 
any hearing loss, Cx43G60S/+ mutant mice, with ∼20% Cx43 channel function, had severe 
hearing loss. There was no evidence of inner ear sensory hair cell loss, suggesting that the 
mechanism for Cx43-linked hearing loss lies downstream in the higher-order auditory 
pathway. Specifically, Cx43G60S/+ mutant mice had decreased ABR waveform amplitudes 
compared to WTs, consistent with an auditory neuropathy phenotype (i.e. higher-order 
auditory deficits). Auditory neuropathy has been previously associated with other connexin 
mutations such as Cx32 causing Charcot Marie Tooth disease harbouring auditory neuropathy 
[14,15]. Additionally, Cx29 that is exclusively expressed in mice and is localized to Schwann 
cells around the spiral ganglion neurons in the cochlea has been associated with auditory 
neuropathy where Cx29 knock-out mice had hearing loss also associated with distortion of 
auditory brainstem waveforms [16]. Since evidence suggests that Cx26 function is essential 
for hearing and may be protective against noise-induced hearing loss [17], we challenged 
Cx43I130T/+ mice with a loud noise and found that they had a similar susceptibility to noise-
induced hearing loss to that found in controls, suggesting that decreased Cx43 function does 
not sensitize the mice for environmentally induced hearing loss. Taken together, this study 
suggests that Cx43 plays an important role in baseline hearing and is essential for auditory 
processing, however, a residual amount of Cx43 GJIC is enough to maintain proper hearing 
function.  
6.1.4. Cisplatin-induced ototoxicity occurs independent of gap junctional 
intercellular communication 
Cisplatin is a very effective chemotherapeutic, but severe and permanent hearing loss remains 
a prevalent side effect. The processes underlining cisplatin-induced ototoxicity are not well 
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understood. Gap junction channels composed of connexin (Cx) subunits allow for the passage 
of small molecules and ions between contacting neighboring cells. These specialized channels 
have been postulated to enhance cisplatin-induced cell death by spreading “death signals” 
throughout the supporting cells of the organ of Corti [18]. This study sought to investigate the 
role of Cx43 in cisplatin-induced ototoxicity using organotypic cochlear cultures from control 
and two different Cx43 mutant mouse strains harbouring either a moderate (Cx43I130T/+) or 
severe (Cx43G60S/+) reduction of Cx43 function. Cochlear cultures from Cx43 mutant mice with 
a severe reduction in Cx43-based GJIC had an enhanced number of hair cells that were positive 
for cleaved caspase 3 after cisplatin treatment. In cisplatin-treated organotypic cochlear 
cultures, there was a decrease in the co-localization of Cx26 and Cx30 compared to untreated 
cultures, suggesting that cisplatin causes reorganization of connexin composition in supporting 
cells. Both Cx26 and Cx30 protein expression as well as GJIC were decreased in organotypic 
cochlear cultures treated with the gap junction blocker carbenoxolone. When cisplatin and 
carbenoxolone were co-administered there were no differences in hair cell loss compared to 
cisplatin treatment alone. Using cisplatin-treated control and Cx43-ablated organ of Corti 
derived HEI-OC1 cells, we found that greatly reducing GJIC led to preferential induction of 
an ER stress pathway. Taken together, this study strongly suggests that inhibition of GJIC in 
organ of Corti cells does not lead to differential susceptibility to cisplatin-induced ototoxicity. 
Although cisplatin causes the same degree of cell death in gap junction competent and 
incompetent cochlear cells, the engagement of the mitochondrial dysregulation and ER stress 
differs.  
6.2. Experimental limitations 
6.2.1. Limitations in distinguishing between connexin and pannexin channels
   
Due to the functional similarity of connexin and pannexin channels it is sometimes difficult to 
fully elucidate their individual roles in physiological processes. Connexin hemichannels are 
thought to have similar roles as pannexins in regulating different processes such as ATP release 
[10]. It has become well known that connexin hemichannels are preferentially opened under 
low extracellular Ca2+ concentrations [19,20]. In contrast, pannexins are thought to be opened 
under normal physiological extracellular Ca2+ concentrations [21]. Due to these distinct 
differences it is possible to selectively examine connexin hemichannel function by lowering 
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the extracellular Ca2+ concentration in order to preferentially induce their opening. However, 
caution is needed when interpreting these results as there is the potential of connexin and 
pannexin channel function cross-over.  
The use of pharmacological blockers for connexin and pannexin channels have been widely 
used to assess their functions where different agents can have preferential blocking 
efficiencies. For example, heptanol has been reported to block connexin hemichannel and gap 
junction channels with little effect on Panx1 channels [22–24]. Similarly, flufenamic acid 
(FFA) inhibited connexin hemichannels and Panx channels, albeit the later was inhibited at 
much lower concentrations [24]. A widely used drug for inhibition of Panx1 channels, 
probenecid, has been reported to block Panx1 channel currents and dye uptake in oocytes with 
no changes in connexin currents [25]. In chapter 4 we used carbenoxolone (CBX) as a gap 
junction blocker which inhibits both connexin and pannexin channels. Previous studies have 
used low concentrations of CBX (i.e. 5-10 µM) to more selectively block  Panx channels [24]. 
On the other hand, higher concentrations (i.e. 50-300 µM) of CBX have been used to block 
connexin channels, allowing for some  distinction between the two channel types [24,26]. For 
all of our studies in chapter 4, we used 100 µM CBX to block connexin channels but at this 
concentration any Panx channels present would also likely be inhibited. Therefore, the use of 
more targeted blockers would be beneficial to develop and use in  future studies.  
The use of peptide mimetics designed to bind specific regions of the Cx43 polypeptide have 
been used to address some of these problems. Gap26 and Gap27 are two peptide mimetics that 
bind to specific amino acid regions on the first and second extracellular domains of Cx43, 
respectively, and have been shown to inhibit Cx43 hemichannels in HeLa cells [27–29]. Even 
so, Gap26 also inhibited Panx1 currents in oocytes [30], suggesting that these mimetics may 
not function by solely mimicking the protein sequence since Panx1 and Cx43 do not share 
similar sequences at the region where the peptide binds. In addition, two other peptides that 
mimic sequences in the intracellular loop of Cx43 were created, Gap19 and TAT-L2. Previous 
studies have shown that Gap19 does not inhibit GJIC but blocks Cx43 hemichannel activity in 
the cardiac system and astroglial network of the brain, therefore enabling a peptide that 
preferentially blocks connexin hemichannels versus gap junction channels [31–33]. Similarly, 
the TAT-L2 Cx43 peptide has previously been reported to have no effect on gap junctions but 
inhibited Cx43 hemichannel function [34]. These peptides have no reported function on Panx1 
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activity, allowing for preferential blocking of connexin channels [32,35]. A mimetic peptide 
of the first extracellular loop of Panx1, 10panx1, significantly attenuates Panx1 channel 
current, dye uptake, and ATP release [36–38].  
Taken together, due to the similar structure and functions of connexins and pannexins, it is 
important to consider the experimental limitations in trying to distinguish between these two 
channels. Caution is also necessary in interpreting studies using connexin and pannexin 
blockers. In chapter 4, we used CBX at an appropriate concentration to block connexin 
channels, however whether this involved gap junctions or hemichannels remains unknown. 
Future studies could use specific connexin peptides that may preferentially block hemichannels 
versus gap junctions (such as Gap19) on organotypic cochlear cultures to examine whether 
cisplatin treatment causes any differential regulation to connexin hemichannels.  
6.2.2. Limitations of genetically-modified mice 
The use of genetically modified mouse models has provided us with novel insights into the 
functions of connexins and pannexins in various disease processes. The work in this thesis 
comprises the compilation of data from five different mouse models (three Panx knock-out 
mice and two different Cx43 mutant mice). When one isoform of a large pore channel is lost, 
another isoform may be upregulated to allow for compensatory upregulation. Thus, it is 
possible that other connexins and/or pannexins may have been altered as a consequence of 
knocking out an entire gene (Panxs) or creating a mutant (Cx43); ultimately allowing for 
compensation of the altered gene. In the inner ear specifically, the original Cx30 knock-out 
mouse was reported to have severe hearing loss and did not form an endocochlear potential, 
which is necessary for proper hearing [39]. Shortly after the generation of this mouse, however, 
it was reported that the Cx26 protein levels were also significantly reduced [40,41]. 
Subsequently, another independent Cx30 knock-out mouse model was created that did not alter 
the expression of Cx26 and these mice were found to have normal hearing function and 
development of the cochlea [42]. Together these studies suggest that Cx26 may compensate 
for the loss of Cx30 in the cochlea and that changes in the cochlear expression of one Cx 
isoform (ex. Cx30) may impact the expression of another isoform (ex. Cx26). Thus, when 
assessing the consequences of connexin or pannexin ablation it is crucial that other related 
members in the tissue of interest also be investigated for any potential alterations. In Chapter 
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4 of this thesis we assessed the potential compensation of Cx26 and Cx30 in the cochlea of the 
two different Cx43 mutant mice, and found that neither Cx43 mutant mice had differential 
mRNA transcript levels expression levels of Cx26 or Cx30, suggesting that Cx26 and/or Cx30 
are not compensating for the loss of Cx43 gap junction function. To support our findings this 
was also found in another system where both Cx26 and Cx30 protein expression remained 
unchanged in mammary glands of Cx43I130T/+ mice compared to WT littermates [43]. Although 
the mRNA transcript levels of Cx26 and Cx30 in the cochlea of both Cx43 mutant mice were 
similar, the functional status of Cx26 and Cx30 gap junction function in the cochlea of 
Cx43I130T/+ mutant mice remain unknown.  
Prior to the completion of Chapter 2, it was reported that two independent mouse models 
harbouring conditional ablations of Panx1 in the cochlea had hearing loss and cell degeneration 
in the cochlea [6,9]. Hence, we hypothesized that global ablation of Panx1 would also have 
hearing deficits which may even be enhanced due to the ubiquitous expression of Panx1 in the 
auditory tract. However, we found that the global Panx1 knock-out mice used in our study did 
not have hearing loss, which was consistent with another report where a second Panx1 global 
knock-out mouse was used [13,44]. Using cochlear organotypic cultures of Panx1-/- mice it was 
shown that ATP-release remained intact [12]. To address the potential issue of Panx 
compensation, in Chapter 3 we found that Panx1 and Panx3 double knock-out mice also did 
not have hearing loss, eliminating the potential of compensation between the two Panx 
channels. The two studies using conditional ablation of Panx1 in the cochlea used two different 
cre- mice and bred them to Panx1tm1a(KOMP)Wtsi mice, in which exon 2 of Panx1 is floxed with 
loxPs, ultimately creating tissue specific knock-outs of Panx1 within cochlear specific regions. 
A recent study evaluating the utility of Panx1-/- mice (distinct from the one used in our studies) 
showed that Panx1tm1a(KOMP)Wtsi mice were hypomorphic and Panx1-/- mice derived from these 
mice still had approximately 30% residual Panx1 mRNA transcript in various tissues including 
the brain, kidney and liver [45]. Further, the Foxg1-conditional Panx1 knock-out mouse that 
was reported to have hearing loss exhibited strong immunoreactivity for Panx1 in the organ of 
Corti as revealed by staining with a chicken anti-human Panx1 antibody which has been shown 
to have questionable specificity for Panx1 [46]. One noticeable difference between our study 
and the two conditional Panx1 knock-out mice were the frequencies tested. In Chapter 2 and 3 
we used a broadband click stimulus to examine general hearing function as well as 4-, 8-, 16- 
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and 24 kHz specific frequency stimuli while the studies using conditional Panx1 knock-out 
mice used 8-, 16-, 24-, 32-, and 40 kHz tonal frequencies. Since the mouse hearing range 
extends from 1 kHz to approximately 100 kHz [47], the conditional Panx1 knockout studies 
included testing higher frequency ranges where hearing loss was more evident. However, in 
support of our findings that hearing is maintained when Panx1 is ablated, a more recent study 
using a different Panx1 global knock-out mouse found no significant differences in hearing 
thresholds even at 32 kHz tones [13]. This suggests that the frequency range tested was not the 
sole reason for the discrepancies between these studies however, it could be a contributing 
factor. Furthermore, all the above studies using Panx1 knock-out mice have been created on a 
C57BL/6 background, however it is unknown how many times, or even if, these mice were 
further backcrossed on other mouse strains, and thus the exact background strain of the mice 
could account for some of the discrepancies between studies.  
Another consideration for the discrepancies between studies are the transcription factors, 
Foxg1 and Pax2, used for the generation of the conditional Panx1 knock-out mice. Both of 
these transcription factors are involved in embryonic development not only of the cochlea but 
also for proper brain development during embryogenesis [48–52]. Importantly, Panx1 is 
abundantly expressed in the central nervous system particularly in neurons [53,54]. Therefore, 
by breeding Panx1 floxed mice with cre mice that use transcription factors involved in 
embryonic development, brain development could also be impaired leading to potential 
damage in the higher-order auditory regions. In addition, the Foxg1 and Pax2 strains must 
express a cre recombinase whereas the global mice do not [13]. Cre expression in mammalian 
cells can produce chromosomal abnormalities depending on cre activity as well as passenger 
mutations [55]. Although genetically modified mice provide us with the tools to assess genes 
of interest in the cochlea, the differences observed in hearing phenotypes with the use of Panx1 
conditional versus global knock-out mice warrants further investigation. With more advanced 
technologies in the generation of genetically modified mice the use of CRISPR-Cas9 to make 
a Panx1 knock-out mouse model may serve to resolve the discrepancies between the current 
published studies.  
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6.3. Screening of connexins in congenital hearing loss 
In most developed countries shortly after children are born, they undergo newborn hearing 
screening to examine their auditory function to ensure that all hearing impaired babies are 
identified as soon as possible. Since age of identification of hearing loss is a critical factor in 
the development of a child’s speech the “Universal Newborn Hearing Screening” program 
where all babies have the opportunity to be screened for hearing impairment has been the 
standard of care in the United States, United Kingdom, and most of Canada [56]. Otoacoustic 
emissions (OAE) tests and/or auditory brainstem responses (ABRs) are used to measure the 
integrity of the hair cells, and general hearing function, respectively [57]. These tests are 
minimally invasive as they are completed while the baby is asleep and gives an indication of 
whether there are any signs of hearing loss. Collectively, approximately 1 in 1000 newborns 
have hearing loss making it one of the most common congenital disorder [58]. When hearing 
loss is suspected, they will be genotyped for various common genes involved in hearing loss 
using DNA samples acquired from either the blood or from oral cavity swabs. Subsequently, 
GJB2 and/or GJB6 are fully sequenced as a first pass test since over 135 mutations in these 
genes account for most congenitally acquired cases of hearing loss [1,59,60]. 
In Chapter 4 we examined auditory function in Cx43 mutant mice harbouring both a moderate 
(Cx43I130T/+) and severe (Cx43G60S/+) reduction of Cx43 gap junctional intercellular 
communication and found that only mice with a severe reduction in Cx43 function led to 
hearing impairment. A previous study examining auditory function in Cx43 heterozygous 
mouse found similar phenotypes where hearing was normal and was only slightly elevated by 
approximately 10 dB at 10 months of age [61]. Patients with ODDD often have many 
additional morbidities  with variable severities and approximately 10-15% of patients with 
ODDD have the comorbidity of hearing loss [62,63], although it is not known why some 
patients do while others do not. Our findings suggest that newborn screening of hearing loss-
linked genes  should perhaps extend to include GJA1, encoding Cx43. Importantly, while the 
I130T mutation has been found in the human population, the G60S mutation has not. It would 
be interesting to assess whether some patients with idiopathic congenitally acquired hearing 
loss is potentially due to a G60S mutation or possibly another gene mutation that severely 
compromises Cx43 function. Our studies also suggest that screening newborns for PANX1 or 
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PANX3  gene mutations would not be beneficial as our studies collectively present the notion 
that Panxs are not essential for normal hearing.  
6.4. Advances in genetic therapies to correct hearing loss-linked 
GJB2 mutations  
Treatment of hearing loss currently consists of either hearing aids for mild to moderate hearing 
loss or cochlear implants for more severe hearing impairments. Although cochlear implants 
can help most deaf patients understand speech, there are many limitations such as poor pitch 
perception and difficulty with tonal discrimination under noisy environments [64,65]. Thus, 
the need for molecular therapies to treat genetically acquired  hearing loss has been a major 
focus in the auditory field.  
6.4.1. Routes of drug delivery to the inner ear 
One of the most pressing challenges for advancing molecular therapeutics for hearing loss is 
the development of methodologies for  safe and efficient drug delivery to the inner ear. Routes 
of drug administration to the inner ear include; systemic, intratympanic, and intracochlear 
routes where local administration becomes imperative in alleviating off target effects [66–69]. 
In many cases, systemic drug delivery has been used for cochlear interventions, however, the 
blood labyrinth barrier (BLB) decreases the effectiveness of drug delivery to the inner ear [70–
72]. In addition, drug toxicity and off target effects within other tissues are also of concern 
[69]. Thus, the need for local administration techniques are required for the efficient drug 
delivery strategies such as intratympanic and intracochlear routes.  
Intratympanic injections involves administration of drugs into the middle ear through the 
tympanic membrane which allows for the direct drug entry into the cochlea [73,74]. Although 
these injections offer an advantage of being mildly invasive, they rely  on proper drug diffusion 
through the round and/or oval windows of the cochlea. Thus, exact drug concentrations that 
enter the inner ear can vary [69]. Further, as this route of drug delivery relies mostly on drug 
diffusion that starts at the base of the cochlea, there may be little or no drug delivery to the 
apex of the cochlea. This can be used to the patient's advantage depending on the specific 
disease. For example, patients with Meniere’s disease are treated with a one-shot application 
of gentamicin through intratympanic injections [75]. This route of drug administration would 
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allow for maximal treatment along the base of the cochlea and minimize the gentamicin 
concentrations in the regions that guide the acquisition of  speech (i.e. middle region). More 
invasive intracochlear delivery methods such as injection into the semicircular canal, round 
window membrane, or the scala media have greatly enhanced the efficiency of drug delivery 
to the inner ear [67]. These routes require surgery, are highly invasive, and extremely risky as 
the surgical techniques needed can sometimes induce hearing loss. Therefore, the benefits must 
outweigh the consequences when considering treatment of restoring hearing loss in human 
patients.  
6.4.2. Cochlear GJB2 restoration with adeno-associated viruses 
Adeno associated viruses (AAVs) are prime candidates for gene therapy as this virus harbors 
no known adverse pathogenicity and is small (less than 20 nm) which helps diffusion across 
the cell membrane  [76]. In addition, AAVs have been successfully used in human clinical 
trials for ocular diseases  [77]. One of the largest obstacles to overcome in cochlear gene 
therapy is to deliver a viral vector into the cochlea without causing hearing loss or damage to 
the cochlea itself. Animal models have shown successful AAV-GFP viral transduction into 
cochlear cells after  injection into different entry points including the posterior semicircular 
canal, round window, or scala media with little to no cochlear damage [78,79]. Further, 
CRISPR-Cas9 genome-editing to correct a dominant deafness mutant caused by a mutation in 
transmembrane channel-like gene family 1 gene (Tmc1, Beethoven) was injected into the 
neonatal cochlea and significantly reduced progressive hearing loss [80]. 
GJB2 hearing loss linked mutants are uniquely positioned to be rescued by viral induction of 
AAVs due to their small packing size (limit of 5 kb) where the entire coding exon of connexins 
can be packed into a single AAV [81]. Additionally, since most GJB2 hearing loss linked 
mutants are recessive, it leaves a therapeutic window available whereby only one WT Cx26 
allele may be required for significant hearing recovery [1,82]. There is no evidence to suggest 
that Cx26 plays a role in hair cell fate or differentiation, however, GJB2 mutants that cause 
hearing loss result in hair cell loss in early postnatal development [83,84]. AAV viral delivery 
of WT Cx26 into the scala media of neonatal Cx26 conditional knock-out mice restored the 
gap junctional intercellular network of cochlear supporting cells and resulted in partial 
improvement in the morphology of the organ of Corti  [85]. However, no functional 
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improvement in hearing thresholds were observed after viral delivery, limiting the potential 
therapeutic value [85]. Another study injecting WT Cx26 packed AAVs into the perilymph 
through the oval window at P0 in Cx26 conditional knock-out mice showed proper formation 
of the organ of Corti and significant hearing preservation [86]. However, when the injection 
was performed in mice at P42 no cochlear morphology or hearing improvement was observed, 
suggesting that one limiting factor of successful hearing restoration is early gene delivery.  
These studies are a promising start to the potential of personalized gene therapy for individual 
GJB2 mutations that may have different mechanisms of action in the in vivo cochlea. However, 
it is also important to note the different developmental stages of hearing in mice versus humans 
where mice acquire mature hearing at P14 while humans can hear at approximately four 
months in utero [87–89]. While most successful AAV deliveries in mice have been performed 
in P0-P1 cochlea, this would translate to a “pre-hearing” phenotype in mice.  In humans, to 
treat the fetus as a similar stage of hearing acquisition would require in utero viral delivery; a 
procedure that would require extreme precision and could cause potential damage. 
Consequently, this approach is somewhat daunting to consider. Preclinical work has shown 
that overexpression of Atoh1 (transcription factor involved in hair cell differentiation) is 
sufficient to rescue hearing impairment by regenerating hair cells [90,91]. A clinical trial 
involving an AAV containing Atoh1-cDNA for the treatment of hearing loss was started in 
2014 and expected to be completed 2021 (clinicaltrials.org). This trial will give us novel insight 
as to the translational capacity of using AAVs to treat hearing loss in human patients. 
6.4.3. Targeted antibodies for GJB2 related hearing loss mutants 
The use of antibodies to block and downregulate specific proteins of interest has proven to be 
a useful approach  in therapeutics. There are at least eight different gain-of function syndromic 
GJB2 mutations causing skin disorders that exhibit  hyperactive or “leaky” hemichannels 
(G11E, G12R, N14K, N14Y, A40V, G45E, D50A, D50N, A88V) [92]. For these particular 
mutations, downregulating Cx26 function may prove to be beneficial. Another study recently 
identified a human recombinant antibody that binds a peptide derived from the first 
extracellular loop of Cx26 and perturbs hemichannel function [93]. This study found that the 
antibody was non-toxic to cells, and reversibly inhibited Cx26 hemichannel currents while 
strongly reducing hemichannel activity of some Cx26 hyperactive mutants. In organotypic 
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cochlear cultures of P5 mice, incubation of the antibody (abEC1.1) for 15-20 minutes 
significantly reduced spontaneous Ca2+ events, a process that is known to involve connexins. 
However, microinjection of Lucifer yellow into cultures showed that pre-incubation of this 
antibody did not affect dye transfer, suggesting that this antibody specifically inhibited 
connexin hemichannel, but not gap junction, function [93]. The antibody also reduced the 
activity of hyperactive hemichannels of Cx26 G45E and D50N in a keratinocyte cell line [93]. 
Further studies using connexin targeted antibodies delivered specifically to the inner ear are 
needed to evaluate whether they provide a novel potential therapeutic strategy in treating 
hearing loss. 
6.5. Potential therapeutic targets of connexins and pannexins 
Collectively our studies show that pannexins are not involved in auditory function, suggesting 
there is  limited utility in developing potential therapies for pannexins in auditory function. 
However, it is important to note that the first human patient with a PANX1 variant was recently 
found to have multiple symptoms including hearing loss leading to a cochlear implant [94]. It 
is unclear if hearing loss is directly correlated to the variant itself or due to one of the other 
many symptoms incurred such as brain developmental deformities. Nonetheless, the need for 
connexin therapeutics whereby increasing GJIC may help to restore normal cochlear function 
would be useful for hearing loss-linked connexin mutations. Many therapeutic targets 
including antisense oligonucleotides and peptide mimetics have been used to alter Cx43 
expression [95]. For example, an oligonucleotide (AsODN) from CoDa Therapeutics has been 
used to treat skin wounds since it is known that decreasing Cx43 expression enhances wound 
healing [96,97]. A promising peptide mimetic produced by First String Research, aCT1, was 
originally shown to decrease scar formation and promote wound healing in preclinical studies 
[98]. In clinical trials, aCT1 reduced the ulcer area and enhanced wound closure in diabetic 
patients [97]. Previous studies have shown that aCT1 prevents the interaction between Cx43 
and ZO-1, ultimately leading to larger gap junctions which may increase communication 
between cells [99,100]. aCT1 has also been shown to promote the incorporation of Cx43 
hemichannels to gap junction plaques, which may in turn lead to enhanced cellular 
communication [100].  
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The potential of drug therapeutics for treatment of hearing loss is theoretically promising due 
documented successes of some key preclinical and clinical trials. The therapeutic approach of 
Cx43 targeted strategies may be useful for patients with ODDD that have sensorineural hearing 
loss as an additional comorbidity. In Chapter 4 we showed that Cx43G60S/+ mutant mice had 
significant hearing loss while Cx43I130T/+ mutant mice did not, where the G60S mutation retains 
only 15-20% of GJIC while the I130T mutant retains approximately 50% [101,102]. 
Importantly, some patients with ODDD have hearing loss while others do not, thus, we propose 
that this phenomenon may be due to the functional level of Cx43 in the auditory system. These 
findings support the notion that Cx43 function in the auditory tract is essential, however, there 
is a therapeutic window where only 50% function is enough to maintain proper hearing. Using 
a peptide, such as aCT1, that would promote Cx43 GJIC could in theory be  beneficial in 
treating hearing loss linked patients with ODDD.  
6.6. Future directions 
In Chapter 4 we found that Cx43G60S/+ had significant hearing loss which was mapped to 
decreases in the neural firing of the auditory brainstem regions (i.e. higher order auditory 
regions). Additionally, we found Cx43 to be localized to the cochlear nerve region where the 
nerves contact the brain region. Since Cx43 is abundantly expressed in astrocytes of the brain, 
it would be beneficial to conduct more higher-order auditory processing tasks to see if these 
mutant mice also have dysfunction in the auditory cortex region. This is of particular 
importance because typically higher-order auditory testing is not generally performed as a first 
pass screening and thus, patients with these mutations could have processing disorders that 
will remain undetected. With future studies examining the role of Cx43 in these regions, more 
insight will be shed on its’ precise role in hearing.  
In Chapter 5 we found that GJIC did not influence the level of cisplatin-induced ototoxicity in 
Cx43 mutant mice and a cochlear relevant cell line. The use of organotypic cochlear cultures 
is useful in maintaining the three-dimensional aspect of the cochlea for the use of drug 
treatments, however, it is not the same environment as is in the in vivo inner ear. For example, 
we and others have found that carbenoxolone treatment did not cause hair cell loss in 
organotypic cochlear cultures [103]. However, when CBX was administered into the in vivo 
cochlea directly, CBX causes significant hair cell loss [103]. This emphasizes the fact that the 
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model may not fully mimic the in vivo setting. Therefore, future directions of this study could 
involve administering cisplatin to Cx43 mutant mice through intravenous injection, as is 
performed in humans, and examine whether loss of Cx43 GJIC impacts cisplatin-induced 
ototoxicity in vivo. Further, because we examined reorganization of Cx26 and Cx30 gap 
junction channels after cisplatin treatment in our organotypic cochlear cultures, it would be 
interesting to see if this also occurred in cochlear supporting cells when cisplatin was 
administered to the mouse directly. Continuing on with these studies, cisplatin administration 
to hearing loss-linked Cx26 mutant mice would provide us with insight as to whether patients 
with Cx-induced hearing loss would be more or less susceptible to drug-induced hearing loss. 
Collectively, these studies would provide us with information that would be informative in a 
translational capacity to patients with hearing loss and undergoing cancer treatment. 
6.7. Overall conclusions 
The compilation of studies presented in this thesis were performed to assess the importance of 
large pore channels, connexins and pannexins, in auditory function. To accomplish this we 
examined three main categories of hearing loss including; genetically acquired-, noise- and 
drug-induced hearing loss. Using both genetically modified mice harboring either global 
ablations of pannexins and point mutations of connexins we were able to phenotype the 
auditory profile of these mice under baseline hearing as well as after exposure to loud noise-
exposure. Finally, to evaluate the molecular processes involved in drug-induced hearing loss 
we used organotypic cochlear cultures treated with cisplatin in connexin mutant mice to 
examine whether connexins exacerbated or prevented cisplatin-induced cell death. The work 
presented in this thesis outlines the first comprehensive evaluation of connexins and pannexins 
in a wide range of hearing loss.  
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Dr.Timothy Regnault, 
Animal Care Committee Chair 
                                                                                                                                       
                                                                                                              The University 
of Western Ontario 
                                                                                      Animal Care Committee / 
University Council on Animal Care 
                                                                                                              London, Ontario 
Canada N6A 5C1 
                                                                                                  519-661-2111 x 88792 
Fax 519-661-2028 
                                                                                  [auspc@uwo.ca]auspc@uwo.ca ï¿½ 
http://www.uwo.ca/research/services/animalethics/index.html  
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